AU2005202068B2 - Quinolinone derivatives as tyrosine kinase inhibitors - Google Patents
Quinolinone derivatives as tyrosine kinase inhibitors Download PDFInfo
- Publication number
- AU2005202068B2 AU2005202068B2 AU2005202068A AU2005202068A AU2005202068B2 AU 2005202068 B2 AU2005202068 B2 AU 2005202068B2 AU 2005202068 A AU2005202068 A AU 2005202068A AU 2005202068 A AU2005202068 A AU 2005202068A AU 2005202068 B2 AU2005202068 B2 AU 2005202068B2
- Authority
- AU
- Australia
- Prior art keywords
- groups
- substituted
- unsubstituted
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
AUSTRALIA
Patents Act 1990 CHIRON CORPORATION COMPLETE SPECIFICATION DIVISIONAL PATENT Invention Title: Quinolinone derivatives as tyrosine kinase inhibitors The following statement is a full description of this invention including the best method of performing it known to us:-
-A-
QUINOLINONE DERIVATIVES AS TYROSINE KINASE
INHIBITORS
FIELD OF THE INVENTION This invention pertains generally to treating diseases characterized by angiogenesis including cancer. More specifically, the invention described herein pertains to treating diseases characterized by activity of vascular endothelial growth factor receptor tyrosine kinases. The present invention provides, small molecule inhibitors of vascular endothelial growth factor receptor tyrosine kinase, pharmaceutical formulations containing such inhibitors, methods of treating patients with such pharmaceutical formulations, and to methods of preparing such pharmaceutical formulations and inhibitors.
BACKGROUND OF THE INVENTION Capillaries reach into almost all tissues of the human body and supply tissues with oxygen and nutrients as well as removing waste products. Under typical conditions, the endothelial cells lining the capillaries do not divide, and capillaries, therefore, do not normally increase in number or size in a human adult.
Under certain normal conditions, however, such as when a tissue is damaged, or during certain parts of the menstrual cycle, the capillaries begin to proliferate rapidly. This process of forming new capillaries from pre-existing blood vessels is known as angiogenesis or neovascularization. See Folkman, J. Scientific American 275, 150-154 (1996). Angiogenesis during wound healing is an example of pathophysiological neovascularization during adult life. During wound healing, the additional capillaries provide a supply of oxygen and nutrients, promote granulation tissue, and aid in waste removal. After termination of the healing process, the capillaries normally regress. Lymboussaki, A. "Vascular Endothelial Growth Factors and their Receptors in Embryos, Adults, and in Tumors" Academic i Dissertation, University of Helsinki, Molecular/Cancer Biology Laboratory and SDepartment of Pathology, Haartman Institute, (1999).
o Angiogenesis also plays an important role in the growth of cancer 0cells. It is known that once a nest of cancer cells reaches a certain size, roughly 1 C 5 to 2 mm in diameter, the cancer cells must develop a blood supply in order for the CI tumor to grow larger as diffusion will not be sufficient to supply the cancer cells Swith enough oxygen and nutrients. Thus, inhibition of angiogenesis is expected to CI halt the growth of cancer cells.
Receptor tyrosine kinases (RTKs) are transmembrane polypeptides that regulate developmental cell growth and differentiation, remodeling and regeneration of adult tissues. Mustonen, T. et al., J. Cell Biology 129, 895-898 (1995); van der Geer, P. et al. Ann Rev. Cell Biol. 10, 251-337 (1994).
Polypeptide ligands known as growth factors or cytokines, are known to activate RTKs. Signaling RTKs involves ligand binding and a shift in conformation in the external domain of the receptor resulting in its dimerization. Lymboussaki, A.
"Vascular Endothelial Growth Factors and their Receptors in Embryos, Adults, and in Tumors" Academic Dissertation, University of Helsinki, Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute, (1999); Ullrich, A. et al., Cell 61, 203-212 (1990). Binding of the ligand to the RTK results in receptor trans-phosphorylation at specific tyrosine residues and subsequent activation of the catalytic domains for the phosphorylation of cytoplasmic substrates. Id.
Two subfamilies of RTKs are specific to the vascular endothelium.
These include the vascular endothelial growth factor (VEGF) subfamily and the Tie receptor subfamily. Class Ill RTKs include VEGFR-1, VEGFR-2, and VEGFR-3.
Shibuya, M. et al., Oncogene 5, 519-525 (1990); Terman, B. et al., Oncogene 6, 1677-1683 (1991); Aprelikova, O. et al., Cancer Res. 52, 746-748 (1992).
Members of the VEGF subfamily have been described as being able to induce vascular permeability and endothelial cell proliferation and further identified as a major inducer of angiogenesis and vasculogenesis. Ferrara, N. et Endocrinol. Rev. 18, 4-25 (1997). VEGF is known to specifically bind to RTKs including VEGFR-1 and VEGFR-2. DeVries, C. et al., Science 255, 989- 00 0 991 (1992); Quinn, T. et al., Proc. Natl. Acad. Sci. 90, 7533-7537 (1993). VEGF stimulates the migration and proliferation of endothelial cells and induces angiogenesis both in vitro and in vivo. Connolly, D. et al., J. Biol. Chem. 264, 20017-20024 (1989); Connolly, D. et al., J. Clin. Invest. 84, 1470-1478 (1989); Ferrara, N. et al., Endocrino. Rew. 18, 4-25 (1997); Leung, D. et al., Science 246, 1306-1309 (1989); Plouet, J. et al., EMBO J 8, 3801-3806 (1989).
Because angiogenesis is known to be critical to the growth of cancer and to be controlled by VEGF and VEGF-RTK, substantial efforts have been undertaken to develop therapeutics that are antagonists of VEGF-RTK to thereby inhibit or retard angiogenesis, and, hopefully, interfere or stop tumor proliferation.
A wide variety of chemical compounds and compositions have been reported as having activity against one of more the VEGF-RTKs. Examples include quinoline derivatives such as described in WO 98/13350, aminonicotinamide derivatives (see, WO 01/55114), antisense compounds (see, WO 01/52904), peptidomimetics (see, WO 01/52875), quinazoline derivatives (see, U.S. Patent No. 6,258,951) monoclonal antibodies (see, EP 1 086 705 Al), various 5,10,15,20-tetraaryl-porphyrins and 5,10,15-triaryl-corroles (see, WO 00/27379), heterocyclic alkanesulfonic and alkane carboxylic acid derivatives (see, DE19841985), oxindolylquinazoline derivatives (see, e.g., WO 99/10349), 1,4-diazaanthracine derivatives (see, U.S. Patent No.
5,763,441), and cinnoline derivatives (see, WO 97/34876), and various indazole compounds (see, WO 01/02369 and WO 01/53268).
Various indolyl substituted compounds have recently been disclosed in WO 01/29025, WO 01/62251, and WO 01/62252, and various benzimidazolyl compounds have recently been disclosed in WO 01/28993. These compounds are reportedly capable of inhibiting, modulating, and/or regulating signal transduction r 1 4; of both receptor-type and non-receptor tyrosine kinases. Some of the disclosed compounds contain a quinolone fragment bonded to the indolyl or benzimidazolyl group.
00 N The synthesis of 4-hydroxy quinolone and 4-hydroxy quinoline c 5 derivatives is disclosed in a number of references. For example, Ukrainets et al.
C' have disclosed the synthesis of 3-(benzimidazol-2-yl)-4-hydroxy-2-oxo-1,2- Sdihydroquinoline. Ukrainets, I. et al., Tet. Lett. 42, 7747-7748 (1995); Ukrainets, I. et al., Khimiya Geterotsiklicheskikh Soedinii, 2, 239-241(1992). Ukrainets has also disclosed the synthesis, anticonvulsive and antithyroid activity of other 4hydroxy quinolones and thio analogs such as 1H-2-oxo-3-(2-benzimidazolyl)-4hyrdoxyquinoline. Ukrainets, I. et al., Khimiya Geterotsiklicheskikh Soedinii, 1, 105-108 (1993); Ukrainets, I. et al., Khimiya Geterotsiklicheskikh Soedinii, 8, 1105-1108 (1993); Ukrainets, I. et al., Chem. Heterocyclic Comp. 33, 600-604, (1997).
The synthesis of various quinoline derivatives is disclosed in WO 97/48694. These compounds are disclosed as capable of binding to nuclear hormone receptors and being useful for stimulating osteoblast proliferation and bone growth. The compounds are also disclosed as being useful in the treatment or prevention of diseases associated with nuclear hormone receptor families.
Various quinoline derivatives in which the benzene ring of the quinolone is substituted with a sulfur group are disclosed in WO 92/18483. These compounds are disclosed as being useful in pharmaceutical formulations and as medicaments.
Quinolone and coumarin derivatives have been disclosed as having use in a variety of applications unrelated to medicine and pharmaceutical formulations. References that describe the preparation of quinolone derivatives for use in photopolymerizable compositions or for luminescent properties include: U.S.
Patent No. 5,801,212 issued to Okamoto et al.; JP 8-29973; JP 7-43896; JP 6-9952; JP 63-258903; EP 797376; and DE 23 63 459.
Despite the exploration of a variety of chemistries to provide VEGF- RTK-antagonist therapies, a continuing need exists for compounds that inhibit the proliferation of capillaries, inhibit the growth of tumors, and/or inhibit vascular endothelial growth factor receptor tyrosine kinase and pharmaceutical formulations that contain such compounds. A need also exists for methods for administering such compounds and pharmaceutical formulations to patients in need thereof.
SUMMARY OF THE INVENTION The present invention provides compounds, pharmaceutical formulations including the compounds, methods of preparing the pharmaceutical formulations, and methods of treating patients with the pharmaceutical formulations and compounds.
The present invention provides a first group of compounds having the structure I. The invention also provides tautomers of the compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutically acceptable salts of the tautomers. Structure I has the following formula:
RR
RR
N
RR 8
R
4
R
9
I
where, in the first group of compounds: Y is selected from -ORO groups, groups, -NRuR 1 3 groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted 4 heterocyclylalkyl groups, substituted or unsubstituted. alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted.
arylaminoalkyl groups, substituted or unsubstituted diarylaninoalkyl groups, 00 substituted or -unsubstituted .(alkyl)(aryl)aniinoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted saturated heterocyclyl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, substituted or unsubstituted. hydroxyalkyl groups, or substituted or unsubstituted aryloxyalkyl groups; Z is selected from 0, S, or NR 14 groups;
R
1 RW, R7, and RW may be the same or different and are independently selected from H, Cl, Br, F, I, -ON, -NO2, -OH, -OR 15 3 groups, -NR1 6 R 1 7 groups, substituted or unsubstituted. amidinyl groups, substituted or unsbbstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary -alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkyihyl groups, substituted or unsubstituted. heterocyclyl groups, -substituted or unsubstittited aminoalkyl groups, substituted or unsubstituted. alkylaminoalkyl groups, substituted or unsubstitated dialkylaminoalkyl groups, substituted or unsubstituted arylamioalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted.
diheterocycly laminoalkyl groups, substituted or unsubstituted.
(heterocyclyl)(alkyl)aminoalyl groups, substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl groups, or O)R' 8 groups; RW, W 6
R
7 and R' may be the same or different and are independently selected from H, Cl,,Br, F, 1, -NO2, -OH, -OR' 9 groups, -NR 2 groups, -SH, -SR22 groups, -S(=O)R23 groups, =O)2R groups, -CN, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted -alkenyl groups, substituted or unsubstituted alknyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, groups, substituted 00 IND or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoaly N- 5 groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted diheterocyclylaninoalcyl groups, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalky groups, substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl groups, substituted or unsubstituted hydroxyalcyl groups, substituted or unsubstituted alkoxyakl groups, substituted or unsubstituted aryloxyalkyl groups, or 'substituted or unsubstituted heterocyclyloxyalkyl .groups;
R
9 and R 1 4 may be tJe same or different and are independently selected from Ii, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstitut ed aryloxy groups, -NIL, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups,, substituted. or. unsubstituted dialkylamino groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (alkyl)(aryl)aniino. groups, substituted. or unsubstituted alk groups,.
substituted or unsubstituted aryl groups, -C(=O0)-.alkyl groups, or -C(=O)-aryl groups; R1 0 is selected from substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl .groups, -C(=O)-alkyl groups, -C(=O)-aryl groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, -C(=Q)N12, -C(=O)NH(alcyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(akyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -NH2, -NH(alcyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(allcyl)(aryl) groups, -N(aryl)2 groups, -NH(heterocyclyl) groups, -N(heterocyClyl)2 groups, -N(alkyl)(heterocyclyl) groups, -N(aryl)(heterocyclyl), O)NH(heterocyclyl) groups, C( =O)N(heterocyclyl)2 groups, O)N(alkyl)(heterocyclyl) groups, O)N(aryl) (heterocyclyl) groups,. or substituted -or unsubstituted heterocyclylalkyl groups; 00 R" is selected from H, -NiH, -NH(alkyl) groups, -NII(aryl) groups, -N(alkl)2 groups, -N(aryl)2 groups, -N(alkl)(aryl) groups, -NH(heterocyc lyl) groups, -N(heterocyclyl)2 groups, -N(alkyl)(heterocyclyl) groups, C1 -N(aryl)(heterocyclyl) groups, -0-alkyl groups, 0-aryl groups, heterocyclyloxyalkyl groups, or substituted or unsubstituted aryl groups; R 1 2 is selected from H, substituted or unsubstituted ailkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups; R 13 is selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, -NiH, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoalkyl. groups, substitut .ed or unsubstituted alkylaininoalkyl groups, substituted or uns ubstituted dWamninoalkyl groups, substituted, or unsubstituted arylaniinoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups,- substituted or unsubstituted (alkyl)(aryl)aniinoalkl groups,- substituted or unsubstituted alkylainino groups, substituted or unsubstituted arylamino groups, substituted or uinsubstituted diallcylainino groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (alkyl)(aryl)amino groups, -C(=O)-alcyl groups, -C(=O)-aryl groups, -C(=Q)O-alkyl groups, -C(=O)O-aryl groups, -C(=O)NH2, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups,, -C(=O)N(alkyl)2 groups, =O)N(aryl)2 groups, )N(alkyl)(aryl). groupst, 0)-heterocyclyl groups, =O)-O-heterocyclyl groups, =O)NH(heterocyclyl) groups, QC=)-N(heterOCYClyl)2 groups, -C(=O)N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalicyl groups, substituted or unsubstituted heterocyclyloxyalicyl groups, or =O)-N(akl)(heterocyclyl) groups; 00 R 1 5 and R' 9 may be the same or different and are independently selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or ttn unsubstituted heterocyclylalkyl groups, -C(=Q)-alkyl groups, -C(=O)-aryl groups, -C(=O)NH2, -C(=O)NII(alkyl) groups, -C(=Q)NH(aryl) groups, -C(=Q)N(akyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)2 groups, -N(alkyl)(heterocyclyl) groups, -N(aryl)(heterocyclyl) groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaininoalkyl groups, substituted or unsubstituted dialkylaniinoalkyl groups, substituted or unsubstituted arylaninoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (akl)(aryl)aminoalkyl groups, substituted. or unsubstituted heterocyclylaminoalkyl, substituted or unsubstituted diheterocyclylaminoalkyl, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkyl, substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstitated aryloxyalkyl'groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; R 1 6 and RWO may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups;
R"
7 and W' may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, C= O)H, )-alkyl groups, )-aryl groups, O)NH2, -C(=O)NH(alcyl) groups, -C(=O)NII(aryl) groups, -C(=O)N(alkyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alcyl)(ary1) groups, -C(0)O-alcyl groups,.
-C(=O)O-ar:yl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, 00 substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl ,)aminoalkyl groups, heterocyclyl groups, O)-O-heterocyclyl groups, -C(=O)NH(heterocyclyl) groups, -C(=O)-N(heterocyclyl)2 groups, -C(=O)N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoakl groups, substituted or unsubstituted diheterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl)(alkyl)aniinoalkyl groups, substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl groups, substituted or unsubstituted hydroxyalcyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, or.
C( =O)-N(allcyl)(heterocyciyl) groups;
R'
8 R21, e, -and Rmay be the; same or different and are independently selected from H1, -Nfih, -NH(alkyl) groups, -NII(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2- groups, substituted or- unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aryloxy groups, heterocyclyloxy groups, -NHOH, -N(alkyl)OH groups, -N(aryl)OH groups, -N(alkyl)Q-alkyl groups, -N(aryl)Q-alkyl groups, -N(alkyl)O-aryl groups, or -N(aryl)O)-aryl groups; and R?2 is selected from substituted or unsubstituted ailkyl groups, substituted or unsubstituted aryl groups, .or substitut ed or unsubstituted heterocyclyl groups.
-11- The invention provides a second group of compounds including compounds having the structure I, tautomers of the compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutically acceptable salts of the 00 IN tautomers.
In the second group of compounds: O Y is selected from -ORIo groups, groups, -NR' 2 R1 groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted alkylaininoalcyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituited or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsuibstituted heterocyclylaminoalkyl groups, substituted or unsubstituted saturated heterocyclyl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, substituted or unsubstituted hydroxyalkyl groups, or substituted or unsubstituted aryloxyalkyl groups; Z is selected from. 0, S, or NR' 4 groups;
R
2
R
3 and R 4 may be the same or different and are independently selected from H, Cl, Br, F, I, -CN, -NO.2, -OH, -OR" 5 groups,
-NR'
6 R17 groups,. substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary,.secondary, and tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or undubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoallcyl groups, substituted or unsubstituted heterocyclylalkyl groups, or -C(=O)R 8 groups; 4 R 5 W, W 6
R
7 and W 8 may be the same or different and are independently selected from H, Cl, Br, F, 1, -NO2, -OH, -OR' 9 groups, -NR 20
R
2 groups, -SH, -SR22 groups., O)e -groups, OWi groups, -CN, substituted 00 or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, 0 5 substituted or unsubstituted primary, secondary, and tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, V) substituted or urisubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, O)Re groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted.
alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalcyl groups, substituted or unsubstituted arylainoalkyl groups, substituted or unsubstituted diarylaminoalcyl groups, substituted or unsubstituted (alkyl)(aryl)aminoallyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; R? is selected from the group consisting of -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted. aryloxy groups, -NH2, substituted or unsubstituted alkylamino groups,* substituted or unsubstituted arylamino, groups, substituted or unsubstituted dialkylarnino groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (alkyl)(aryl)amino groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted. aryl groups, -C(=O)-alkyl groups, or -C(=O)-aryl groups;
WO
0 is selected from substituted or unsubstituted. aryl groups, substituted or unsubstituted heterocyclyl- groups, -C(=O)-akl groups, =O)-aryl groups, )0-alkyl groups, =0)0-aryl groups, =O)NH2, -C(=O)NH(alkyl) groups, -C(=-O)NH(aryl) groups, -C(=O)N(alkyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -NH2, -NH(alkyl) groups, -NH(aryl) groups, -N(alcyl)2 groups, -N(alkyl)(aryl) groups, -N(aryl)2 groups, =O)NH(heterocyclyl) groups, =O)N(heterocyclyl)2 groups, )N(alkyl)Qieterocyclyl) groups, )N(aryl)(heterocyclyl) groups, or substituted or unsubstituted heterocyclylalkyl groups; R" is selected from H, -NH2, -NH(alkyl) groups, -NI{(aryl) groups, -N(alkl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)2 groups, -N(alkyl)(heterocyclyl) g roups, -0-alkyl groups, 0-aryl groups, substituted or unsubstituted alkyl1 groups, or substituted or unsubstituted aryl groups;
R"
2 is selected from H, substituted or unsubstituted ailkyl groups, substituted or nsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups; R 1 3 is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or urisubstituted heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, -NM2, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted diallcylamio groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (allcyl)(aryl)aniino groups, -C(=O)-alkyl groups, -C(=O)-aryl groups, -C(=Q)O-alcyl groups., -C(=O)O-aryl gr oups, -C(=O)NH2, -C(O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=0)N(alyl)2 groups, -C(=O)N(ary)2 groups, -C(=O)N(alkyl)(aryl) groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted amrinoalcyl groups, substituted or unsubstituted alkylaniinoalkyl groups, substituted or unsubstituted dialkylamninoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, 0)-heterocyclyl groups, -C(=O)-O-heterocyclyl groups, .=O)NH(heterocyclyl) groups, Q)-N(heterocyclyl) 2 groups, O)N(aryl)(heterocyclyl) groups, =O)-N(alkyl)(heteroqyclyl) groups, substituted or unsubstituted heterocyclylamioalcyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups' substituted or unsubstituted aryloxyallcyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; 00 R" -is selected from H, -OH, substituted or unsubstituted alicoxy groups, substituted or unsubstituted aryloxy groups, -NH2, substituted or unsubstituted alkylamino group s, substituted or unsubstituted arylanino groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (alkyl)(aryl)arnino groups, substituted or unsubstituted ailkyl -groups, substituted or unsubstituted aryl groups, -C(=O)-alkyl groups, or -C(=O)-aryl groups;
R
1 5 and R 1 9 may be the same or different and are independently selected from -substituted or unsubstituted. alkyl groups, substituted or unsubstituted.
aryl groups, substituted or unsubstituted. heterocyclyl groups, substituted or unsubstituted. heterocyclylalkyl groups, O)H, -C(=O0)-alkyl groups, -C(=O)-aryl groups, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkcylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted beterocyclylaniinoalkyl, substituted or unsubstituted diheterocyclylaminoakl, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalcyl, substituted or unsubstituted (heterocyclyl)(aryl)aminoalcl, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstitut ed aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; R1 6 and R0 may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted. aryl groups, or substituted or unsubstituted heterocyclyl groups; R1 7 and R 2 'may be the same or different and are independently selected from H, substituted or'unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, 00 IND-C(=O)H, 0)-alkyl groups, 0)-aryl groups,-C(=O)NHM, N- 5 -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -d(=O)N(alkyI)2 groups, c-i -C(O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -C(=O)Q-alkyl groups,.
-C(=O)O-aryl groups, substituted or unsubstituted heterocyclylalkyl groups, c-i substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted aklaininoakl groups, substituted or unsubstituted dialkylaminoalcyl groups, substituted or unsubstituted arylaminoakl groups, substituted or unsubstituted diarylaininoalcyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, )-heterocyclyl groups, =O)-O-heterocyclyl groups, -C(=O)NH(heterocyclyl) groups, i=Q)-N(heterocyclyl)2 groups, -C(=O)N(aryl)Qieterocyclyl) groups, O)-N(alkyl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaniinoalkyl groups, substituted or unsubstituted hydroxyalkyl group substituted or unsubstituted alkoxyalkyl groups, substituted o r unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkylgroups; R, and e~ may be the same or different and are.
independently selected from H, -NH(alkyl) groups,. -NH(aryl),groups, -N(alkyl)2 groups, -N(aryl)2 grOUPS,.-N(alkyl)(aryl) groups, -NH(heterOCYClyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2 groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -OH1, substituted or unsubstituted alkoxy groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aryloxy groups, -NHQH, -N(alkyl)OH groups, -N(aryl)OH groups, -N(alkyl)O-aly groups, -N(aryl)O-alkl groups, -N(alkyl)O-aryl groups, or -N(aryl)O-aryl groups; and
R
2 2 is selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups.
00 0 The invention provides a third group of compounds including CN 5 compounds having the structure I, tautomers of the compounds, pharmaceutically c acceptable salts of the compounds, and pharmaceutically acceptable salts of the Stautomers.
In the third group of compounds: Y is selected from -OH, SH, alkylthio groups, arylthio groups, -ORO groups, groups, -NR 2
R'
3 groups, -CN, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted aralkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, or substituted or unsubstituted aryloxyalkyl groups; Z is selected from 0, S, or NR' 4 groups;
R
2
R
3 and R 4 may be the same or different and are independently selected from H, Cl, Br, F, I, -CN, -NO2, -OH, -OR 1 5 groups,
-NR'
6
R
1 7 groups, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaniinoalcyl. groups, substituted or unsubstituted 00 INDarylaminoalkyl groups, substituted or unsubstituted diarylaniinoalcyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, or -C(=O)R 8 groups;
W
5
R
6 and R' may be the same or different and are c-I independently selected from H, Cl, Br, F, 1, -N02, -OH, -O'R' 9 groups, -NR 2 groups, -SH, -SRW groups, groups, groups, -CN, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl. groups, substituted or unsubstituted primary, secondary, or tertiary ailkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or uflsubstituted dialkylaminoalcyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalcyl groups, substituted or unsub stituted (allcyl(aryl~aminoakyl groups, substituted or unsubstituted beterocyclylalkyl groups, groups, substituted or unsubstituted aininoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstit-uted aryloxyalkyl groups, or. substituted or unsubstituted heterocyclyloxyalkyl groups; R? and R' 4 may be the same or different and are independently selected from H, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, -NiH, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamio groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstituted diarylanino groups, substituted or unsubstituted (alkyl)(aryl)amnino groups, sub .stituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -Cx=O)H, -C(=O)-alkyl groups, or -C(=O)-aryl groups; 4 RW 0 is selected from substituted or. unsubstituted. ailkyl groups, substituted or unsubstituted aryl groups, substituted orunsubstituted -heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups,. 00 ~-C(=O0)-alkl groups, O)-aryl groups, -C(=O)Q-alkyl, groups, O)O-aryl 0 5 groups, -C(=O)NIL, -C(=Q)NH(alkyl) groups, -c(=o)NH(aryl) groups, -C(=O)N(akl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(-alkyl)(aryl) groups, tn -NH2, -NH(alkyl) groups, -NH(aryl) groups, N(alkyl)2 groups, -N(alkyl)(aryl) groups, -N(aryl)2 groups, -C(=O)NH~heterocyclyl) groups, O)N(heterocyclyl)2. groups, =O)N(alcyl)(heterocyclyl) groups, or -C(=O)N(aryl)(heterocyclyl) groups;
R"
1 is selected from H, -OH, alkoxy groups, aryloxy groups, -Nib, -NH(alkyl) groups,. -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 -groups, -N(alkyl)(aryl) groups, substituted or unsubstituted. alkl -groups, -NH~heterocyclyl) groups, -N(heterocyclyl)2 groups, -N(alkyl)(heterocyclyl) groups, or substituted or unsubstituted aryl groups; R i 2 is select .ed- from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted hieterocyclyl groups; R 1 3 is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubst ituted heterocyclyl.
groups, -OH, alkoxy groups, aryloxy groups, -Nib, substituted or tunsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoalicyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylamninoalkyl groups, substituted or unsubstituted arylaininoalicyl groups, substituted or unsubstituted diarylanoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylarnino groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (alkyl)(aryl)amino groups, -C(=O)-alkyl groups, -19- -C(=O)-aryl groups, -C(=O)0-alkyl groups, -C(=O)0-aryl groups, -C(=O)NH 2 -C(=O)NH(alkyl) groups, -C(=0)NH(aryl) groups, -C(=0)N(alcyl)2 groups, =O)N(arYl)2 groups, O)N(allcyl)(aryl) groups, -C(=O)-heterocyclyl groups, )-O-heterocyclyl groups, )NH~heterocyclyl) groups, -C(=0)N(heterocycyl)2 groups, 0)N(alkyl)(heterocyclyl) groups, -C(=O)N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; R 15 and R' 9 may be the same or different and are independently selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylaky groups, )11, C( )-alkyl groups, groups, -C(=0)Nffi, -C(=O)NH(alkyl) groups, .=Q)NH(aryl) groups, -C(=0)N(alkyl)2 groups, -C(=0)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl, substituted or unsubstituted diheterocyclyLaminoalkyl, substituted or. unsubstituted (heterocyclyl)(alkyl)aminoalkyl, substituted or unsubstituted (heterocyclyl)(aryl)aminoalk, substituted or unsubstituted alkoxyalkyl. groups, substituted or -unsubstituted hydroxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;.
R 1 6 and R 0 may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups; and RW' may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups,.substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, 0C) -C(=Q)-alkyl groups, -C(=O)-aryl groups,-C(=O)NH2, -C(=O)NII(alkyl) groups, -C(=Q)NH(aryl) groups, -C(=O)N(akl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -C(=Q)O-alkyl groups, -C(=O)O-aryl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoallcyl groups, substituted -or unsubstituted alkylaninoalicyl groups, substituted or unsubstituted dialkylaininoalkyl groups, substituted or unsubstituted arylaminoakl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, 0)-heterocyclyl groups, O)-O-heterocyclyl groups, -C(=O)NH(heterocyclyl) groups, =O)-N(heterocyclyl)2 groups, O)N(alkyl)(hetero .cyclyl) groups, -C(='O)-N(aryl)Qi (eterocyclyl) groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;
R"
3 R?47 and R?5 may be the same or different and are independently selected from H, NIL, -NH(alkyl) groups, -NH(aryl).groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups,. -NH(heterocyclyl).
groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyc-lyl)(aryl). groups, -N(heterocyclyl)2 groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -OH, substituted or unsubstituted alkoxy groups, substituted. or unsubstituted aryloxy groups, substituted or. unsubstituted heterocyclyl groups, -NHOH, -N(allcyl)QH groups, -N(aryl)OH groups, -N(alkyl)O-alkyl groups, -N(aryl)O -alkyl groups, -N(alkyl)O-aryl groups, or -:N(aryl)O-aryl groups; and RF is selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl 00 groups.
In the third group of compounds, at least one of R, R 6 W, or R' is selected from substituted or unsubstituted amidinyl groups, substituted or ttn unsubstituted guanidinyl groups, substituted or unsubstituted saturated heterocyclyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl. groups, substituted or unsubstituted arylaininoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyaikyl groups; -OR 9 groups where R" 9 is selected from substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=O)-aryl. groups, -C(=O)NH2, O)NH(alcyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl)2 groups,. -CQ=O)N(aryl)2 groups, -C(=0)N(alkl)(aryl) groups, substituted or unsubstituted aminoallcyl groups, substituted or unsubstituted alkylaminoalkyl. groups, substituted or unsubstituted diaklaininoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalcyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted. diheterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl1)(alkyl)aniinoalcyl groups, substituted or unsubstituted' (lieterocyclyl)(aryl)aminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted -or unsubstituted aryloxyalcl groups, or substituted and unsubstituted heterocyclyloxyalkyl groups; -NR 2 0
R
2 groups where RO is selected from substituted or unsubstituted heterocyclyl groups; -NR 2 0
R
2 groups where R 2 s selected from substituted or unsubstituted heterocyclyl groups, 0)11, 0)-aryl groups,-C(=O)N~H, -22- -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -CQ=O)N(alcyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, substituted or unsubstituted aminoalkyl groups, substituted 00 o nusiue lyaio~lgopsbtttdo nusiue oruIbtttdaNyaDnaklgrus usiuedo nusiue dialkylanilnoakl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaininoalkyl groups, substituted or unsubstituted (alkyl)(aryl)arminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or.
unsubstituted alkoxyalkyl. groups, substituted or unsubstituted aryloxyalcyl groups, substituted or unsubstituted heterocyclylalcyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; or groups where R?5 is selected from H, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)7 groups, -N(ary)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2 groups., substituted or unsubstituted aryl groups, substituted or unsubstituted aryloxy groups, or substituted or unsubstituted heterocyclyl groups.
The invention provides a fourth group of compounds having. the structure 1, tautomers of the compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutically acceptable salts of the -tautomers., In the fourth group of compounds: Y is selected from -OH, SH, alkylthio groups, aryithio groups, -OR' 0 groups, groups, -NR1 2 R 1 3 groups, -CN, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkenlyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted aralkyl groups,'substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaniinoalcyl'groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalcyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted orunsubstituted heterocyclyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, 00 IND or substituted or unsubstituted aryloxyalkyl groups; Z is selected from O, S, or NR' groups;
R
2
R
3 and R 4 may be the same or different and are CI independently selected from H, Cl, Br, F, I, -CN, -NO2, -OH, -OR's groups,
-NR'
6
R'
7 groups, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or.unsubstituted diarylaminoalkyl groups, substituted or.unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups,.or O)R' 8 groups;.
R, R, R 7 and R may be the same or different and are independently selected from H, Cl, Br, F, I, -NO2, -OH, -OR" groups, -NR"R 2
I
groups, -SH, -SR groups, groups, -S(=O)2Re groups, -CN, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkylainoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=O)R5 groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted. heterocyclylaininoalkyl groups, substituted or unsubstituted. hydroxyalcy groups, substituted or unsubstituted alkoxyalkyl groups, -substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted 00 heterocyclyloxyalkyl groups; le and R 1 4 may be the same or different and are independently selected from H, -OH, substituted or unsubstituted ailkoxy groups, substituted or unsubstituted aryloxy groups, -NIR; substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylanino groups, substituted or unsubstituted diarylaniino groups, substituted or unsubstituted (alkyl)(aryl)amino groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -C(=O)-alkyl groups, or -C(=O)-aryl groups; R1 0 is selected -from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=O)-alkyl groups, -C(=Q)-aryl groups, -C(=O)O-alkyl groups, -C(=O)O-aryl.
groups, O)NH21 O)NH(alkyl) groups, O)NH(aryl) groups,: -C(=O)N(alkyl)2 groups, -C(=O).N(aryl)2* groups, -C(=O)N(alky)(aryl) groups, -NHM, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(alkyl)(aryl) groups, -N(aryl)2 groups, -C(=O)NH(heterocyclyl) groups, -C(=O)N(heterocyclyl)2 groups., =O)N(alkyl)(heterocyclyl) groups, or =O)N(aryl)(heterocyclyl) groups; R" is selected from H, -OH, ailcoxy groups, aryloxy groups, -Nib, -NiI(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, substituted or unsubstituted alkyl groups, -NH~heterocyclyl) groups, -N(heterocyclyl)2 groups, -N(allcyl)(heterocyclyl) groups, or substituted or unsubstituted aryl groups; R 1 2 is selected from H, substituted or unsubstituted alkyl groups, substituted or uxisubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups; 00 R' is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted. or unsubstituted heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, -N112, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaninoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalcyl groups, substituted or unsubstituted alkylanno groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylamnino groups, substituted or unsubstituted diarylaniino groups, substituted or unsubstituited (allcl)(aryl)amino groups, )-alkyl groups, -C(=O)-aryl groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, -C(=O)N1, -C(=O)NH(alcyl) groups, -C(=O)NH(ary) groups, -C(=O)N(alkyl)2 groups, O)N(aryl)i groups, -C(=O)N(alkyI)(aryl) groups, -C(=-O)-heferocyclylgroups, =)-O-heterocyclyl groups, -C('=O)NH(heterocyclyl) groups,.
C(=O)N(heterocycly)2 groups, -C(=O)N(alky)(hterocycIly) groups, -C(=O)N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylanuinoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted aloxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalcyl groups;
R'
5 and R'may be the. same or different and are independently selected from substituted or unsubstituted. alkyl groups, substituted or unsubstituted aryl groups, substituted or. unsubstituted heterocyclyl groups, substituted or unsubstituted. heterocyclylalkyl groups, O)H, 0)-alkyl groups, -CQ=O)-aryl groups, -C(=O)NE2, C(:=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(akl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, substituted or unsubstituted amioalkyl groups, substituted or unsubstituted alkylaminoalcyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups; substituted or unsubstituted (allcyl)(aryl)aniinoalkyl 00 groups, substituted or unsubstituted heterocyclylaminoalcyl, substituted or: NOn u si u e i e e o y l l ni oal y, s b tt t d o n u si u e 0 5 unubtite(dheterocyclyl)akl aminoalkyl, substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl, substituted or unsubstitutedakoalygrus substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclylox'yalkyl groups; R' and e~ may be the same or different and are independently selected from H, substituted. or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups; RI 7 and RW' may be the same or different And are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups,.
-C(=O)-alkyl groups, -C(=O)-aryl groups,-C(.=Q)N~H, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl)2.groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -C(=0)O-aikyl groups, -C(=O)Q-aryl groups, substituted or unsubstituted heterocyclylatkyl groups,substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylamninoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aniinoalkyl groups, )-heterocyclyl groups, O)-O-heterocyclyl groups, ±O)NH(heterocyclyl) groups, O)-N(heterocyclyl)2 groups, zO)-N(alcyl)(heterocyclyl) groups, -C(=O)-N(ary)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaniinoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl -groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; -27-
R'
8 R~ 2 ,and may be the same or dferent and are independently selected from H, -NiH, -NH(alcyl) groups, -NH(aryl) groups, 00 -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) IND groups,. -N(heterocycly)(all) groups, -N(heterocyc-lyl)(aryl) groups, Nl 5 -N(heterocyclyl)2 groups, substituted or unsubstituted alkyl groups, substituted or c-I unsubstituted aryl groups, -OH1, substituted or unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, substituted or unsubstituted heterocyclyl c-i groups, -NHOH, -N(allcyl)OH groups, -N(aryl)OH groups, -N(alkyl)O-alkyl groups, -N(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, or -N(aryl)Q-aryl groups; and.
R22 is* selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups.
In the fourth -group of compounds, at least one of R 2 or R 4 is an -OR' 5 group'and R' is selected from substituted or unsubstituted heterocycl ylalkyl groups, substituted or unsubstituted'dialkylarninoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted .(alyl)(aryl)aminoalkyl groups, substituted or unsubsti 'tuted heterocyclyl -groups, substituted or unsubstituted. heterocyclylaminoalkyl groups, substituted or unsubstituted diheterocyclylaminoalcyl groups, substituted or unsubstituted (beterocyclyl)(ak)aniinoalkyl groups, or substituted or unsubstituted (becterocyclyl)(aryl)anoalkyl groups.
Preferred compounds in any of the first, second, or third groups described above are provided in Which Z is an _Np1 4 preferred compound. of the fourth group are also provided in which Z is an -NR'O group.
1 Preferred compounds according to the first, second, third, and fourth groups of compounds are provided in which Y-is an -ORo group, an-NR 2
R
1 group, or a substituted or unsubstituted alkynyl group.
00 IN Other preferred compounds of the first, second, third, and fourth S 5 groups are provided in which R' is selected from H, substituted or unsubstituted alkoxy groups, substituted or unsubstituted heterocyclylalkoxy groups, substituted Sor unsubstituted heterocyclyloxy groups, or substituted or unsubstituted heterocyclyl groups.
Still further provided are compounds of the first, second, third, and fourth groups in which R 2 is selected from the group consisting of H, F, Cl, -N02, substituted and unsubstituted heterocyclylalkoxy groups, and substituted and unsubstituted heterocyclyl groups.
Still further provided are compounds of the first, second, third, and fourth groups in which R 6 or R 7 is an alkyl group. Still further preferred compounds of the four groups are those in which R 6 or R 7 is an -OR 1 9 group and
R
1 9 is an alkyl group, an aryl group, a heterocyclyl group, or a heterocyclylalkyl group.
Preferred compounds of the fourth group of compounds are provided in which R' is an -ORu group and R" is selected from substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted diheterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkyl groups, or substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl groups.
-29- The invention further provides compounds having the structure II.
The invention provides tautomers of the compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutically acceptable salts of the tautomers.
00 IDStructure II has the following formula R6 R' N 3 R 7R NXL -X
H
II
where: Y is selected from H, -OH, -OR 0 .groups, -SH, -SR" groups, -NR1RI3 groups, -CN, 4 groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted aralkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalcyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;
X
2
X
3 and X are selected from C or N, and at least one of X', x, X 3 and X 4 is N;
W
2 RI, R 4 ,W RW R 7 and.R 8 may be the same or different and are independently selected from H, Cl, Br, F, I, -NO2., -CN, -OH, -OR 5 groups,
-NR
7 groups, -C(=O)R 8 groups, -SH, -SR' 9 groups, groups, 0C) S(=O)2R 2 groups, substituted or unsubstituted ainidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or te rtiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alcenyl groups, substituted or unsubstituted alkynyl. groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkylaniinoalkyl. groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylamioalkyl groups, substituted or unsubstituted.
diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted anulnoalkyl groups, substituted or unsubstituted.
heterocyclylanuinoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; W is.absent oris HifX' is N;RWis absent oris Hif X 2 is N; R 7 is absent or is HifX is N; and R 8 isabsent or is HifX0is N; R! is selected from H, -OH, substituted or unsubstituted alkoxy groups, substituted or-unsubstituted aryloxy groups, -NiH, substituted or unsubstituted alkylamino groups, substituted or .unsubstituted. arylamino groups, substituted or unsubstituted diallcylamino groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (alkyl)(aryl)amino groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -C(=O)-alcyl groups, or, C(=O)-aryl groups;
WO
0 is selected from substituted or unsubstituted. ailcyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(0)H, -C(=O)-alkyl groups, -C(=O)-aryl groups, -C(=O)O-alkyl. groups, -C(=O)O-aryl groups, -C(=O)NH2, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=Q)N(alcyl)2 groups, O)N(aryl)2 'groups, O)N(alkyl) (aryl) groups, -NH2, NH(alkyl) groups, -NH(aryl) groups, -N(alcyl)2 groups, -N(alkyl)(aryl) groups, -N(aryl)2 groups, -C(=O)NH(heterocyclyl) groups, IND -C(=O)N(heterocyclyl)2 groups, -C(=Q)N(alkyl)(heterocyclyl) groups, or N 5 -C(=O)N(aryl)(heterocyclyl) groups; ttn R" and R1 9 may be the same or different and are independently selected from substituted or unsubstituted alkyl groups, or substituted or unsubstituted aryl groups; R 1 2 is selected from H, substituted or unsubstituted aikyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups; R 1 3 is S elected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -01H, alkoxy groups, aryloxy groups, -NH2,. substituted or unsubstituted .heterocyclylakl groups, substituted or unsubstituted aminoalkyl. groups, -substituted or uusubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylamiiioalkyl groups, substituted or unsubstituted arylaminoalkyl-groups, substituted or unsubstituted diarylaininoalkyl -groups, -substituted -or. unsubstitu ted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted alkylamino- groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstituted diarylaniino groups, substituted or unsubstituted (alkyl)(aryl)amino groups, -C(=O)-alcyl groups,: C(=0)-aryl groups, -C(=Q)O-alkyl groups, O)Q-aryl. groups, -C(=O)NH2, -C(=O)NH(alcyl).groups, -C(=O)NH(aryl) groups, -C(-=O)N(all)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alcyl)(aryl) groups, -C(=O)-heterocyclyl groups, =O)-O-heterocyclyl groups, =O)NH(heterocyclyl) groups., =O)N(heterocycly)2 groups, O)N(alkyl)(heterocyclyl) groups, -C(=O)N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoalcyl groups, substituted or unsubstituted hydroxyalkyl groups, 4 substituted or unsubstituted alkoxyakl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;.
R 1 4 is selected from H, -OH, alkoxy groups,. aryloxy groups, -Nfl2, IND-NH(alkyl) groups, -NH(aryl) groups, -N(alkl)2 groups, -N(aryl)2 groups, CI 5 -N(alkyl)(aryl) groups, substituted or unsubstituted ailkyl groups, substituted or c-I unsubstituted aryl groups, -NH(heterocyclyl) groups, -N(heterocyclyl)2 groups, N(alkyl)(heterocyclyl) groups, or -N(aryl)(heterocyclyl) groups; R'1 2 and k1 3 may join together to form a 5 to 7 membered saturated or unsaturated, substituted or unsubstituted N-containing ring; R15 is selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted. or unsubstituted heterocyclylalkyl groups, -C(=0)-alkyl -groups, -C(=O)-aryl groups, -C(=O)NH(alkyl) groups, -C(=O)NII(aryl) groups, =O)N(akyl)2 groups, O)N(aryl)2 groups, O)N(alkyl)(aryl) groups, substituted or unsubstituted aninoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups,:substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaininoalkyl groups, -substituted or unsubstituted (allcyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted diheterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl)(allcyl)aminoalkyl groups, substituted or unsubstituted (heterocyclyl)(aryl)aminoalcyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstitute d aryloxyalkyl groups, -substituted or unsubstituted hydroxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;
R'
6 i§ selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups;
R"
7 is selected from H, -substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -C(=O)-alcyl groups, -C(=O)-aryl groups, 00 IND-C(=O)NH(akl) groups, -C(=O)NH(aryl) groups, -C(=O)N(akl)2 groups, ci 5 -C(=O)N(aryl)2 groups, -C(=O)N(alkl)(aryl) groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, substituted or unsubstituted ammnoalcyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalcyl groups, substituted or unsubstituted arylaminosilcyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (aryl)(alkyl)aniinoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=O)-heterocyclyl groups, =O)-O-heterocyclyl groups, Q)NH(heterocyclyl) groups, )-N(heterocyclyl)2 groups, Q)-N(alkyl)(heterocyclyl) groups, =O)-N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoakl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, -0OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted. aryloxy groups, or. -NFIh groups;,
R
1 6 and R 17 may join together to form a 5 to 7 membered saturated or unsaturated, substituted or unsubstituted N-containing ring; and R1 8 Rand W' may be the same or different and are independently selected from H, -NH2, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups-, -N(aryl)2 groups, -N(alkyl)(aryl) groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, substituted or unsubstituted heterocyclyl groups, -NHOH, -N(alkyl)QH groups, -N(aryl)OH. groups,.
-N(alkyl)O-alkyl groups, -N(aryl)O-alkyl groups, -N(alkl)O-aryl groups, or -N(aryl)O-aryl groups.
I -34- Preferred compounds having structure II are also provided where Y is selected from H, -OH, -OR' 1 groups, or -NR' 2 R' groups.
Still other preferred compounds having structure II are provided IO where at least two of X 2
X
3 and X 4 are C and the corresponding substituents
O
c 5 R 5
R
6
R
7 and R 8 are hydrogen, and at least one of X 2
X
3 and X 4 is N, and C- the rest of the compound is consistent with any of the above-described compounds.
SStill other more preferred compounds of structure II are provided in which R 6 or R 7 is an alkyl group and the rest of the compound is consistent with any of the above-described compounds.
Still other compounds of structure II are provided in which R 6 or R 7 is an -OR" 5 group and Ru is an alkyl, aryl, heterocyclyl, or heterocyclylalkyl group and the rest of the molecule is consistent with any of the above-described compounds.
Still further compounds having the formula of structure II are provided in which R' is selected from H, substituted or unsubstituted alkoxy groups, substituted or unsubstituted heterocyclylalkoxy groups, substituted or unsubstituted heterocyclyloxy groups, or substituted or unsubstituted heterocyclyl groups.
Still other compounds having the Structure If are provided in which In other compounds having the structure II, R 2 is selected from H, F, Cl, -NO2, substituted or unsubstituted heterocyclyl groups, or substituted or unsubstituted heterocyclylalkoxy groups.
Pharmaceutical formulations according to the present invention are provided which include any of the compounds described above in combination with a pharmaceutically acceptable carrier.
A method of treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase is provided which includes CcO administering an effective amount of the. pharmaceutical formulation according to the present invention to a patient in need thereof.
00 \O Further objects, features and advantages of the invention will be apparent from the following detailed description.
In DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel compounds that act as antagonists of receptor tyrosine kinases, and, more particularly, as inhibitors of bFGF and/or VEGF-RTK function. The compounds provided herein can be formulated into pharmaceutical formulations that are useful in treating patients with a need for an inhibitor of VEGF-RTK, especially, in particular embodiments, to provide compositions and methods for reducing capillary proliferation and in the treatment of cancer.
The following abbreviations and definitions are used throughout this application: "VEGF" is an abbreviation that stands for vascular endothelial growth factor.
"RTK" is an abbreviation that stands for receptor tyrosine kinase.
"VEGF-RTK" is an abbreviation that stands for vascular endothelial growth factor receptor tyrosine kinase.
"Flt-1" is an abbreviation that stands for fins-like tyrosine kinase-1, also known as vascular endothelial growth factor receptor-i or "VEGFR1".
"KDR" is an abbreviation that stands for kinase-.insert domaincontaining receptor, also known as vascular endothelial growth factor.receptor-2 or "VEGFR2".
S-36- "bFGF" is an abbreviation that stands for basic fibroblast growth factor.
00 "bFGFR" is an abbreviation that stands for basic fibroblast growth I factor receptor.
S 5 Generally, reference to a certain element such as hydrogen or H is meant to include all isotopes of that element. For example, if an R group is defined to include hydrogen or H, it also includes deuterium and tritium.
The phrase "unsubstituted alkyl" refers to alkyl groups that do not contain heteroatoms. Thus the phrase includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. The phrase also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following which are provided by way of example: -CH(CH3)2, -CH(CH3)(CH2CH3), -CH(CH2CH3)2, -C(CH3)3, -C(CH2CH3)3, -CH2CH(CH)2,. -CH2CH(CH3)(CH2CH3), -CH2CH(CH2CH3)2, -CH2C(CH3)3, -CH2C(CH2CH3)3, -CH(CH3)CH(CH3)(CH2CH), -CH2CH2CH(CH)2, -CH2CH2CH(CH3)(CH2CH3), -CH2CH2CH(CH2CH3)2, -CH2CH2C(CH3)3, -CH2CH2C(CH2CH3)3, -CH(CH3)CH2CH(CH3)2, -CH(CH3)CH(CHI)CH(C H3) 2 -CH(CH2CH3)CH(CH3)CH(CH3)(CH2CH), and others. The phrase also includes cyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl and such rings substituted with straight and branched chain alkyl groups as defined above. The phrase also includes polycyclic alkyl groups such as, but not limited to, adamantyl norbornyl, and bicyclo[2.2.2]octyl and such rings substituted with straight and branched chain alkyl groups as defined above. Thus, the phrase unsubstituted alkyl groups includes primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups. Unsubstituted alkyl groups may be bonded to one or more carbon atom(s), oxygen atom(s), nitrogen atom(s), and/or sulfur atom(s) in the parent compound.
Preferred unsubstituted alkyl groups include straight and branched chain alkyl groups and cyclic alkyl groups having 1 to 20 carbon atoms. More preferred such -37unsubstituted alkyl groups have from 1 to 10 carbon atoms while even more preferred such groups have from 1 to 5 carbon atoms. Most preferred unsubstituted alkyl groups include straight and branched chain alkyl groups having from 1 to 3 00 \0 carbon atoms and include methyl, ethyl, propyl, and -CH(CI3)2.
O
The phrase "substituted alkyl" refers to an unsubstituted alkyl group I as defined above in which one or more bonds to a carbon(s) or hydrogen(s) are 0 replaced by a bond to non-hydrogen and non-carbon atoms such as, but not limited to, a halogen atom in halides such as F, Cl, Br, and I; and oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, Noxides, imides, and enamines; a silicon atom in groups such as in trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl. groups, and triarylsilyl groups; and other heteroatoms in various other groups. Substituted alkyl groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carbonyl, carboxyl, and ester groups; nitrogen in groups such as imines, oximes, hydrazones, and nitriles. Preferred substituted alkyl groups include, among others, alkyl groups in which one or more bonds to a carbon or hydrogen atom is/are replaced by one or-more bonds to fluorine atoms.. One example of a substituted alkyl group is the trifluoromethyl group and other alkyl groups that contain the trifluoromethyl group. Other alkyi groups include those in which one or more bonds to a carbon or hydrogen atom is replaced by a bond to an oxygen atom such that the substituted alkyl group contains a hydroxyl, alkoxy, aryloxy group, or heterocyclyloxy group. Still other alkyl groups include alkyl groups that have an amine, alkylamine, dialkylamine, arylamine, (alkyl)(aryl)amine,diarylamine, heterocyclylamine, (alkyl)(heterocyclyl)amine, (aryl)(heterocyclyl)amine, or diheterocyclylamine group.
The phrase "unsubstituted aryl" refers to aryl groups that do not contain heteroatoms. Thus the phrase includes, but is not limited to, groups such as phenyl, biphenyl, anthracenyl, naphthenyl by way of example. Although the phrase "unsubstituted aryl" includes groups containing condensed rings such as naphthalene, it does not include aryl groups that have other groups such as alkyl or halo groups bonded to one of the ring members, as aryl groups such as tolyl are considered herein to be substituted aryl groups as described below. A preferred unsubstituted aryl group is phenyl. Unsubstituted aryl groups may be bonded to one or more carbon atom(s), oxygen atom(s), nitrogen atom(s), and/or sulfur atom(s) in the parent compound, however.
The phrase "substituted aryl group" has the same meaning with respect to unsubstituted aryl groups that substituted alkyl groups had with respect to unsubstituted alkyl groups. However, a substituted aryl group also includes aryl groups in which one of the aromatic carbons is bonded to one of the non-carbon or non-hydrogen atoms described above and also includes aryl groups in which one or more aromatic carbons of the aryl group is bonded to a substituted and/or unsubstituted alkyl, alkenyl, or alkynyl group as defined herein. This includes bonding arrangements.in which two carbon atoms of an aryl group are bonded to two atoms of an alkyl, alkenyl, or alkynyl group to define a fused ring system (e.g.
dihydronaphthyl or tetrahydronaphthyl). Thus, the phrase. "substituted aryl" includes, but is not limited to tolyl, and hydroxyphenyl among others.
The phrase "unsubstituted alkenyl" refers to straight and branched chain and cyclic groups such as those described with respect to unsubstituted alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Examples include, but are not limited to vinyl, -CH=C(H)(CH3), -CH= C(CH3) 2 -C(CH3)=C(H)2, -C(CH3)=C(H)(CH3), -C(CH2CH3)=CH2, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.
-39- The phrase "substituted alkenyl" has the same meaning with respect to unsubstituted alkenyl groups that substituted alkyl groups had with respect to unsubstituted alkyl groups. A substituted alkenyl group includes alkenyl groups in which a non-carbon or non-hydrogen atom is bonded to a carbon double bonded to another carbon and those in which one of the non-carbon or non-hydrogen atoms is bonded to a carbon not involved in a double bond to another carbon.
The phrase "unsubstituted alkynyl" refers to straight and branched chain groups such as those described with respect to unsubstituted alkyl groups as defined above, except that at least one triple bond exists between two carbon atoms.
Examples include, but are not limited to -C-C(CH3), -C-C(CH2CH3), -C(H)2C=C(CH3), and -C(H)2C=C(CH2CH3) among others.
The phrase "substituted alkynyl" has the same meaning with respect to unsubstituted alkynyl groups that substituted alkyl groups had with respect to unsubstituted alkyl groups. A substituted alkynyl group includes alkynyl groups in which a non-carbon or non-hydrogen atom is bonded to a carbon triple bonded to another carbon and those in which a non-carbon or non-hydrogen atom is bonded to a carbon not involved in a triple bond to another carbon.
The phrase "unsubstituted aralkyl" refers to unsubstituted alkyl groups as defined above in which a hydrogen or carbon bond of the unsubstituted alkyl group is replaced with a bond to an aryl group as defined above. For example, methyl (-CH 3 is an unsubstituted alkyl group. If a hydrogen atom of the methyl group is replaced by a bond to a phenyl group, such as if the carbon of the methyl were bonded to a carbon of benzene, then the compound is anunsubstituted aralkyl group a benzyl group). Thus the phrase includes, but is not limited to, groups such as benzyl, diphenylmethyl, and 1-phenylethyl (-CH(C6Hs)(CH3)) among others.
The phrase "substituted aralkyl" has the same meaning with respect to unsubstituted aralkyl groups that substituted aryl groups had with respect to unsubstituted aryl groups. However, a substituted aralkyl group also includes i groups in which a carbon or hydrogen bond of the alkyl part of the group is replaced by a bond to a non-carbon or a non-hydrogen atom. Examples of substituted aralkyl groups include, but are not limited to, -CH2C(=O)(C6H5), and 00 -CH2(2-methylphenyl) among others.
O
N 5 The phrase "unsubstituted heterocyclyl" refers to both aromatic and C. nonaromatic ring compounds including monocyclic, bicyclic, and polycyclic ring Scompounds such as, but not limited to, quinuclidyl, containing 3 or more ring C members of which one or more is a heteroatom such as, but not limited to, N, O, and S. Although the phrase "unsubstituted heterocyclyl" includes condensed heterocyclic rings such as benzimidazolyl, it does not include heterocyclyl groups that have other groups such as alkyl or halo groups bonded to one of the ring members as compounds such as 2-methylbenzimidazolyl are substituted heterocyclyl groups. Examples of heterocyclyl groups include, but are not limited to: unsaturated 3 to 8 membered rings containing 1 to 4 nitrogen atoms such as, but not limited to pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl 4H-1,2,4-triazolyl, 1H-1,2,3triazolyl, 2H-1,2,3-triazolyl etc.), tetrazolyl, IH-tetrazolyl, 2H tetrazolyl, etc.); saturated 3 to 8 membered rings containing 1 to 4 nitrogen atoms such as, but not limited to, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl; condensed unsaturated heterocyclic groups containing 1 to 4 nitrogen atoms such as, but not limited to, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl; unsaturated 3 to 8 membered rings containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms such as, but not limited to, oxazolyl, isoxazolyl, oxadiazolyl 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5oxadiazolyl, etc.); saturated 3 to 8 membered rings containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms such as, but not limited to, morpholinyl; unsaturated condensed heterocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, benzoxazolyl, benzoxadiazolyl, benzoxazinyl 2H-1,4benzoxazinyl etc.); unsaturated 3 to 8 membered rings containing 1 to 3 sulfur atoms and 1 to 3 nitrogen atoms such as, but not limited to, thiazolyl, isothiazolyl, thiadiazolyl 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5a -41thiadiazolyl, etc.); saturated 3 to 8 membered rings containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms such as, but not limited to, thiazolodinyl; saturated and unsaturated 3 to 8 membered rings containing 1 to 2 sulfur atoms such as, but not IND limited to, thienyl, dihydrodithiinyl, dihydrodithionyl, tetrahydrothiophene, CN 5 tetrahydrothiopyran; unsaturated condensed heterocyclic rings containing 1 to 2 C sulfur atoms and 1 to 3 nitrogen atoms such as, but not limited to, benzothiazolyl, Sbenzothiadiazolyl, benzothiazinyl 2H-1,4-benzothiazinyl, etc.), C1 dihydrobenzothiazinyl 2H-3,4-dihydrobenzothiazinyl, etc.), unsaturated 3 to 8 membered rings containing oxygen atoms such as, but not limited to furyl; unsaturated condensed heterocyclic rings containing 1 to 2 oxygen atoms such as benzodioxolyl 1,3-benzodioxoyl, etc.); unsaturated 3 to 8 membered rings containing an oxygen atom and 1 to 2 sulfur atoms such as, but not limited to, dihydrooxathiinyl; saturated 3 to 8 membered rings containing 1 to 2 oxygen atoms and 1 to 2 sulfur atoms such as 1,4-oxathiane; unsaturated condensed rings containing 1 to 2 sulfur atoms such as benzothienyl, benzodithiinyl; and unsaturated condensed heterocyclic rings containing an oxygen atom and 1 to 2 oxygen atoms such as benzoxathiinyl. Heterocyclyl group also include those described above in which one or more S atoms in the ring is double-bonded to one or two oxygen atoms (sulfoxides and sulfones). For example, heterocyclyl groups include tetrahydrothiophene, tetrahydrothiophene oxide, and tetrahydrothiophene 1,1dioxide. Preferred heterocyclyi groups contain 5 or 6 ring members. More :preferred heterocyclyl groups include morpholine, piperazine, piperidine, pyrrolidine, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, thiomorpholine, thiomorpholine in which the S atom of the thiomorpholine is bonded to one or more O atoms, pyrrole, homopiperazine, oxazolidin-2-one, pyrrolidin-2-one, oxazole, quinuclidine, thiazole, isoxazole, furan, and tetrahydrofuran.
The phrase "substituted heterocyclyl" refers to an unsubstituted heterocyclyl group as defined above in which one of the ring members is bonded to a non-hydrogen atom such as described above with respect to substituted alkyl groups and substituted aryl groups. Examples, include, but are not limited to, 2- S •methylbenzimidazolyl, 5-methylbenzimidazolyl, 5-chlorobenzthiazolyl, 1-methyl piperazinyl, and 2-chloropyridyl among others.
00 The phrase "unsubstituted heterocyclylalkyl" refers to unsubstituted N alkyl groups as defined above in which a hydrogen or carbon bond of the S 5 unsubstituted alkyl group is replaced with a bond to a heterocyclyl group as defined above. For example, methyl (-CHI) is an unsubstituted alkyl group. If a hydrogen Satom of the methyl-group is replaced by a bond to a heterocyclyl group, such as if c-l the carbon of the methyl were bonded to carbon 2 ofpyridine (one of the carbons bonded to the N of the pyridine) or carbons 3 or 4 of the pyridine, then the compound is an unsubstituted heterocyclylalkyl group.
The phrase "substituted heterocyclylalkyl" has the same meaning with respect to unsubstituted heterocyclylalkyl groups that substituted aralkyl groups had with respect to unsubstituted aralkyl groups. However, a substituted heterocyclylalkyl group also includes groups in which a non-hydrogen atom is bonded to a heteroatom in the heteroeyclyl group of the heterocyclylalkyl group.
such as, but not limited to, a nitrogen atom in the piperidine ring of a piperidinylalkyl group.
The phrase "unsubstituted alkylaminoalkyl" refers to an unsubstituted alkyl group as defined above in which a carbon or hydrogen bond is replaced by a bond to a nitrogen atom that is bonded to a hydrogen atom and an unsubstituted alkyl group as defined above. For example, methyl (-CH3) is an unsubstituted alkyl group. If a hydrogen atom of the methyl group is replaced by a bond to a nitrogen atom that is bonded to a hydrogen atom and an ethyl group, then the resulting compound is -CH2-N(H)(CH2CIH) which is an unsubstituted alkylaminoalkyl group.
The phrase "substituted alkylaminoalkyl" refers to an unsubstituted alkylaminoalkyl group as defined above except where one or more bonds to a carbon or hydrogen atom in one or both of the alkyl groups is replaced by a bond to a non-carbon or non-hydrogen atom as described above with respect to substituted -43c alkyl groups except that the bond to the nitrogen atom in all alkylaminoalkyl groups does not by itself qualify all alkylaminoalkyl groups as being substituted. However, substituted alkylaminoalkyl groups does include groups in which the hydrogen I bonded to the nitrogen atom of the group is replaced with a non-carbon and non- C 5 hydrogen atom.
It The phrase "unsubstituted dialkylaminoalkyl.' refers to an O unsubstituted alkyl group as defined above in which a carbon bond or hydrogen bond is replaced by a bond to a nitrogen atom which is bonded to two other similar or different unsubstituted alkyl groups as defined above.
The phrase "substituted dialkylaminoalkyl" refers to an unsubstituted dialkylaminoalkyl group as defined above in.which one or more bonds to a carbon or hydrogen atom in one or more of the alkyl groups is replaced by a bond to a noncarbon and non-hydrogen atom as described with respect to substituted alkyl groups. The bond to the nitrogen atom in all dialkylaminoalkyl groups does not by itself qualify all dialkylaminoalkyl groups as being substituted.
The phrase "unsubstituted heterocyclyloxyalkyl" refers to an unsubstituted alkyl group as defined above in which a carbon bond or hydrogen Sbond is replaced by a bond to an oxygen atom which is bonded to an unsubstituted heterocyclyl group as defined above.
The phrase "substituted heterocyclyloxyalkyl" refers to an unsubstituted heterocyclyloxyalkyl group as defined above in which a bond to a carbon or hydrogen group of the alkyl group of the heterocyclyloxyalkyl group is bonded to a non-carbon and non-hydrogen atom as described above with respect to substituted alkyl groups or in which the heterocyclyl group of the heterocyclyloxyalkyl group is a substituted heterocyclyl group as defined above.
The phrase "unsubstituted arylaminoalkyl" refers to an unsubstituted alkyl group as defined above in which a carbon bond or hydrogen bond is replaced -44-
S
by a bond to a nitrogen atom which is bonded to at least one unsubstituted aryl group as defined above.
00 The phrase "substituted arylaminoalkyl" refers to an unsubstituted I arylaminoalkyl group as defined above except where either the alkyl group of the arylaminoalkyl group is a substituted alkyl group as defined above or the aryl group of the arylaminoalkyl group is a substituted aryl group except that the bonds to the Snitrogen atom in all arylaminoalkyl groups does not by itself qualify all
C
1 arylaminoalkyl groups as being substituted. However, substituted arylaminoalkyl groups does include groups in which the hydrogen bonded to the nitrogen atom of the group is replaced with a non-carbon and non-hydrogen atom.
The phrase "unsubstituted heterocyclylaminoalkyl" refers to an unsubstituted alkyl group as defined above in which a carbon or hydrogen bond is replaced by a bond to a nitrogen atom which is bonded to at least one unsubstituted heterocyclyl group as defined above.
The phrase "substituted heterocyclylaminoalkyl" refers to unsubstituted heterocyclylaminoalkyl groups as defined above in which the heterocyclyl group is a substituted heterocyclyl group as defined above and/or the alkyl group is a substituted alkyl group as defined above. The bonds to the nitrogen atom in all heterocyclylaminoalkyl groups does not by itself qualify all heterocyclylaminoalkyl groups as being substituted. However, substituted heterocyclylaminoalkyl groups do include groups in which the hydrogen bonded to the nitrogen atom of the group is replaced with a non-carbon and non-hydrogen atom.
The phrase "unsubstituted alkylaminoalkoxy" refers to an unsubstituted alkyl group as defined above in which a carbon or hydrogen bond is replaced by a bond to an oxygen atom which is bonded to the parent compound and in which another carbon or hydrogen bond of the unsubstituted alkyl.group is bonded to a nitrogen atom which is bonded to a hydrogen atom and an unsubstituted alkyl group as defined above.
The phrase "substituted alkylaminoalkoxy" refers to unsubstituted alkylaminoalkoxy groups as defined above in which a bond to a carbon or hydrogen atom of the alkyl group bonded to the oxygen atom which is bonded to the parent 00 \D compound is replaced by one or more bonds to a non-carbon and non-hydrogen C 5 atoms as discussed above with respect to substituted alkyl groups and/or if the hydrogen bonded to the amino group is bonded to a non-carbon and non-hydrogen Satom and/or if the alkyl group bonded to the nitrogen of the amine is bonded to a Snon-carbon and non-hydrogen atom as described above with respect to substituted alkyl groups. The presence of the amine and alkoxy functionality in all alkylaminoalkoxy groups does not by itself qualify all such groups as substituted alkylaminoalkoxy groups.
The phrase "unsubstituted dialkylaminoalkoxy" refers to an unsubstituted alkyl group as defined above in which a carbon or hydrogen bond, is replaced by a bond to an oxygen atom which is bonded to the parent compound and in which another carbon or hydrogen bond of the unsubstituted alkyl group is bonded to a nitrogen atom which is bonded to two other similar or different unsubstituted alkyl groups as defined above.
The phrase "substituted dialkylaminoalkoxy" refers to an unsubstituted dialkylaminoalkoxy group as defined above in which a bond to a carbon or hydrogen atom of the alkyl group bonded to the oxygen atom which is bonded to the parent compound is replaced by one or more bonds to a non-carbon and non-hydrogen atoms as discussed above with respect to substituted alkyl groups and/or if one or more of the alkyl groups bonded to the nitrogen of the amine is bonded to a non-carbon and non-hydrogen atom as described above with respect to substituted alkyl groups. The presence of the amine and alkoxy functionality in all dialkylaminoalkoxy groups does not by itself qualify all such groups as substituted dialkylaminoalkoxy groups.
i The phrase "unsubstituted heterocyclyloxy" refers to a hydroxyl Sgroup in which the bond to the hydrogen atom is replaced by a bond to a ring atom of an otherwise unsubstituted heterocyclyl group as defined above.
00 OO N The phrase "substituted heterocyclyloxy" refers to a hydroxyl group C 5 in which the bond to the hydrogen atom is replaced by a bond to a ring atom C, of an otherwise substituted heterocyclyl group as defined above.
SThe term "protected" with respect to hydroxyl groups, amine groups, and sulfhydryl groups refers to forms of these functionalities which are protected from undesirable reaction with a protecting group known to those skilled in the art such as those set forth in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. John Wiley Sons, New York, NY, (3rd Edition, 1999) which can be added or removed using the procedures set forth therein. Examples of protected hydroxyl groups include, but are not limited to, silyl ethers such as those obtained by reaction of a hydroxyl group with a reagent such as, but not limited to, t-butyldimethyl-chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers such as, but not limited to methoxymethyl ether, methythiomethyl ether, benzyloxymethyl ether, tbutoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate, and trifluoracetate. Examples of protected amine groups include, but are not limited to, amides such as, formamide, acetamide, trifluoroacetamide, and benzamide; imides, such as phthalimide, and dithiosuccinimide; and others. Examples of protected sulfhydryl groups include, but are not limited to, thioethers such as S-benzyl thioether, and S-4-picolyl thioether; substituted S-methyl derivatives such as hemithio, dithio and aminothio acetals; and others.
A "pharmaceutically acceptable salt" includes a salt with an inorganic base, organic base, inorganic acid, organic acid, or basic or acidic amino acid. As salts of inorganic bases, the invention includes, for example, alkali metals -47- Ssuch as sodium or potassium; alkaline earth metals such as calcium and magnesium or aluminum; and ammonia. As salts of organic bases, the invention includes, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, \D diethanolamine, and triethanolamine. As salts of inorganic acids, the instant C 5 invention includes, for example, hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid. As salts of organic acids, the instant invention Sincludes, for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. As salts of basic amino acids, the instant invention includes, for example, arginine, lysine and ornithine. Acidic amino acids include, for example, aspartic acid and glutamic acid.
Generally, the invention provides compounds including having the structure I. The invention also provides tautomers of the compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutically acceptable salts of the tautomers. Structure I has the following formula:.
R
6 R R" R R7Y Y Y N R R R N O
I
Preferred compounds having structure I are those within one of four groups.
-48- 4 In the first -group of compounds: Y is selected from -OR' 0 groups, groups, -NRJ 2 R1 3 groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted IND heterocyclylalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, NI 5. substituted or unsubstituted dialIcylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (allcyl)(aryl)aminoalkyl groups, substituted or N- unsubstituted heterocyclylaininoalkyl groups, substituted or unsubstituted satu rated heterocyclyl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, substituted or unsubstituted hydroxya .lkyl groups, or substituted or unsubstituted aryloxyalkyl groups; Z is selected from 0, S, or NR' 4 groups; RR and R 4 may be the same or.'different and are: independently selected from H, Cl, Br, F, I, -CN, -NO z, -OH, -OR' groups, _NR16R17 groups,- substituted or unsubstituted'amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaininoalkyl groups, substituted or unsubstituted dialkylarninoalkyl groups, substituted or unsubstituted arylaminoalcyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted diheterocyclylaminoalcyl groups, substituted or unsubstituted (hetprocyclyl)(alkyl)aminoalkyl groups, substituited or unsubstituted (heterocyclyl)(aryl)aniinoalkyl groups, or =O)R' 8 groups;
RRR
7 and W 8 may be the same or different and are independently selected from H, Cl, Br, F, 1, -N02, -OH, -OR"9 groups, -NRWR 2 1 groups, -SH, -SR22groups, -S(=O)Re groups, -S(=O)2R 24 groups', -CN, substituted or unsubstituted anidinyl groups, substituted or unsubstituted guanidinyi groups, substituted or unsubstituted primary, .secondary, or tertiary alkyl groups, substituted 00 g iue IDor unsubstituted aryl groups, -substituted or unsubstituted alkenyl goups, substiue or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, O)Re groups*, substituted or unsubstituted aruinoalkyl groups, substituted or unsubstituted allcylanuinoalkyl c-i groups, substituted or unsubstituted diallcylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)amnnoalkyl groups, substituted or unsubstituted heterocyclylanunoalkyl groups, substituted or unsubstituted diheterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkyl groups, substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxy alkcyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; le, and R 1 4 may be the same or different and-are independently selected from H, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, -NH2, substituted or unsubstituted aklamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (alkyli)(aryl)anuno groups, substituted or unsubstituted alkyl groups, substituted. or unsubstituted aryl groups, O)H, -C(=O0)-alkyl groups,. or -C(=O)-aryl groups; Rio) is selected from substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -C(=O)-akl groups, )-aryl groups, )0-alkyl groups, =)0-aryl groups, -C(=O)NH2, -C(=O)NH(alcl) groups, -C(=O)NH(aryl) groups, -C(=O)N(akl)2 groups, -C(=O)N(aryl)2 groups,.-C(=O)N(alkyl)(aryl) groups, -NH2, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(allcyl)(aryl) groups, -N(aryl)2 groups, -NH(heterocyclyl) groups,,-N(lieterocyclyl)2 grouips, -N(alkyl)(heterocyclyl) groups, -N(aryl)(heterocyclyl), =O)NH(heterocyclyl) groups, )N(heterocyclyl)2 groups, =O)N(alkyl)(heterocyclyl) groups, 00 -C(=O)N(aryl)(heterocyclyl) groups,. or substituted or unsubstituted 0 5 heterocyclylalkyl groups; R11 is selected from H, -NH2, -NH(alk) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)L.groups, -N(alkyl)(aryl) groups, NH(heterocyclyl) groups, -N(heterocyclyl)2 groups, -N(alkyl)(heterocyclyl) groups, -N(aryl)(heterocyclyl) groups, -0-alkyl groups, 0-aryl groups, heterocyclyloxyalkyl groups, or substituted or unsubstituted aryl groups; is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups; R 1 3 is selected from substituted or unsubstituted alkyl groups, substituted or umsbstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -0OH, alkoxy groups, aryloxy groups, -NH2, substituted or -unsubstituted lieterocYclylalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkyLaminoalkyl groups, -substituted or unsubstituted dialkylaminoalkl groups.- substituted, or unsubstituted arylaminoaHlcy groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylanino groups, substituted or unsubstituted.
dialkylamino groups, substituted or unsubstituted diarylanino -groups, substituted or unsubstituted (alkyl)(aryl)aniino groups, -C(=O)-alkyl groups, 0)-aryl groups, O)O-alkyl groups, O)O-aryl groups, O)NH2, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl); groups, 0)N(aryl)2 groups, -C(=0)N(Alyl)(aryl) groups, )-heterocyclyl groups, )-0-heterocyclyl groups, )NH(heterocyclyl) groups, -C(=0)-N(heterOCYClyl)2 groups, )N(arYl)(heterocyclyl) groups, substituted -51or unsubstituted heterocyclylaminoalcyl groups, substituted or unsubstituted hydroxyalcyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, substituted or unsubstituted heterocyclyloxyalkyl 00 INDgroups, -or C( =O)-N(alkl)(heterocyclyl) groups;
R'
5 and R 9 may be the same or different and are independently selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=0)-alkyl groups, 0)-aryl groups, -C(=O)NIh, O)NII(akl) groups, =O)NH(aryl) groups, -C(=O)N(akl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyClyl)2 groups, -N(alkyl)(heterocyclyl) groups, -N(aryl)(heterocyclyl) groups, substituted or unsubstituted arninoalkyl groups, substituted or unsubstituted alkylaniinoalkyl groups, substituted or unsubstituted dialkylaminoalkl groups, substituted or unsubstituted arylaminoalkyl 'groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (allcyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl, substituted or unsubstituted diheterocyclylaminoalkyl, substituted or unsubstituted (heterocyclyl)(akl)aniinoalkyl, substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl, substituted or unsubstituted alkoxyalkyigroups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted -aryloxyalkyl groups, or substituted -or-unsubstituted heterocyclyloxyalkyl groups;
R"
6 and R 0 may be the same or different and are independently.
selected from H, substituted or unsubstituted ailkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups;
R"
7 and W 2 may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -C(=O)-alkyl groups, -C(=O)-aryl groups,-C(=O)NH2, -C(=O)NH(alcyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl)2 groups, C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -C(=O)O-alcyl groups, -C(=O)O-aryl groups, substituted or unsubstituted heterocyclylalkyl groups, 00 substituted or unsubstituted andnoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkl groups, substituted or unsubstituted (alkyl)(aryl)aniinoa lkyl groups, -C(=O0)-heterocyclyl 'g'iroups, -C(=O)-O-heterocyclyl groups, O)NH(heterocyclyl) groups, Q)-N(heterocyclyl)2 groups, -C(=O)N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted diheterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkl groups, substituted or unsubstituted (heterocyclyl)(aryl)aniinoalkyl groups, substi .tuted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, subst ituted or unsubs .ti .tuted heteroc yclyloxyalkylq groups, or -IC( O)-N(alkyl)(heterocyclyl) g'roups;,
R
18 RRand R2' may be the same or different- and are.
independently selected from H, -NH2, -NH(alkyl). groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups,.
-N(heterocyclyl)2 groups, substituted or unsubstituted ailkyl groups, substituted or unsubstituted aryl groups, -OH, substituted or unsubstituted alicoxy groups, substituted. or unsubstituted heterocyclyl groups, substituted or unsubstituted aryloxy groups, heterocyclyloxy groups, -NHOH, -N(alkyl)OH groups, -N(aryl)QH groups, -N(alkyl)O-allcyl groups, -N4(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, or -N(aryl)O-aryl groups; a nd R' is selected from substituted or unsubstituted alkyl groups, substituted or unsubstit uted aryl groups, or substituted or unsubstituted heterocyclyl groups.
-53- In other embodiments of the invention, compounds of formula I above include a second group of compounds having the substituents described below: 00 IDY is selected from -OR'O groups, groups, -NR4R' 3 groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted.dialkylaminoalky groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted saturated heterocyclyl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, substituted or unsubstituted hydroxyalkyl groups, or substituted or unsubstituted aryloxyalkyl groups; Z is selected from 0, S, or NR'" groups;
R
2
R
3 and R 4 may be the same or different and are.
independently selected from H, Cl, Br, F, I, -CN, -NO2, -OH, -OR groups,
-NRR'
6 7 groups, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, and tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalky groups, substituted or unsubstituted heterocyclylalkyl groups, or -C(=O)R 8 groups; R, R 6
R
7 and R 8 may be the same or different and are independently selected from H, Cl, Br, F, I, -N02, -OH, groups, -NRR 2 groups, -SH, -SR groups, groups, -S(=O)2R groups, -CN, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, and tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, 00 substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl 0 5 groujps, substituted or unsubstituted heterocyclylailkyl groups, -C(=O)Re groups, substituted or unsubstituted axninoallcyl groups, substituted or unsubstituted *alkylamninoalkcyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyallcyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; R! is selected from the group consisting of -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, -NH2, substituted or. unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylanino groups, -substituted or unsubstituted diarylamino groups, substituted. or unsubstituted (alkyl)(aryl)amino groups, substituted or unsubstituted alkyl groups,. substituted or unsubstituted aryl groups, -C(=O)-alkyl groups, or -C(=O)-aryl gr oups;
R'
0 is selected from substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -C(=O)-alkyl -groups, -C(=O)-aryl. groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, -C(=O)NH2, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alcyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -NiH, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(alkyl)(aryl) groups, -N(aryl)2 groups, O)NH(heterocyclyl) groups, O)N(heterocycyl)2 groups, =O)N(alkyl)(heterocyclyl) groups, -C(=O)N(aryl)(heterocyclyl) groups, or substituted or unsubstituted heterocyclylalkyl groups; is selected from H, -NH2, NH(allcyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkl)(aryl) groups, -NH(heterocyclyl) groups, -N,(heterocyclyl)2 groups, -N(alkyl)(heterocyClyl) groups, -0-alkyl groups, 00 Oay rus usiue rnusiue ly rus rsbtttdo INDlgopsbtiue r'nusittdaklgop, rsbtttdo unsubstituted aryl groups; R 1 2 is selected from H, substituted or unsubstituted ailkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl C1 groups.; R 1 3 is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstitut ed aryl groups, substituted or unsubstituted heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, -NH2, substituted or unsubstituted ailkylamino groups, substituted or unsubstituted arylanino groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstitated diarylamino groups, substituted or unsubstituted (alkyl)(aryl)axnino groups, C(=O)-alk groups, -C(=O)-aryl groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, -C(0)NH2, -C(=O)NH(alkYl) groups, -C(=Q)NH(aryl) groups, -C(=O)N(alkyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) gro Iups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaninoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups,. substituted or unsubstituted diarylamnoalkyl groups, substituted or unsubstituted (allcyl)(aryl)arninoalkyl groups, =0)-heterocyclyl groups, O)-O-heterocyclyl groups, -C(=O)NH(heterocyclyl) groups, Q)N(heterocyclyl)2 groups, )N(aryl)(heterocyclyl) groups, -C(=O)N(alkyl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaninoalkyl. groupsj substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkylI groups, substituted or unsubstituted aryloxyalkyl groups;, or substituted or unsubstituted heterocyclyloxyalk groups; -56- R 1 4 is selected fromn H, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted'aryloxy groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylarnino groups, 00susiueorusbtttddaklmogopsbtttdo susiue susiueIruNbDtte ilyann rus ubtttdo nusiue diarylamino groups, substituted or unsubstituted (alkyl)(aryl)amino groups, substituted or unsubstituted. alkyl groups, substituted or unsubstituted aryl groups, -C(=O)-alkyl groups, or -C(=O)-aryl groups; Cl R' 5 and R" 9 may be the, same or different and are independently selected from substituted or unsubstituted ailkyl groups, substituted or unsubstituted.
aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=O)-alkyl groups, -C(=O)-aryl groups, -C(=O)NH2, -C(=O)NH(alkyl) groups, -C(=O)NE{(aryl) groups, -C(=O)N(alkyl)2 groups, -C(=O)N(ary)2 groups, -C(=-O)N(alcyl)(aryl) groups, substituted or unsubstituted anunoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted diallcylaminoalkyl groups, substituted or unsubstituted arylam inoalkyl groups, substituted or unsubstitated diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl, substituted or unsubstituted dffheterocyclylaminoalkyl, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkyl, substituted or unsubstituted (heter ocyclyl)(aryl)aininoalkyl, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted hydroxyalkyl. groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;
R
1 6 and R0 may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl -groups; R 1 7 and W 2 may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted. heterocyclyl groups, -57- )-alkyl groups, -C(=O)-aryl groups =O)NH2, =O)NH(alcyl) groups, =O)NH(aryl) groups, =O)N(alcyl)2 groups, 00-C( =O)N(aryl)2 groups, =O)N(alkyl)(aryl) groups, 0)-alkyl groups, IND-C(=Q)O-aryl groups, substituted or unsubstituted heterocyclylakl groups, ci 5 substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted c-i ~alcylaminoakl groups, substituted or unsubstituted dialkylarnioalcyl groups, substituted or unsubstituted arylainoalkyl groups, substituted. or unsubstituted c-i diarylarninoalkyl groups, substituted or unsubstituted (alkyl)(aryl)axninoalkyl groups, 0)-heterocyclyl groups, )-O-heterocyclyl groups, =O)NH(heterocyclyl) groups, =O)-N(heterocyclyl)2 groups, -C(=O)N(aryl)(heterocyclyl) groups, =O)-N(alkyl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyakl groups;
R"
8 W3, R?4, and may be the same 'or different and. are independently selected from H, -Nffh, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groirps, -N(aryl)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alky) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2 groups, substituted or -unsubstituted alkylgroups, .substituted or unsubstituted aryl groups, -OH, substituted or unsubstituted ailcoxy groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aryloxy groups, -NHIOH, N(alkyl)QH groups, -N(aryl)OH groups, -N(alkyl)O-alkyl groups, -N(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, or.-N(aryl)O-aryl groups; and Ris selected from substituted or unsubstituted alk groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl.
groups- -58- 4 In another embodiment, the present invention provides a third group of compounds having the general formula I above with substituents selected from the following: 00 ND Y is selected from -OH, SH, allylthio groups, arylthio groups, -OR'O CN 5 groups, groups, -NR' 2 R" groups, -CN, substituted or unsubstituted N alkyl groups, substituted or unsubstituted alkenyl groups, substituted or O unsubstituted alkynyl groups, substituted or unsubstituted aralkyl groups, substituted c or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, or substituted or unsubstituted aryloxyalkyl groups; Z is selected from O, S, or NR' 4 groups;
R
2
R
3 and R 4 may be the same or different and are independently selected from H,.Cl, Br, F, I, -CN, -NO2, -OH, -OR' 5 groups, -NRR'k 7 groups, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, or O)R';
R
5
V
6
R
7 and R' may be the same or different* and are independently selected from H, Cl, Br, F, 1, -N02, -OH, -OR" 9 groups, -NR2OR 2 1 00groups., -SH, -SRW groups, -S(=O)RO groups, -S(=O)2R 2 groups, -CN, substituted IND or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, Ni 5 substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted c-i or unsubstituted aryl groups, substituted or unsubstituted ailkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkylanin oalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaninoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, O)R' groups, substituted or unsubstituted amninoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl. groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyldxyalkyl groups; R! and R may be the same or different and are independently selected from. H, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, -NH2, substituted or unsubstituted alkylamino -groups, substituted or unsubstituted arylanino groups, substituted or unsubstituted dialkylanino groups, substituted or unsubstituted diarylamino groups, -substituted or unsubstituted (allcyl)(aryl)aniino groups, substituted or unsubstituted ailkyl groups, substituted or unsubstituted aryl groups, -C(=O)-alcyl groups,.or -C(=O)-aryl groups; RV6 is selected from substituted or unsubstituted alkyl group Is, substituted or unsubs tituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -akyl groups, -C(=O)-aryl groups, -C(=O)O-alcyl groups, -C(=O)O-aryI groups, -C(=O)NH2, -C(=O)NII(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alcl)2 groups, C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, 04 -NH2, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(alkyl)(aryl) grus N(aryl)2 groups, -C(=O)NH(heterocyclyl) groups, =O)N(heterocycy)2 groups, =O)N(alkyl)(heterocyclyl) groups, or.
00 -C(=O)N(aryl)(heterocyclyl) groups; NI 5 R" is selected from H, -01H, alkoxy grqups, aryloxy groups, -NH2, c-I -NH(alkl) groups, -NH(aiyl) groups, -N(alkl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, substituted or unsubstituted alkyl groups, -NH~heterocyclyl) c-I groups, -N(heterocyclyl)2 groups, -N(alkyl)(heterocyclyl) groups, or substituted or unsubstituted aryl groups; R12 is selected from H, substituted or unsubstituted alyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted h eterocyclyl groups;
R"
3 is selected from H, substituted. or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, substituted or unsubstituted heterocyclylaikyl groups, substituted or unsubstituted'aninoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkaminoalkyl. groups, substituted or unsubstituted arylamtdioalkyl: groups, substituted or unsubstituted diarylaminoalkyl groups, substituted'or unsubstituted (alk)(aryl)aminoalkyl groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted diafllkyaxinq groups, substituted or unsubstituted diarylamrino groups,, substituted or unsubstituted (alk)(aryl)ainino groups, 0)11, )-alcyl groups, -C(=O)-aryl groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, -C(=O)NIh2, O)NH(alkyl) groups, -C(~=O)NH(aryi) groups, -C(=Q)N(alcyl)2 groups =O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, 0)-heterocyclyl groups, O)-O-heterocyclyl groups, -C(=O)NH~heterocyclyl) groups, =O)N(heterocycy)2 groups, O)N(alkyI)(heterocyclyl) groups, -C(=O)N(aryl)(heterocyclyl) groups, substituted or unsubstituted -61heterocyclylaminoalcyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted 00 aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalk groups; R's and R 19 may be the same or different and are independently 0 5 selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted kn aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(0)-alkyl groups, -C(=O)-aryl groups, -C(=O)NH2, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl )2 groups, -C(=O)N(aryl)2 groups, -C(=Q)N(alkyl)(aryl) groups, substituted or unsubstituted anunoalkyl groups, substituted or unsubstituted alkylamninoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aniinoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl, substituted or unsubstituted. diheterocyclylaminoalkyl, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkyl,' substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl, substituted or unsubstituted alkoxyalkyl groups, -substituted or unsubstituted bydroxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;
R
16 and e 2 may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted. or. unsubstituted heterocyclyl groups; R 17 and R 2 may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or tunsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, O)H, 0)-alyl groups, =0)-aryl groups O)NH2, -C(=O)NH(alkyl) groups, -C(=O)NII(aryl) groups, -C(=O)N(alkyl)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -C(=O)Q-alkyl groups, -C(=O)O-aryl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalcy groups, substituted. or unsubstituted dialkylamnoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted 00 diarylaminoalkyl groups, substituted or unsubstituted (alkyl. )(aryl)aminoalkyl groups, -C(=O)-heterocyclyl groups, -C(=O)-O-heterocyclyl groups, -C(=O)NH(heterocyclyl) group s, -C(=O)N(heterocyclyl)2 Ig roups, -C(:=O)N(allcl)(heterocyclyl) groups, =O)N(aryl)(heterocyclyl) groups,.
substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;
R"
8 R u, and.R?5 may be the same or different and are independently selected- from H, -Nffh, -NH(alkyl) groups, -NH(aryl) groups, -N(alkl)2 -groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterbcyclyl)(alkyl). groups, N(heterocyclyl)(aryl) groups, -N(hieterocyclyl)2 groups, substituted or unsubstituted alkyl groups, substituted or unsubstitutedaryl groups, -OH, substituted or unsubstituted alkoxy groups, substitutedi or unsubstituted aryloxy groups, substituted or unsubstituted heterocyclyl groups, -NHOH,.-N(alkyl)Oi -groups, -N(aryl)OH groups, ;.N(alkyl)Q-alkyl groups, -N(aryl)O-allyl groups, -N(alkyl)O-aryl groups, or -N(aryl)O-aryl groups; and' R~is selected from -substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups.
In the third: group of compounds, at least one of RR R or RI is selected from substituted -or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted saturated heterocyclyl groups, substituted or unsubstituited alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl -groups, substituted or unsubstituted arylaminoalkyl -63groups, substituted or unsubstituted diarylaminoalkyl groups, substituted,,or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl 00 IND groups, substituted or unsubstituted hydroxyalkyl. groups, substituted or N- 5 unsubstituted alkoxyalkyl groups,. substituted or unsubstituted aryloxyalkyl groups, N- or substituted or unsubstituted heterocyclyloxyalcyl groups; -OR 9 groups where R 9 is selected from substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, 0)1, -C(=O)-aryl groups, -C(=O)NH2, O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl)2 groups, -C(=O)N(aryl)2 groups, O)N(alcyl)(aryl) groups, substituted or umsubstituted ami oalkyl groups, substituted or unsubstituted alicylaminoalkyl groups, substituted or unsubstituted dialkylaniinoalkyl groups, substituted or unsubstituted arylaninoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aniinoalcyl groups, substituted. or unsubstituted heterocyclylaminoalcyl ,groups, substituted or unsubstituted diheterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkyI groups, substituted or unsubstituted .(heterocyclyl)(aryl)aminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups*, or substituted and unmubstituted heterocyclyloxyall groups; -N2R1groups where R"is selected from substituted. or unsubstituted. heterocyclyl groups; -NR 2
R
2 1 groups where R 2 is selected. from substituted or unsubstituted heterocyclyl groups, 0)11, -C(=0)-aryl groups,-C( =O)N112, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, O)N(alkyl)2 groups, -C(=O)N(arYl)2 groups, -C(=O)N(alkl)(aryl) groups, -C(=O)O-allcyl'groups, -C(=O)O-aryl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsub stituted dialkylandnoalkyl groups, substituted or unsubstituted arylarninoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted'or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted. hydroxyakl groups, substituted. or -64unsubstituted alkoxyalkyl groups, substituted or unsubsti .tuted aryloxyalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups; or groups where R0 is selected from H,' 00 -N .H2, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocycly])(aryl) groups, -N(heterocyclyl)2 groups, substituted or unsubstituted aryl groups, substituted or unsubstituted aryloxy groupsj or substituted or unsubstituted heterocyclyl groups.
In yet another embodiment, the present invention encompasses compounds of formula I in which the substituents described below define a fourth group of compounds: Y is selected from -OH, SH, alkylthio groups, arylthio groups, -ORw0 groups, groups, -NIR1 2 R1 3 groups, -CN, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted aralkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aikylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl, groups, substituted or unsubstituted.
diarylaminoakl groups,- substituted or unsubstituted (alkyl)(aryl)aminoalk groups-, substituted or unsubstituted heterocyclylaminoalcyl groups, substituted or unsubstituted h eterocyclyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, substituted or* unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, or substituted or unsubstituted aryloxyalkyl groups; Z is selected from 0, S, or NR1 4 grus
R
2
W
3 and R 4 may be the same or different .an d are independently selected from H, Cl, Br, F, I, -CN, -N02, -OH4, -OR groups,
-NR'
6 R 1 7 groups, substituted or unsubstituted amidinyl g r oup's, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted 00 O aminoallyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted C 5 or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or O8 unsubstituted heterocyclylalkyl groups, or 8 groups; R, R 6
R
7 and R 8 may be the same or different and are independently selected from H, Cl, Br, F, I, -NO2, -OH, -OR' 9 groups, -NR20R 2 t groups, -SH, -SR groups, groups, -S(=O)2R groups, -CN, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or.unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, groups, substituted or unsubstituted aminoalkyl groups,.
substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;
R
9 and R" 4 may be the same or different and are independently selected from H, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, -NH2, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstituted diarylamino.groups, substituted or unsubstituted (alkyl)(aryl)amino groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -C(=O)-alcyl groups, or -C(=O)-aryl groups;
WO
0 is selected from substituted or unsubstituted alkyl groups, IND substituted or unsubstituted aryl groups, substit uted or unsubstituted. heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl gr oups, C=O)-alcyl groups, -C(=O)-aryl groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, -C(=O)Nffh, -C(=O)NH(alcyl) grolips, -C(=O)NH(aryl) groups, CI -C(=O)N(alkyl)2 groups, -C(=O)N(aryl)2 groups, -C(=Q)N(alk)(aryl) groups, -NIH2, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(alkyl)(aryl) groups, -N(aryl)2 groups, -C(=O)NH(heterocyclyl) groups, =O)N(heterocyclyl)2 groups, O)N(alkyl)(hetero-cyclyl) groups, or O)N(aryl)(heterocyclyl) groups; is selected from H, -OH, alkoxy groups, aryloxy groups, -NH2, -NII(allcyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, substituted. or unsubstituted alkyl groups, -NH(heterocyclyl) groups, -N(heterocyClyl)2 groups, -N(alkyl)(heterocyciyl) groups, or substituted or unsubstituted aryl groups; R2 is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups;
R'
3 is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, -NH2, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoallcyl groups, substituted or unsubstituted dialkylaininoalkyl groups, substituted or unsubstituted, arylaminoalkyl groups, substituted or unsubstituted diarylaininoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted -67dialkylamino groups, substituted or unsubstituted diarylamino groups, substituted or unsubstituted (allcyl)(aryl)amino groups, -C(=O)-alkyl groups, -C(=O)-aryl groups, -C(=O)O-alcyl groups, -C(=O)O-aryl groups, -C(=O)NH2, IND -C(=O)NH(alcyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl)2 groups, -C(=Q)N(aryl)7 groups, -C(=O)N(alkyl)(aryl) groups, -C(=O)-heterocyclyl groups, -C(=O)-O-heterocyclyl groups, -C(=O)NH(heterocyclyl) groups, C= O)N~heterocyclyl)2 groups, 7C( =O)-N(alkyl)(heterocyclyl) groups, C1 C= O)N(aryl)(heterocyclyl) groups, substituted or'unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or umsubstituted alkoxyalcyl groups, substituted or unsubstituted aryloxyalcl groups, or substituted or urisubstituted heterocyclyloxyalkyl groups; R i 5 and R1 9 may be the same ordifferent and are independently selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=O)-alkyl groups, )-aryl groups, -C(=O)N12, =O)NII(alkyl) groups, =O)NH(aryl) groups, =O)N(alkyl)i groups, =O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, -substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted. heterocyclylaminoalkyl, substituted or unsubstituted diheterocyclylaminoalkyl, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkyl, substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyakl groups; R 16 and k 20 may be the same or different and are independently selected from H, substituted or unsubstituted ailkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups-,
R"
7 and W' may be the same or different and are independently selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl gr oups, 0C) -C(=O)-alkyl groups, -C(=O)-aryl groups, O)NH2, rus,-(ON~rl rus -(QNaly) rus -C(=O)N(ayl) groups, -C(O)NHlcl(ary) groups, -C=O)Oalkylgroups, -C(=Q0)Q-aryl groups, substituted or unsubstituted heterocyclylalkyl -groups,.
substituted or unsubstituted aninoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups,. substituted or unsubstituted dialkylaminoalcyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, )-heterocyclyl groups, O)-O-heterocyclyl groups, QC=)NH(heterocyclyI). groups, =Q)-N(heterocycly)2 groups, =Q)-N(alkyl)(heterocyclyl) groups, =O)-N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstitated aryloxyalcyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups;
WI
8 W4, and R5 -may be the same or different and are independently splected from H, -NI1h, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alky1) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2* groups, substituted or unsubstituted ailkyl groups, substituted or unsubstituted aryl groups, -OH, substituted or unsubstituted -alkoxy groups, substituted or unsubstituted aryloxy groups, tsubstituted or unsubstituted heterocyclyl groups, -NHOH, -N(alkcl)OH grou ps, -N(aryl)OH4 groups, -N(allcyl)O-alkyl groups, -N(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, or -N(aryl)Q-aryl groups; and R' is selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups.
00 O In the fourth group of compounds, at least one of R 2 Rl, or R 4 is an -OR" group and R' 5 is selected from substituted or unsubstituted In heterocyclylalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted diheterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl)(alkyl)aminoalkyl groups, or substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl groups.
In the first, second, or third group of compounds Z is preferably an -NR4 group, more preferably where R' 14 is H. Preferred compounds of the fourth group include those compounds in which Z is an -NRwo group, more preferably where R'O is H.
Y is preferably an -OR' 0 group, an -NR' 2
R'
3 group, or a substituted or unsubstituted alkynyl group, or more preferably is an -NR' 2
N'
3 group in the first, second, third, and fourth groups of compounds. In more preferred compounds of the,first group, Y is a NR' 2
RI
3 group and is H. In more preferred compounds of the second and third groups, Y is a NR' 2
R'
3 group and one or both of R' 2 and R' 3 are H.
Other preferred compounds of the first, second, and third groups include those where Y is selected from -N(CH)2, -NH(CHa), -NH(CH2CH3), -N(CH2CHs)2, -NH(aryl) groups, -N(aryl)2 groups, -NHNH2, -NHN(CH)2, -N(CH3)NH(CH3), -NH(CH2)mNH2 groups, -NH(CH2)mNH(alkyl) groups, -NH(CH2)N(alkyl)2 groups, -N(alkyl)(CH2)NH2 groups, -N(allcyl)(CH2)m-NH(alcl) groups, -N(alkyl)(CH2i)N(alkyl)2 groups, -NH(CH2)n(lieterocyclyl) groups, -N(Sallyl)[(CH2)(heterocyclyl)J groups, -NH(CH2)mOH groups, -NH(C12).OCH3 groups, -HCH2CH(NH2i)CH(C~b) 2 00 N 2-mnycoey) N cylhxl,-HC3 N N-opoiy) IND-rioylhey) N~ylhey) NOH,.N(-opoiy) -NH(quinuclidyl), especially -NH(quinuclid-3-yl), or groups where R 12 and R1 3 join to form a substituted or unsubstituted saturated 5 or 6 mnembered N-containing ring, where m is an integer ranging from 2 to 4 such as 2, 3, or 4 and n is an integer ranging from 0to 3such as0, 1, 2, or 3.
More preferred compounds of the first,.second, and third also include those in which Y is selected from -NH(CH2)2N(CL3)2, -NH(CH2)20H, -NH(CH2)(4-imidazolyl), -NH(CMh)(3inidazolyl), -NHF(CH2)(4-pyridyl), -NII(C~H)(2-pyridyl), -NI{(CH2)(3-pyridyl), -NH(CIHz)(2-tetrahydrofuranyl), -NH(CI-b)(4-piperidinyl), -NH(CH2)(3piperidinyl), -NII(C~H)2[2-(N-methylpyfrolidinyl)], -NH(CH2)2(2-pyr-rolidinyl), -NII(CH2)[2-(N-methylpyrrolidinyl)], -NH(CH2)(2-pyrrolidinyl), -NH(3piperidinyl), or -NH(3-pyrrolidinyl).
Preferred compounds of the first and second groups include those compounds where W, W 3
W
4 W, R 7 and R' are all H. Other preferred compounds of the first, second, third, and fourth groups include those where RI is selected from H, substituted or unsubstituted alkoxy groups, substituted or unsubstituted heterocyclylalkoxy groups, substituted or unsubstituted heterocyclyloxy groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkyl-, heterocyclyl-, or aryl-aminoalkyl groups, substituted or unsubstituted dialkylaniinoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)axuinoalkyl groups, substituted or unsubst~tuted alkyl- or aryl-aminoalkoxy groups, substituted or unsubstituted dialkylaniinoalkoxy groups, or substituted or unsubstituted diarylaminoalcoxy groups. Still other compounds of the first, second, third, and fourth groups include those in which R' is selected from F, Cl, substituted or unsubstituted alkoxy groups, substituted or unsubstituted heterocyclylalkoxy groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted aiy-, heterocyclyl-, or aryl-aminoalcyl groups, substituted or unsubstituted 00 dialkylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, IND substituted or unsubstituted (alkyl)(aryl)aminoalcyl groups, substituted or Ni 5 unsubstituted alkylaminoalkoxy groups, substituted or unsubstituted c-i arylarninoalkoxy groups, substituted or unsubstituted dialkylaminoalcoxy groups, substituted or uns~ubstituted diarylaminoalkoxy groups, or substituted-or unsubstituted (alkyl)(aryl)aminoalkoxy groups. Particular examples include: -OCH3, -OCH2CU2(N-morpholinyl), -N-morpholinyl, -N-cis--dialkyhnorpholinyl, -N-(4-alkyl)piperazinyl, -QCH2CILN(alkyl)2 groups, -OCH2CH2NH(alkyl) groups, -OCMICI-LNH2, -OCMLCH2NH(aryl) groups, -OCH12CJ{ZN(aryl)2 groups, -QCH2CH2N(allcyl)(aryl) groups, alkoxy groups, -0(4-piperidinyl), alkyl)piperidinyl] groups, -O(3-(1-alkyl)piperidinyl] group -O[3-quinuclidinyl], -0C112(2-pyridyl), -OCH2(4-pyridyl), -0(3-pyrrolidinyl), or -0f5-(l allcy)pyrrolidinyl) groups.
Still other preferred compounds of the first, second, third, and fourth groups -include those in which W 2 is selected from F, Cl, -N02,. -O(211s, Nmorpholinyl, -N-cis-dialkyhnorpholinyl, -N-(4-allcyl)piperazInyl,. or. OCH2(2pyridyl).. Other preferred compounds of the. first, second, third, and fourth groups include those where W 2 is selected from H, F, -Cl, -NO2, substituted or unsubstituted heterocyclylalicoxy groups, or substituted or unsubstituted heterocyclyl groups. Yet other preferred compounds of the first, second, third, and fourth groups -include those where V 2 is selected -from F, Cl, -NOh, substituted or unsubstituted alkoxy groups, substituted or unsubstituted heterocyclylalkoxy groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alicyl-, heterocycyl-, and aryl-aminoalkyl groups, substituted or unsubstituted dialkyl- and di arylaminoalkyl groups, substituted or unsubstituted alkylarylamninoalkyl groups, substituted or unsubstituted alkl- and aryl -amninoalkoxy groups, substituted or unsubstituted dialkyl- and diaryl-aminoalkoxy groups, or substituted or unsubstituted alkylarylaminoalkoxy groups.
I
Still further preferred compounds of the first, second, third, and.
fourth groups include those where R 6 is an alkyl group having from one to four carbon atoms. In other preferred compounds of the first, second, third, and fourth groups, R 7 is an alkyl group having from one to four carbon atoms. Still further preferred compounds of the four groups are those in which R 6 or R 7 is an -OR' 9 group and R' 9 is an alkyl group, an aryl group, a heterocyclyl group, or a heterocyclylalkyl group.
In still other preferred compounds of the first, second, third, and fourth groups, R 6 or R 7 is a -OCH2(CH2)q(heterocyclyl) group and q is 0, 1, 2, 3,or 4, more preferably where the heterocyclyl group of the -OCH2(CH2)q(heterocyclyl) group is a heterocycle selected from substituted or unsubstituted morpholine, substituted or unsubstituted piperazine, substituted or unsubstituted piperidine, substituted or unsubstituted pyrrolidine, substituted or unsubstituted pyrrole, substituted or unsubstituted imidazole, substituted or unisubstituted pyrazole, substituted or unsubstituted 1,2,3-triazole, substituted or unsubstituted 1,2,4triazole, substituted or unsubstituted tetrazole, substituted or unsubstituted thiomorpholine, substituted or unsubstituted homopiperazine, substituted or unsubstituted oxazolidin-2-one, substituted or unsubstituted pyrrolidin-2-one, substituted or unsubstituted pyridine, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted thiazole, substituted or unsubstituted isothiazole, substituted or unsubstituted furan, substituted or unsubstituted thiophene, substituted or unsubstituted tetrahydrofuran, substituted or unsubstituted tetrahydrothiophene, substituted or unsubstituted benzimidazole, substituted or unsubstituted benzoxazole, or substituted orunsubstituted benzothiazole.
In groups including heterocyclyl groups, the heterocyclyl may be attached in various ways. For example, in the -OCH2(CH2)q(hleterocyclyl) group, the heterocyclyl group may be bonded to a methylene carbon of the -OCH2(CH2)q group of the -OCH2(CH2)q(heterocyclyl) through various ring members. By way of non-limiting example, where q is 1 and the heterocyclyl group is tetrahydrofuran, -73the group could be represented by the formula -OCH2CH2(tetrahydrofuranyl) which corresponds to the following two structures: a ll
IV
\0
IV
where structure III represents the group that can be referred to as the -OCH2CH2(2tetrahydrofuranyl) group and structure IV represents the group that can be referred to as the -OCH2CH2(3-tetrahydrofuranyl) group. When the heterocyclyl group is a N-containing heterocycle, such as, but not limited to piperidine, piperazine, morpholine, or pyrrolidine, the heterocycle can be bonded to the methylene carbon through a ring carbon atom or through a nitrogen atom in the ring of the Ncontaining heterocycle. Both of these are preferred. Where the heterocyclyl group is a piperidine and q is 2 for an -OCH2(CH2)q(heterocyclyl) group, the following structures are possible and preferred: 0 0 V
VI
VII VIII Structure V is an example of a -O(CH2)3(N-piperidinyl) or -O(CH2)3(1-piperidinyl) group. Structure VI is an example of a -O(CH2)3-(2piperidinyl) group. Structure VII is an example of a -O(CH2)3(3-piperidinyl) group. Structure VIII is an example of a -O(CH2)3(4-piperidinyl) group. Where the heterocycly] group is a piperazine and q is 1 for an -OCH2(CH2)q(heterocyclyl) group, the following structures are possible and preferred: 00
INN
NN
~KI
N
N
Ixx Structure IX is an example of a -O(CH2)2(2-piperazinyl) group, and structure X is an example of a -O(CH2)2(1-piperazinyl) or -Q(CH2)2(Npiperazinyl)group. Where the heterocyclyl group is a morpholine and q is 1 for an OCH2(CH2)q(heterOCYClyl) group, the followinig structures are possible and preferred:
NN
N
XIII
Structure XI is an example of a -O(C112)2(3-Inorpholinyl) group, structure XII is an example of a -0(CH2)2(4-morpholinyl) or -O(CH2)2(Nmorpholinyl) group, and structure XIII is an example of a -O(C.H2)2(2-morpholinyl) group.- It will be observed that where the group is a pyrrolidine, and q is 1, the structures available include -O(CH2)2(1-pyrrolidinyl) or -O(CH2)2(N-pyrrolidinyl), -O(CL2)2(2-pyrrolidinyl), and -O(CH2)2(3-pyrrolidinyl).
Yet other preferred compounds of the first, second, third, and fourth groups include those where at least one of R 5
W
6
R
7 and W 8 is a substituted or unsubstituted heterocyclyl group, more specifically a substituted or unsubstituted 00 110 heterocyclyl group. comprising at least one 0 or N atom, still more particularly a substituted or unsubstituted heterocyclyl group selected from morpholine, piperazine, piperidine, 1 ,2,3-triazole, 1 ,2,4-triazole, tetrazole, pyrrolidine, pyrazole, pyrrole, thiomorpholine, thiomorpholine in which the S atom of the thiomorpholine group is bonded to one or more 0 atoms, homopiperazine, benzimidazole, oxazolidin-2-one, pyrrolidin-2-one, imidazole, isoxazole, oxazole, isothiazole, thiazole, thiophene, furan, pyran, tetrAhydrothiophene, tetrahydrofuran,.
tetrahydropyran, or pyridine.
Other preferred compounds of the first, second, third, and fourth groups include those in which at least one of R' 9 or R 2 '.is selected from substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalcyl groups, :substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted dialklaminoalkyl groups, substituted or unsubstituted diarylamintoalkyl groups, (alkyl)(aryl)aminoalkyl groups, or substituted or.
unsubstituted. heterocyclylalkyl groups, including: -CH2b(CH2)pNH2 groups, -CH2(CH2)pNH(alkyl) groups, -CIHz(CML)pNH(aryl) groups, -CH2(C~H)pN(alkyl)2 groups, -C112(CH2)pN(aryl)2 groups, -C112(C112)pN(allcyl)(aryl) groups,. or -CH2(CH2)p(heterocyclyl) groups, wherein p is an integer ranging from. 0 to .4 and the heterocyclyl group of the -Cffi(C~H)p(heterocyclyl) group is a N-containing heterocycle selected from substituted. or unsubstituted morpholine, substituted or unsubstituted pyrrolidine, substituted or unsubstituted piperazine, substituted or unsubstituted piperidine, substituted or unsubstituted pyrrole, substituted or unsubstituted imidazole, substituted or unsubstituted pyrazole, substituted or unsubstituted 1 ,2,3-triazole, substituted or unsubstituted I ,2,4-triazole, substituted or unsubstituted tetrazole, substituted or unsubstituted thiomorpholine, substituted or unsubstituted homopiperazine, substituted or unsubstituted oxazolidin-2-one, substituted or unsubstituted pyrrolidin-2-one, substituted or unsubstituted pyridine, substituted or unsubstituted oxazole, substituted or unsubstituted. isoxazole, -76substituted or unsubstituted thiazole, substituted or unsubstituted isothiazole, substituted or unsubstituted benzimidazole, substituted or unsubstituted benzoxazole, or substituted or unsubstituted benzothiazole.
00 IDStill further preferred compounds according to the first, second, NC 5 third, and fourth groups include those in which R2 is selected from substituted or CN unsubstituted aryl groups, substituted or unsubstituted alkyl groups, -NH2, -NH(alkyl) groups, -N(alkyl)2 groups, -NH(aryl) groups, -N(aryl)2 groups, CN -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2 groups, or N-containing heterocycles. In such compounds, the N-containing heterocycles are bonded to the carbonyl carbon of the group through either a nitrogen atom or a carbon atom in the rings of the N-containing heterocycles. In more preferred such comnpounds that are provided, the N-containing heterocycle of the R" group is selected from substituted or unsubstituted morpholine, substituted or unsubstituted pyrrolidine, substituted or unsubstituted piperazine, substituted or unsubstituted piperidine, substituted or unsubstituted pyrrole, substituted or unsubstituted imidazole, substituted or unsubstituted pyrazole, substituted or unsubstituted 1,2,3triazole, substituted or unsubstituted 1,2,4-triazole, substituted or unsubstituted tetrazole, substituted.or unsubstituted thiomorpholine, substituted or unsubstituted homnopiperazine, substituted or unsubstituted oxazolidin-2-one, substituted or unsubstituted pyrrolidin-2-one, substituted or unsubstituted pyridine, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted thiazole, substituted or unsubstituted isothiazole, substituted or unsubstituted benzimidazole, substituted or unsubstituted benzoxazole, or substituted or unsubstituted benzothiazole.
Preferred compounds according to the first, third, and fourth groups of compounds are also those where R is H.
Preferred compounds of the fourth group of compounds include those where R' is an -OR" group and R' 5 is selected from substituted or unsubstituted.
-77heterocyclylalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted aminoallyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted INDor unsubstituted arylaminoallkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclyl groups, N substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted diheterocyclylaminoalkyl groups, substituted or unsubstituted N (heterocyclyl)(alkyl)aminoalkyl groups, or substituted or unsubstituted (heterocyclyl)(aryl)aminoalkyl groups.
Other particularly preferred inhibitors of VEGF-RTK are compounds having the structure II, tautomers of the compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutically acceptable salts of the tautomers.
Structure II has the following formula:
R
\1 R x x2/ Fe N 0 4 19X
RR
II
In compounds having structure II, Y is selected from H, -OH, -OR'o groups, -SH, -SR" groups, -NR' 2
R
13 groups, -CN, O)-R 4 groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted aralkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted alkylamninoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted 00 aryl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups.
In preferred compounds of structure I1, Y is selected from H, -OH,:11 c-i -OR' groups, or -NR"R grus ore preferably, Y is a -NR 11 R' group. Still more preferably, Y is a -NR"R 12 group and both R" and R 1 2 are hydrogen. In other preferred compounds having the structure HI, Y is selected from -N(CH 3 b) 2 -NH(CHL), -NH(CH2CIL), -N(CH2CH3), -NH(aryl) groups, -N(aryl)2 groups, -NHN~H, -NHN(CH3)2, -N(CHL)NH(CHs), -NH(CH2)mNJJ2 groups, -NH(C~H)mNII(alkyl) groups, -NH(CH2)mN(alky)2 groups, -N(Alkyl)(C~h)mNH 2 groups, -N(allcyl)(CH2)mNII(akl) groups, -N(alkyl)(CH2)mN(alkyI )2 groups, -NH(CH2)n(heterocyclyl) groups, -N(alkyl)[(CH2i).(heterocyclyl)] groups, NH(Clb)mOH groups, -NH(CH2)mOCH3 groups, -NHCMhCH(NH2)CH(CH3), -NH(2-aminocyclohexyl), -NH(cyclohexyl), -NHOCH3, -NH(N-morpholinyl), -NH(quinuclidyl), especially -NH(quinucid-3-yl), and groups where and R'1 2 join to form a substituted or unsubstituted saturated 5 or 6 membered N-containn ring, Where m is 2, 3, or 4 and n is 0, 1, 2, or 3. Still more preferred compounds of this type are those in which Y is selected from -NH(CH2)2N(CH3)2, -NH(CH2)2QH, -NH(CH2)(4-imidazolyl), -NH(CH2)(3imidazolyl), -NH(CH2)(4-pyridyl), -NH(Cir-1)(2-pyridyl), -NH(CH2)(3-pyridyl), -NII(CH2)(2-tetrahydrofilranyl), -NH(CH2)(4-piperidinyl), -NH(CH2)(3piperidinyl), -NII(CH2M22-(N-methyl-pyrrolidinyl)], -NH(CH2)2(2-pyrrolidinyl),.
-NH(CH2)[2-(N-methylpyrrolidinyl)], NH(CH2)(2-pyrrolidinyl), -NH(3piperidinyl), or -NH(3-pyrrolidinyl).
In compounds of structure 11, X 1
X
2
V
3 and V 4 are selected from C or N and at least one of V 1 XV, X 3 and V 4 is N. In some preferred compounds of structure II,XV is N,W is absent or H,andX 2 0, X3,andXV are all C. Inother -79preferred compounds of structure II, X 2 is N, R 6 is absent or H, and X, X 3 and X 4 are C. In other preferred compounds of structure II, X 3 is N, R 7 is absent or H, and X 2 and X 4 are all C. In still other preferred compounds of structure II, X 4 is N, R 8 is absent or H, and X 2 and X 3 are all C.
In compounds of structure II, R 2
R
4 R, R 6
R
7 and R 8 may be the same or different and are independently selected from H, Cl, Br, F, I, -NO2, -CN, -OH, -OR 5 groups, -NR' 6
R'
1 groups, -C(=O)R 8 groups, -SH, groups, groups, S(=O)2R 2 groups, substituted or unsubstituted amidinyl groups, substituted or unsubstituted guanidinyl groups, substituted or unsubstituted primary, secondary, or tertiary alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted alkenyl groups, substituted or unsubstituted alkynyl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalkyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups. In compounds of structure II, R is absent or is H if X' is N, R 6 is absent or is H if X is N, R 7 is absent or is H ifX 3 is N, and R' is absent or is H if X 4 is N.
Some preferred compounds have the structure II where at least one of RW, R 3
R
4
R
5
R
6
R
7 or R 8 is a substituted oi unsubstituted heterocyclyl group, and, in more particular embodiments, a substituted or unsubstituted heterocyclyl group selected from morpholine, piperazine, piperidine, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyrrolidine, pyrazole, pyrrole, thiomorpholine, homopiperazine, benzimidazole, oxazolidin-2-one, pyrrolidin-2-one, imidazole, isoxazole, oxazole, isothiazole, thiazole, thiophene, furan, pyran, tetrahydrothiophene, tetrahydrofuran, tetrahydropyran, and pyridine.
Still other preferred compounds havin structure H- are those in which W 2
W
3 and W 4 are H. In some preferred embodiments,.R' is gelected from H, substituted or unsubstituted alkoxy groups, substituted or unsubstituted 00 eeoyyakoygopsbtttdo nusiue eeoyllxgrus hIeoNDlloygop, usiue rusbttte eeoyllx rus substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkyl-, heterocyclyl-, or aryl-aminoalkyl group s, substituted or unsubstituted dialkylaninoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aniinoalkyl groups, substituted or unsubstitu ted alkyl- or aryl-aminoalkoxy groups, substituted or unsubstituted dialkylanioalkoxy groups, or substituted or unsubstituted diar .ylaminoalkoxy groups. In other preferred compounds, W 1 is selected from F, Cl, substituted or.
unsubstituted alkoxy groups, substituted or unsubstituted heterocyclylalkoxy groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted alkyl-, heterocyclyl-, or aryl-a minoalkyl groups, substitu .ted .or .unsu b stituted.
disilylamioalkyl1 groups, substituted or unsubstituted diarylaminmo'akl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted alkylaminoalkoxy groups, substituted or unsubstituted arylaminoalkoxy groups, substituted 'or unsubstituted dialkylaminoalkoxy groups, substituted or unsubsttte diarylaminoalkoxy groups, ior substituted or unsubstituted (alkyl)(aryl)aminoalkoxy groups. Particular examples include: -OC113, -OC~H2CH2(N-morphoinyl), -N-morphoin yl,'-N-cis-dimethylmorpholinyl, -N-(4-allc-rl)piperazinyl, -OCH2CH2N(alkyl)2 groups, -OCH12CH2NH(alkyl) groups, -OCH2CH2NH2, -OCH2CH2NH(aryl) groups, -OCH2CffiN(ary)2 groups, alkoxy groups, -OCH2CH.2N(allcyl)(aryl) groups, -0(4-piperidinyl), alk)piperidinyl] groups, 7O[3-(1-alkyl)piperidinyl] groups, -013-quinuclidinyl], -0C112(2-pyridyl), -OCH2(4-pyridyl), -0(3-pyrrolidinyl), alkql)jpyrrblidinyl], or other -O(heterocyclyl) groups not listed in this paragraph.
In other compounds having the structure HI, W 2 is selected from F, Cl, -N402, -OClia, -N-morpholinyl, -N-cis-dialkylmorpholinyl, alkyl)piperazinyl, or -OCH2(2-pyridyl). In yet other compounds having the structure EI, R 2 is *selected from H, F, Cl, -N02, substituted or unsubstituted heterocyclylalkoxy groups, or substituted or unsubstituted heterocyclyl groups. Yet other preferred compounds having the structure II include those where R is selected from F, Cl, -N02, substituted or unsubstituted alkoxy groups, substituted or 00 INDunsubstituted heterocyclylalkoxy groups, substituted or unsubstituted heterocyclyl CN 5 groups, substituted or unsubstituted alkyl-, heterocycyl-, and aryl-aminoalkyl Ci groups, substituted or unsubstituted dialkyl- and diaryl-aminoalkyl groups, substituted or unsubstituted alkylarylaminoalkyl groups, substituted or unsubstituted c-i alkyl- and aryl-aminoalkoxy groups, substituted or unsubstituted dialkyl- and diarylaminoalkoxy groups, or substituted or unsubstituted alkylarylaminoalkoxy groups.
In some preferred compounds having structure I, at least two of X',
X
3 and X are C and the corresponding substituents RS, R 6
R
7 and R' are hydrogen, and at least one of X 2 X, and X is N. In yet other preferred compounds having structure II, three of RS, R 6
R
7 and R are hydrogen and one of X, X 3 and X' is N. In still other more preferred compounds of structure II,
R
6
R
7 or both R 6 and R 7 are alkyl groups such as those having from one to four carbon atoms. In yet other preferred compounds of structure II, R' or R 7 is an OR" group and R" is an alkyl, aryl, heterocyclyl, or heterocyclylalkyl group. In still further compounds of structure II, R 6 or R 7 is a -OCH2(CH2)q(heterocyclyl) group and q is 0, 1, 2, 3, or 4. In niore preferred compounds in which R 6 or R 7 is a -OCH2(CH)q-(heterocyclyl) group, the heterocyclyl group of the -OCH2(CH2)n(heterocyclyl) group is a heterocycle selected from substituted or unsubstituted morpholine, substituted or unsubstituted piperazine, substituted or unsubstituted piperidine, substituted or unsubstituted pyrrolidine, substituted or unsubstituted pyrrole, substituted or unsubstituted imidazole, substituted or unsubstituted pyrazole, substituted or unsubstituted 1,2,3-triazole, substituted or unsubstituted 1,2,4-triazole, substituted or unsubstituted tetrazole, substituted or unsubstituted thiomorpholine, substituted or unsubstituted thiomorpholine in which the S atom of the thiomorpholine group is bonded to one or more O atoms, substituted or unsubstituted homopiperazine, substituted or unsubstituted oxazolidin- 2-one, substituted or unsubstituted pyrrolidin-2-one, substituted or unsubstituted pyridine, substituted or unsubstituted oxazole, substituted or unsubstituted -82- 4 isoxazole, substituted or unsubstituted thiazole, substituted or unsubstituted isothiazole, substituted or unsubstituted furan, substituted or unsubstituted thiophene, substituted or unsubstituted tetrahydrofuran, substituted or unsubsti tuted 00 tetrahydrothiophene, substituted or unsubstituted benzimidazole, substituted or C) 5 unsubstituted benzoxazole, or substituted or unsubstituted benzothiazole.
In compounds of structure Hl, R 9 is selected from H, -OH, substituted or. unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, -NH2, CI substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylamino groups, substituted or unsubstituted diarylanulno groups, substituted or unsubstituted (alkyl)(aryl)amino groups, substituted or unsubstituted alicyl groups, substituted or unsubstituted aryl groups, -C(=O)-alkyl groups, or -C(=O)-aryl groups. One group of particularly preferred compounds of structure are those in which R! is hydrogen'.
In compounds of structure 111, R 10 is selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=O)-alkyl groups, -C(=O)-aryl groups,. -C(=O)O-alkyl groups, -C(=O)O-aryl groups, -C(=O)NH2, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alcy)2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(akyl)(aryl) groups, -NH2, -NH(alkyl) groups, -NH(ar yl) groups, -N(alkyl)2 groups, -N(alkl)(aryl) groups, -N(aryl)2 groups, =O)NH(heterocyclyl) groups, =O)N(heterocyclyI)i groups, =O)N(alkyl)(heterocyclyl) groups, or =O)N(aryl)(heterocyclyl) groups; In compounds of structure I1, R" and R' 9 may be the same or different and are independently selected from substituted or unsubstituted alkyl groups, or substituted or unsubstituted aryl groups whereas R 12 is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups.
-83- In compounds of structure HI, R" 3 is selected from H, -substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or 0C) u nsubstituted heterocyclyl groups, -OH, alkoxy groups, aryloxy groups, -NH2, IND substituted or unsubstituted heterocyclylalkyl -groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoallcyl. groups, substituted CI or unsubstituted dialkylaininoalkyl groups, substituted or unsubstituted arylaininoalkyl groups, substituted or unsubstituted diarylaminosilcyl groups, CI substituted or unsubstituted (alkyl)(aryl~aniinoalkyl groups,. substituted or unsubstituted alkylamino groups, substituted or unsubstituted arylamino groups, substituted or unsubstituted dialkylamino groups, substituted. or unsubstituted diarylamino groups, substituted or unsubstituted (alkyl)(aryl)amino groups, -C(=O)-alkyl groups, -C(=O)-aryl groups, -C(=O)O-alkyl groups, -C(=O)Q-aryl groups, -C(=O)N112, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, )N(alkyl)2 groups, =O)N(aryl)2 groups, =O)N(alkyl)(aryl) groups, )-heterocyclyl groups, =O)-O-heterocyclyl1 groups, O)NH(heterocyclyl) groups, =O)-N~heterocyclyl)2 groups, O)N(alkyl)(heterocyclyl) groups, Q)-N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaininoalkyl groups, substituted or' unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyaly groups, substituted or unsubstituted aryloxyalkyl groups, or'substituted or unsubstituted heterocyclyloxyalkl groups. R 1 2 and R" 3 may join togethe .r Ito form 5 to 7 membered saturated or unsaturated, substituted or unsubstituted N-containing ring.
In compounds of structure II, R" 4 is selected from H, -OH1,-alkox groups, aryloxy groups, -NI12, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(allcyl)(aryl) groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl g roups, -NH(heterocyclyl) groups, -N(heterocyclyl)2 groups, alkyl)(heterocyclyl) groups, or -N(aryl)(heterocyclyl) groups.
In compounds of structure H, R' 5 is selected from substituted or.
unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or -84unsubstituted heterocyclyl groups, substituted or unsubstituted heterocyclylalkyl groups, -C(=O)-alkyl groups, -C(=O)-aryl groups, -C(=O)NH2, -C(=O)NII(alcl) groups, C(=O)NH(aryl) groups, -C(=O)N(alkyl)2 'groups, 00 -(ONay) rus C=)~ly)ay)gopsbtttdo nusiue IND)~rl2gops .(ONakl(iy~rus usiutdo nusiue aminoalkyl groups, substituted or unsubstituted alkylaininoalkyl groups, substituted or unsubstituted dialkylaminoalkyl groups, substituted. or unsubstituted arylaminoalkyl groups, substituted or unsubstituted diarylaminoalkyl groups, substituted or unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted or unsubstituted heterocyclylaminoaicyl groups, substituted or unsubstituted dibeterocyclylaminoalkyl groups, substituted or unsubstituted (heterocyclyl)(alkyl)aniinoalkyl groups, substituted or unsubstituted (heterocyclyl)(aryl)aniinoalcy groups, substituted-or unsubstituted alkoxyalkyl groups, substituted or unsubstituted aryloxyalcyl groups, substituted or unsubstituted hydroxyalicyl groups, or substituted or unsubstituted heterocyclyloxyalkyl groups.
In compounds of structure HI, R' 6 is selected from HI, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted heterocyclyl groups whereas R" 7 is selected from H, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, substituted or unsubstituted. heterocyclyl groups, O)H, -C(=Q0)-alkyl groups, -C(=O0)-aryl groups, -C(=Q)NMh, -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, O)N(alkyl)2 groups, Q)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, -C(=O)O-alkyl groups, -C(=O)O-aryl groups, substituted or unsubstituted aminoalkyl groups, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted diallcylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituited diarylaminoalkyl groups, substituted or unsubstituted (aryl)(alkyl)aminoalkyl groups, substituted or unsubstituted heterocyclylalkyl groups, )-heterocyclyl groups, -C(=O)-Oheterocyclyl groups, =O)NH(heterocyclyl) groups,.
O)N(heterocyclyl)2 groups, )-N(alkyl)(heteroqyclyl) groups, -C(=O)N(aryl)(heterocyclyl) groups, substituted or unsubstituted heterocyclylaminoalkyl groups, substituted or unsubstituted hydroxyalkyl groups, substituted or unsubstituted alkoxyalkyl groups, substituted or unsubstituted 00 aryloxyalkyl groups, substituted or unsubstituted heterocyclyloxyalkyl groups, -OH, IDsubstituted or unsubstituted aloxy groups, substituted or unsubstituted aryloxy groups, or -NH2 groups. R' 6 and R' 7 may join together to form a 5 to 7 membered saturated or unsaturated, substituted or unsubstituted N-containing ring.
Finally, in compounds of structure II, R' 8 R, and R 21 may be the same or different and are independently selected from H, -NiH2, -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)2 groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -OH, substituted or unsubstituted alkoxy groups, substituted or unsubstituted aryloxy groups, substituted or unsubstituted heterocyclyl groups, -NHOH, -N(alkyl)OH groups, -N(aryl)OH groups, -N(alkyl)O-alkyl groups, -N(aryl)O-allyl groups, -N(alkyl)O-aryl groups, or -N(aryl)O-aryl groups.
Compounds having the structure II may include those in which is selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted aryl groups, -NH2, -NH(alkyl) groups, -N(alkyl)2 groups, -NH(aryl) groups, -N(aryl)2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2 groups, or N-containing heterocycles, and the N-containing heterocycles are bonded to the carbonyl carbon of the 0)-R' 8 group through either a nitrogen atom or a carbon atom in the rings of the N-containing heterocycles. In still more preferred compounds in which R'8 is a N-containing heterocycle, the N-containing heterocycle of the R 8 group is selected from substituted or unsubstituted morpholine, substituted or unsubstituted pyrrolidine, substituted or unsubstituted piperazine, substituted or unsubstituted piperidine, substituted or unsubstituted pyrrole, substituted or unsubstituted imidazole, substituted or unsubstituted pyrazole, substituted or unsubstituted 1, 2 3 -triazole, substituted or unsubstituted 1,2,4triazole, substituted or unsubstituted tetrazole, substituted or unsubstituted thiomorpholine, substituted or unsubstituted homopiperazine, substituted or 4 unsubstituted oxazolidin-2-one, substituted or unsubstituted pyrrolidm-2-one, substituted or unsubstituted. pyridine, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted thiazole, 00 substituted or unsubstituted isothiazole, substituted or unsubstituted benzimidazole, C) 5 substituted or unsubstituted beuzoxazole, or substituted or unsubstituted C) benzothiazole.
Other preferred compounds having structure II are provided in which CR1 or R" 7 is selected from substituted or unsubstituted aminoalkyl groups,, substituted or unsubstituted alkylaminoalkyl groups, substituted or unsubstituted arylaminoalkyl groups, substituted or unsubstituted dialkylanunoalkyl groups, substituted or unsubstituted diarylaininoalkyl groups,. substituted or unsubstituted (alkyl)(aryl)aminoalyl groups, or substituted or unsubstituted heterocyclylaininoalkyl groups including: CH2(CH2)pN~H groups, -CH2(CH2)pNH(alkyl) groups, -CfiL(CH12)pNI(aryl) groups, -CHi2(CH2)pN(alkyl)2 groups, -C112(C112)pN(aryl)2 groups, -CH2(CH2)pN(alkyl)(aryl) groups, or Cfih(CH2)p~eterocyclyl) groups, where p is an integer ranging from 0 to 4 and the heterocyclyl group of the -CH2(C~h)p(heterocyclyl) group is a N-containing heterocycle selected from substituted or unsubstituted morpholine, substituted or viisubstituted pyrrolidine, substituted or unsubstituted piperazine, substituted or unsubstituted piperidine, substituted or unsubstituted pyrrole, substituted or unsubstituted iniidazole, substituted. or unsubstit uted pyrazole, substituted or unsubstituted 1,2,3-triazole, substituted or unsubstituted 1,2,4-triazole, substituted or unsubstit uted tetrazole, substituted or unsubstituted thiomorpholine, substituted or unsubstituted homopiperazine, substituted or unsubstituted oxazolidin-2-one, substituted or unsubstituted pyrrolidin-2-one, substituted or unsubstituted pyridine, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted thiazole, substituted or unsubstituted isothiazole, substituted or unsubstituted benzimiidazole, substituted or unsubstituted benzoxazole, or sub stituted or unsubstituted benzotbiazole.
Compounds of structure I are readily synthesized from simple starting molecules as shown in the following Examples. Compounds of structure I may generally be prepared using benzene substituted with nitrile or carboxylic acid groups in addition to other optional groups.
Compounds of structure I may be synthesized from simple starting molecules as shown in Schemes 1-4 and exemplified in the Examples. As shown in Scheme 1, compounds of structure I may generally be prepared using aromatic compounds substituted with amines and carboxylic acid groups.
Scheme 1.
R
R CHCO 2
H
CO
2 H 0 0 .\rCO 2
.NH
2 C CMMe e H H H2N R 1 H
R
heat N
H
As shown in Scheme 1, a substituted aromatic compound such as a substituted or unsubstituted 2-aminobenzoic acid may be reacted with an acyl halide such as methyl 2-(chlorocarbonyl)acetate to produce an amide that will react with a substituted or unsubstituted 1,2-diaminobenzene. The resulting product is a 4hydroxy-substituted compound of structure I. One skilled in the art will recognize that the procedure set forth in Scheme 1 may be modified to produce various compounds.
A method for preparing 4-amino substituted compounds of structure I is shown in Scheme 2. As shown in Scheme 2, aromatic compounds substituted with amine and nitrile groups may be used to synthesize 4-amino substituted compounds of structure I. A compound such as ethyl 2-cyanoacetate may be reacted with ethanol to produce ethyl 3-ethoxy-3-iminopropanoate hydrochloride.
Subsequent reaction with a substituted or unsubstituted 1,2-phenylenediamine provides substituted or unsubstituted ethyl 2-benzimidazol-2-ylacetate. Reaction of 0 0 a substituted or unsubstituted ethyl 2-benzimidazol-2-ylacetate with an aromatic O 5 compound having an amine and nitrile group such as substituted or unsubstituted 2- O aminobenzonitrile with a base such as lithium bis(trimethylsilyl)amide or a Lewis t acid such as tin tetrachloride provides the substituted or unsubstituted 4-amino O substituted compound of structure I.
Scheme 2. H2N /R' S EtOH O NH HCI H 2 N N tO CN REtOH E SHCI Et OEt heat EtO 2
C
NR CN R R'
NH
2
NH
2 LIHMDS R
I
or CC SnCk Scheme 3 illustrates a general synthetic route that allows for the synthesis of 4-dialkylamino and 4-alkylamino compounds of structure I. An inspection of Scheme 3 shows that 4-hydroxy substituted compounds of structure I may be converted into the 4-chloro derivative by reaction with phosphorous oxychloride or thionyl chloride. The 4-chloro derivative may then be reacted with an alkylamine or dialkylamine to produce the corresponding 4-alkylamino or 4dialkylamino derivative. Deprotection affords the final 4-alkylamino or 4dialkylamino compounds of structure I. Other groups that may be reacted with the 4-chloro derivative in this manner include, but are not limited to, ROH, RSH, and CuCN.
-89- Scheme 3. H 2
N
0 EtOH 0 NH H HCI H 2 Ne t Et H EtO----OE heat HCI EtO OEt heat Et02C 0 NO R P N titiH UHMDS; heat (P protecting group) CI
R
POCI3 RA- R'NH 2 SOCI p SOC12 P As shown in Scheme 4, the synthesis of compounds of structure I having a H, alkyl group, aryl group, or heterocyclyl group in the 4-position may be accomplished using a substituted or unsubstituted 2-benzimidazol-2-ylacetate prepared as shown in Schemes 2 and 3.
Scheme 4.
EtO 2
C
H
R
COR"
NH
2 piperidine HOAc R" H, alkyl aryl, heterocyclyl H R'
H
Heteroaromatic diamines may be used as precursors of compounds of structure II. The synthesis of compounds of structure H where Y= NH2 is depicted in Scheme Scheme
R
R'
R'
O CN NH2 Heat NC 'R HCI, EtOH 0 N N EtO,-' I- NC. H I EtO N NH 2 H 2 0 EtO'-N 00
H
IND EtOH, heat c EtOH 0 NH'HCINH EtO C N HCI EtO'- OEt N NH 2 0R FV RNH 2 0-I 0 NR>A N o LiUHMDSN EtO( %RCN
NH
2 A compound such as ethyl cyanoacetate may be condensed with a substituted or unsubstituted heterocycle containing two ortho amino groups such as substituted or unsubstituted 1,2-diaminopyridine to obtain a substituted or unsubstituted 2-imidazolo[5,4-b]pyridin-2-ylethanenitrile, which may subsequently be hydrolyzed in acidic medium to provide a substituted or unsubstituted ethyl 2imidazolo[5,4-b]pyridin-2-ylacetate. As an alternate route, a substituted or unsubstituted ethyl 2-imidazolo[5,4-b]pyridin-2-ylacetate may be obtained from a compound such as the hydrochloride salt of 3-ethoxy-3-ininopropanoate and a substituted or unsubtituted 1,2-diaminopyridine. Reaction of a substituted or unsubstituted ethyl 2-imidazolo[5,4-b]pyridin-2-ylacetates with an aromatic compound having an amine and nitrile group such as substituted or unsubstituted 2aminobenzonitrile with a base such as lithium bis(trimethylsilyl)amide provides the substituted or unsubstituted compound of structure II.
The instant invention also provides for compositions which may be prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like, to treat or ameliorate a variety of disorders related to the activity of VEGF-RTK, more particularly angiogenesis associated with cancer. A therapeutically effective dose further refers to that amount of one or more compounds of the instant invention sufficient to result in amelioration of symptoms of the disorder. The pharmaceutical compositions of the instant invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, .emulsifying or levigating processes, among others. The compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. The instant compositions can be formulated for various routes of administration, for example, by oral administration, by transmucosal administration, by rectal administration, or subcutaneous administration as well as intrathecal, intravenous, intramuscular, intraperitoneal, intranasal, intraocular or intraventricular injection. The compound or compounds of the instant invention can also be administered in a local rather than a systemic fashion, such as injection as a sustained release formulation. The following dosage forms are given by way of example and should not be construed as limiting the instant invention.
For oral, buccal, and sublingual administration, powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive or excipient such as a starch or other additive. Suitable additives or excipients are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, sorbitol, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides, methyl cellulose, hydroxypropylmethyl-cellulose, and/or polyvinylpyrrolidone Optionally, oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Additionally, dyestuffs or pigments may be added for identification. Tablets and pills may be further treated with suitable coating materials known in the art.
I
-92- Liquid dosage forms for oral administration may be in the form of c pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, slurries and solutions, which may contain an inactive diluent, such as water. Pharmaceutical 00 formulations may be prepared as liquid suspensions or solutions using a sterile 0 5 liquid, such as, but hot limited to, an oil, water, an alcohol, and combinations of Sthese. Pharmaceutically suitable surfactants, suspending agents, emulsifying Iagents, may be added for oral or parenteral administration.
As noted above, suspensions may include oils. Such oil include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil.
Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
For nasal administration, the pharmaceutical formulations may be a spray or aerosol containing and appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these. A propellant for an aerosol formulation may include compressed air, nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent. The compound or compounds of the instant invention are conveniently delivered in the form of an aerosol spray presentation from a nebulizer or the like.
Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending C agents. Preferably, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
00 0\0 For injection, the pharmaceutical formulation may be a powder suitable for reconstitution with an appropriate solution as described above.
Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. For Sinjection, the formulations may optionally contaii stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The compounds may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion. A unit dosage form for injection may be in ampoules or in multi-dose containers.
For rectal administration, the pharmaceutical formulations may be in the form of a suppository, an ointment, an enema, a tablet or a cream for release of compound in the intestines, sigmoid flexure and/or rectum. Rectal suppositories are prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers of the compound, with acceptable vehicles, for example, cocoa butter or polyethylene glycol, which is present in a solid phase at normal storing temperatures, and present in a liquid phase at those temperatures suitable to release a drug inside the body, such as in the rectum.. Oils may also be employed in the preparation of formulations of the soft gelatin type and suppositories. Water, saline, aqueous dextrose and related sugar solutions, and glycerols may be employed in the preparation of suspension formulations which may also contain suspending agents such as pectins, carbomers, methyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.
Besides those representative dosage forms described above, pharmaceutically acceptable excipients and carries are generally known to those skilled in the-art and are thus included in the instant invention. Such excipients and -94carriers are described, for example, in "Remingtons Pharmaceutical Sciences" Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
00 The formulations of the invention may be designed for to be short- D acting, fast-releasing, long-acting, and sustained-releasing as described below.
Thus, the pharmaceutical formulations may also be formulated for controlled release or for slow release.
The instant compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect.
Therefore, the pharmaceutical formulations may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.
Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant invention.
A therapeutically effective dose may vary depending upon the route of administration and dosage form. The preferred compound or compounds of the instant invention is a formulation that exhibits a high therapeutic index. The therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LDso and EDso. The LDo is the dose lethal to 50% of the population and the EDso is the dose therapeutically effective in 50% of the population. The LDso and ED5o are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.
C, "Treating" within the context of the instant invention, means an alleviation of symptoms associated with a disorder or disease, or halt of further progression or worsening of those symptoms, or prevention or prophylaxis of the IN disease or disorder. For example, within the context of treating patients in need of an C 5 inhibitor of VEGF-RTK, successful treatment may include a reduction in the C proliferation of capillaries feeding a tumor or diseased.tissue, an alleviation of symptoms related to a cancerous growth or tumor, proliferation of capillaries, or C-1 diseased tissue, a halting in capillary proliferation, or a halting in the progression of a disease such as cancer or in the growth of cancerous cells. Treatment may also include administering the pharmaceutical formulations of the present. invention in combination with other therapies. For example, the compounds and pharmaceutical formulations of the present invention may be administered before, during, or after surgical procedure and/or radiation therapy. The compounds of the invention can also be administered in conjunction with other anti-cancer drugs including those used in antisense and gene therapy.
A method of treating a patient'in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase includes administering an effective amount of a pharmaceutical formulation according to the invention to a patient in need thereof.
A method for inhibiting tumor growth in a patient includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a patient having a tumor.
A method for inhibiting the proliferation of capillaries in a patient includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to a patient in need.
A method of preparing pharmaceutical formulations includes mixing any of the above-described compounds with a pharmaceutically acceptable carrier and water or an aqueous solution.
In another aspect the invention provides a method for synthesizing a 4amino substituted quinolinone compound, comprising: reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with a substituted or unsubstituted 2-aminobenzonitrile and a base or a Lewis acid, wherein the 4-amino substituted quinolinone compound is provided and the 4-amino substituted quinolinone compound comprises a benzimidazole group.
In another aspect the invention provides the 4-amino substituted quinolinone compound provided has structure I: wherein, Y is a -NR"R' group; Z is a NR 14 group;
R
2
R
3 and R 4 may be the same or different and are independently selected from the group consisting of H, CI, Br, F, I, -CN, -NO 2 -OH,
OR
1 5 groups, -NR 6R 7 groups, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and unsubstituted primary, secondary, and tertiary alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl 165118 1 Sgroups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted 00aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, 00 5 substituted and unsubstituted arylaminoalkyl groups, substituted and 0 unsubstituted diarylaminoalkyl groups, substituted and unsubstituted S(alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and 8 groups;
R
5
R
7 and R 8 may be the same or different and are independently selected from the group consisting of H, Cl, Br, F, I, -NO 2 -OH, -OR 1 9 groups, -NR2 0
R
21 groups, -SH, -SR 22 groups, -S(=O)R 23 groups, S(=0)2R 24 groups, -CN, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and unsubstituted primary, secondary, and tertiary alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=O)R 25 groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
R
9 and R' 4 are H;
R
12 is H; 165118 1
SR
13 is H; 0 R 5 and R 9 may be the same or different and are independently selected from the group consisting of substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted 00 I 5 heterocyclyl groups, substituted and unsubstituted heterocyclylalkyl Sgroups, -C(=O)-alkyl groups, -C(=O)-aryl groups,
SC(=O)NH
2 -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, SC(=O)N(alkyl) 2 groups, -C(=O)N(aryl) 2 groups, -C(=O)N(alkyl)(aryl) groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl, substituted and unsubstituted diheterocyclylaminoalkyl, substituted and unsubstituted (heterocyclyl)(alkyl)aminoalkyl, substituted and unsubstituted (heterocyclyl)(aryl)aminoalkyl, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups;
R
16 and R 20 may be the same or different and are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups;
R
1 7 and R 2 1 may be the same or different and are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, -C(=O)-alkyl groups, C(=O)-aryl groups, -C(=O)NH 2 -C(=O)NH(alkyl) groups, 165118 1 C(=O)NH(aryl) groups, -C(=O)N(alkyl) 2 groups, -C(=O)N(aryl) 2 n groups, -C(=O)N(alkyl)(aryl) groups, -C(=O)O-alkyl groups, 00 aryl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted aminoalkyl groups, substituted and 00 5 unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl Sgroups, substituted and unsubstituted diarylaminoalkyl groups, Ssubstituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, heterocyclyl groups, -C(=O)-O-heterocyclyl groups, C(=O)NH(heterocyclyl) groups, -C(=O)-N(heterocyclyl) 2 groups, C(=O)-N(alkyl)(heterocyclyl) groups, -C(=O)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; R R 24, and R25 may be the same or different and are independently selected from the group consisting of H, -NH 2 -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl) 2 groups, -N(aryl) 2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2 groups, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, -OH, substituted and unsubstituted alkoxy groups, substituted and unsubstituted aryloxy groups, substituted and unsubstituted heterocyclyl groups, -NHOH, -N(alkyl)OH groups, -N(aryl)OH groups, -N(alkyl)O-alkyl groups, -N(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, and -N(aryl)O-aryl groups; and 165118 1 22 R22 is selected from the group consisting of substituted and n unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups; and further wherein at least one of R 5
R
6
R
7 or R 8 is selected from the 00 group consisting of substituted and unsubstituted amidinyl groups, N substituted and unsubstituted guanidinyl groups, substituted and unsubstituted saturated heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; -OR 9 groups wherein R' 9 is selected from the group consisting of substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=O)-aryl groups, -C(=O)NH 2 -C(=O)NH(alkyl) groups, C(=O)NH(aryl) groups, -C(=O)N(alkyl) 2 groups, -C(=O)N(aryl) 2 groups, -C(=O)N(alkyl)(aryl) groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted diheterocyclylaminoalkyl groups, substituted and unsubstituted (heterocyclyl)(alkyl)aminoalkyl groups, substituted and unsubstituted 165118 1 S(heterocyclyl)(aryl)aminoalkyl groups, substituted and unsubstituted Shydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, 00 _substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; -NR 2 0R 21 groups wherein 00 5 R20 is selected from the group consisting of substituted and O unsubstituted heterocyclyl groups; -NR20R 2 1 groups wherein R 2 1 is Sselected from the group consisting of substituted and unsubstituted heterocyclyl groups, -C(=O)-aryl groups, -C(=O)NH 2 C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl) 2 groups, C(=O)N(aryl) 2 groups, -C(=O)N(alkyl)(aryl) groups, C(=O)O-alkyl groups, -C(=O)O-aryl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; and -C(=O)R 25 groups wherein R 25 is selected from the group consisting of H, -NH 2 -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl) 2 groups, -N(aryl) 2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl) 2 groups, substituted and unsubstituted aryl groups, substituted and unsubstituted aryloxy groups, and substituted and unsubstituted heterocyclyl groups.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of 165118 1 C providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general
;Z
knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
00 Throughout this specilication the word "comprise", or variations such as
IND
"comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
165118 1 -96- .The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provi ded -by way of illustration and are not intended to be limiting of thepresent invention.
EXAMIPLES
ATP:
BSA:
DMA:
DMF:
dppf:
DTT:
EDTA:
EtOAc: EtOH: H1n3TU: ICso value: LiHMDS: MeOH,:
NMP:
THF:
The following abbreviations are used in the Examples: Adenosine triphosphate Bovine Serum Albumin N,N-Dimethylacetamide N,N-Dimethylformamide 1,1 '(diphenylphosphino)ferrocene DL-Dithiothreitol- Ethylene diamine tetraacetic acid Ethyl acetate Ethanol O.-Benzotriazol-1-yl-N,N,N' ,N'-tetramethyluronium hexafluorophosphate The concentration of an inhibitor that causes a 50 reduction in a measured activity.
Lithium bis(trimethylsilyl)amide Methanol N-methylpyrrolidone Tetrahydrofuran The compounds were named using Nomenclator 3.0 v. .0 from Cmemlnovation Software, Inc. and ACD/Name v. 4.53.
The various aryl diamine starting materials used to synthesize benzimidazole acetates may be obtained from commercial sources,* prepared by methods know to one of skill in the art, or prepared by the following general Methods 1-15.
-97- Method 1 F NH 2 bNO 2
NH
2 F R'RN 2,4-Difluoronitrobenzene (1.0 eq) was placed in a dry roundbottomed flask equipped with a dry ice condenser charged with acetone and dry ice.
Ammonia was condensed into the flask and the resulting solution was stirred at reflux for 7 hours. A yellow precipitate formed within 1 hour. After 7 hours, the condenser was removed and the liquid ammonia was allowed to evaporate over several hours. The crude product was purified by flash chromatography on silica gel (85:15 hexanes:ethyl acetate, product at Rf 0.32, contaminant at Rr 0.51); GC/MS m/z 156.1 R 11.16 minutes.
The resulting 5-fluoro-2-nitrophenylamine (1.0 eq) and an amine (1.1 .eq) e.g. N-methyl piperazine, were dissolved in NMP and triethylamine (2.0 eq) was added. The reaction mixture was heated at 100 0 C for 3 hours. The solution was then cooled to room temperature and diluted with water. The resulting precipitate was filtered and dried under vacuum to provide the 2-nitro-diamino product. Alternatively, the same product may be obtained from commercially available 5-chloro-2-nitrophenylamine under identical conditions except heating at 130 0 C for 1-2 days. In some examples, the displacement on either 5-fluoro-2nitrophenylamine or 5-chloro-2-nitrophenylamine can be conducted in neat amine eq) at 100 0 C or 130 respectively. The product is isolated in an identical manner. LC/MS m/z 237.1 Ri 1.304 minutes.
The nitroamine (1.0 eq) and 10% Pd/C (0.1 eq) was suspended in anhydrous ethanol at room temperature. The reaction flask was evacuated and subsequently filled with 12. The resulting mixture was then stirred under a hydrogen atmosphere overnight. The resulting solution was filtered through Celite and concentrated under vacuum to provide the crude product which was used without further purification.
4e Method 2 m NO2
NH
2
NH
2 NH 2 00 F F IN F NRR' A round-bottom flask was charged with 2,3-difluoro-6- Initrophenylamine (1 eq) and enough NMP to make a viscous slurry. An amine eq), e.g. N-methyl piperazine, was added and the solution was heated at 100 0
C.
After 2 hours, the solution was cooled and poured into water. A bright yellow solid formed which was filtered and dried. The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification. LC/MS m/z 225.1 P 0.335 minutes.
Method 3
NO
2 NH 2 F F R'RN. NH 2 To a 0.1 M DMF solution of 1,3-difluoro-2-nitrobenzene was added EtbN (2 eq) followed by an amine (1 eq), e.g. morpholine. The mixture was stirred for 18 hours and then diluted with water and extracted with ethyl acetate. LC/MS m/z 227.2 R 2.522 minutes. The combined organic layers were dried over MgSO4, filtered, and concentrated. Ammonia was condensed into a bomb containing the crude product. The bomb was sealed and heated to 100°C (over 400 psi). After 72 hours the bomb was allowed to cool and the ammonia was evaporated to provide a reddish solid. The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification. LC/MS m/z 194.1 Rt 1.199 minutes.
-99- Method 4
NH
2
NH
2 SNO2
NH
2 F RO c" To a stirred NMP solution containing NaH (1.3 eq) was added an 0 alcohol (1.0 eq), e.g. 2-methyloxyethanol. The resulting mixture was then stirred C< 5 for 30 minutes. A slurry of 5-fluoro-2-nitrophenylamine in NMP was then added slowly. The mixture was then heated to 100°C. After 2 hours, the reaction mixture was cooled and water was added. The mixture was then filtered and the captured solid was washed with water and purified by silica gel chromatography (1:1 ethyl acetate:hexane). LC/MS m/z 213.2 .I2.24 minutes. The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification. LC/MS m/z 183.1 R0.984 minutes.
Method
NH
2 NH 2 ,a N02 NH2 HO'O
RON
Diisopropyl azodicarboxylate (1.1 eq) was added dropwise to a stirred solution of 4-amino-3-nitrophenol (1.0 eq), triphenylphosphine (1.1 eq), and an alcohol, e.g. N-(2-hydroxyethyl)morpholine (1.0 eq), in tetrahydrofuran at 0°C.
The mixture was allowed to warm to room temperature and stirred for 18 hours.
The solvent was evaporated, and the product was purified by silica gel chromatography (98:2 CH2Ch:methanol) to yield 4-(2-morpholin-4-ylethoxy)-2nitrophenylamine as a dark reddish-brown oil. LC/MS m/z 268.0 Rt 1.01 minutes. The nitroamine was reduced as in Method 1 to give the crude product which was used without further purification. LC/MS m/z 238.3 RI 0.295 minutes.
-100- Method 6
NH
2
NH
2
NH
2
NH
2 N0 2
NO
2
NO
2 NH2 OH O(4 Br O NRR' Ot NRR' cI To a flask charged with 4-amino-3-nitrophenol (1 eq), K2CO3 (2 eq), and 2-butanone was added an alkyl dibromide, e.g. 1,3-dibromopropane C1 (1.5 eq). The resulting mixture was then heated at 80 0 C for 18 hours. After cooling, the mixture was filtered, concentrated, and diluted with water. The solution was then extracted with CH2Ch (3 x) and the combined organic layers were concentrated to give a solid that was then washed with pentane. LCMS m/z 275.1 R2.74 minutes.
An acetonitrile solution of the bromide prepared above, an amine, e.g. pyrrolidine (5 eq), Cs2CO3 (2 eq) and Bu4NI (0.1 eq) was heated at 70*C for 48 hours. The reaction mixture was cooled, filtered, and concentrated. The residue was dissolved in CH2Ch, washed with water, and concentrated to give the desired nitroamine, 2 -nitro- 4 -(3-pyrrolidin-1-ylpropoxy)phenylamine. LCMS m/z 266.2 R 1.51 minutes. The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification.
Method 7
NH
2 NH 2 N- N 0 2 N NH 2 Cl
NR'R.
To a suspension of 6-chloro-3-nitropyridin-2-amine (1 eq) in acetonitrile was added an amine, e.g. morpholine (4 eq). The resulting reaction mixture was stirred at 70 0 C for 5 hours. The solvent was evaporated under reduced pressure, and the residue triturated with ether to provide the desired compound as a bright yellow powder. LC/MS m/z 225.0 R 1.79 minutes.
-101c The nitroamine was reduced as in Method 1 to provide the crude product which was used without further purification.
00 Method 8:
,NO
2 DMF NO 2 0 A O H r NH Ar^H CI NH 2
K
2 C0 3 Ar"o I NH 2 In A phenol (1 equivalent) and 5-chloro-2-nitro aniline (1 equivalent) were dissolved in DMF, and solid K2C03 (2 equivalents) was added in one portion.
The reaction mixture was heated at 120 0 C overnight. The reaction mixture was cooled to room temperature, most of the DMF was distilled off, and water was added to the residue to obtain a precipitate. The solid was dried and purified by chromatography on silicagel (2-10% MeOH/CH2C) to afford the desired product.
The nitroamine was reduced as in method 1 to give the crude product that was used without further purification.
Method 9
H
2 N- O Me KOH N 2
N'R
2 z N 2. RjR 2 NH N H H N^0 ^N H H Furthermore, the introduction of substituents on the benzimidazole ring need not be limited to the early stages of the synthesis and may arise after formation of the quinolinone ring. For example, the crude methyl ester shown in the figure above was dissolved in a 1:1 mixture of EtOH and 30% aqueous KOH and stirred overnight at 70*C. The reaction mixture was then cooled and acidified with 1N HC1 to give, a precipitate. The solid was filtered, washed with water and dried to obtain 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-yl)-1H-benzimidazole-6carboxylic acid 2 4 -amino-2-oxo-3-hydroquinolyl)benzimidazole-6-carboxylic acid as a brown solid. LC/MS m/z: 321.1 R 2.26 minutes.
-102- A mixture of 2-(4-amino-2-oxo-1,2-dihydroquinolin-3-yl)-lHbenzimidazole-6-carboxylic acid (1 eq) the amine (1 eq), EDC dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1.2 eq), HOAT (1- 00 hydroxy-7-azabenzotriazole, 1.2 eq) and triethylamine (2.5 eq) in DMF, was stirred at 23 *C for 20 h. The reaction mixture was partitioned between water and ethyl 0acetate. The combined organic layers were dried (Na2SO4) and concentrated.
t Water was added and the precipitate thus formed was filtered off and dried to afford the desired product.
The various 2-amino benzoic acid starting materials used to synthesize isatoic anhydrides may be obtained from commercial sources, prepared by methods know to one of skill in the art, or prepared by the following general Methods 10-11. General isatoic anhydride synthesis methods are described in J.
Med. Chern. 1981, 24 735 and J. Heterocycl. Chem. 1975, 12(3), 565.
Method
NH
2 1.NaN02 CN H 2 S0 4 C0 H MeO NO 2 2. CuCN MeO NO 2
H
2 0 MeO NO 2 1 2 3 Pd/C CO 2 H Bn(Me) 3 NBr 3 Br CO 2
H
NH
4 H, 50C MeO NH 2 CaCO 3 DCM. MeO NH 2 MeOH 4 Compounds 1-3 were made using similar procedures as found in U.S.
Patent No. 4,287,341. Compound 3 was reduced using standard hydrogenation conditions of 10% Pd/C in NH40H at 50 0 C over 48 hours. The product was precipitated by neutralizing with glacial acetic acid, filtering, and washing with water and ether. Yields were about 50%. Compound 5 was prepared in a manner similar to that disclosed in U.S. Patent No. 5,716,993.
-103- Method 11 1. Iodine, 2 Ag 2
SO
4
CO
2 Me EtOH I CO2H Cl NH 2 2. NaOH 3N CI NH 2 3. aq. HCI 1. Iodine, F Ag 2
SO
4
F
^.CO
2 Me EtOH I CO 2
H
SNH
2 2. NaOH 3N NH2 3. aq. HCI 1. Iodine, Ag 2
SO
4 KYCO2Me EtOH I CO 2
H
F" NH 2 2. NaOH 3N F NH 2 3. aq. HCI lodination of aniline containing compounds: lodination was done by a similar procedure as in J. Med. Chem. 2001, 44, 6, 917-922. The anthranilic ester in EtOH was added to a mixture of silver sulfate (1 equivalent) and 12 (1 equivalent). The reaction was typically done after 3 hours at room temperature.
The reaction was filtered through celite and concentrated. The residue was taken up in EtOAc and washed with aqueous saturated NaHCO3 water brine (lx), dried (MgSO4), filtered, and concentrated. The crude product g) was dissolved in MeOH (60-100 ml), NaOH 6N (25 ml), and water (250 ml). The reactions were typically done after heating at 70-80°C for 4 hours. The reaction mixture was extracted with EtOAc neutralized with aqueous HCI, filtered to collect the solids, and the solid products were washed with water. The products were dried in vacuo.
In various instances, substitutions on the quinolinone ring may also be introduced after coupling as shown in the general methods 12-15.
-104- Method 12
H
NO0
H
Pd, Gui, CO NHIR N H0 2 C~
I~
NO
H
X Br, TfO Conversion of the C-6 or C-7 halides to an acid group was accomplished using procedures in the following references Koga, et al., Tet.
Let., 1995, 36, 1, 87-90 and Fukuyaina, et al., J. Am. Chem. Soc., 1994, 116, 3125-3126.
Method 13 NHR
N_
xN
N
H
Pd, KCN or NaCN Gui, THF NC,1:) I N
H
NO
H
X 1 Br, TfO Conversion of the .0-6 or C-7 halides to a cyano group was accomplished using procedures in the following reference Anderson, et al., J. .Org. -Chem., 1998, 63, 8224-828.
Method 14 NHIR NIx
'N
H
NO
H
X 1 Br, TfO Pd(dPPf)01 2 /Ci 2
CH
2 Y B(OH) 2 or Sn(nBu) 3 7 FIR
N
N
H
H
Conversion of the C-6 or C-7 halides to an aryl group was accomplished using standard Suzuki or Stille procedures such as described below.
-105c Suzuki Method: To a 1 dram (4 ml) vial was added sequentially the quinolone (1 equivalent), boronic acid (1.2-1.5 equivalents), Pd(dppf)Ch, C12CH2 (0.2 equivalents), DMF (0.5 1 ml) and TEA (4 equivalents). The reaction was 00 \0 flushed with argon, capped and heated at 85 0 C for 12 hours. Once done, the C 5 reaction is cooled to room temperature, and filtered with a syringe filter disk. The C clear solution is then neutralized with TFA (a couple of drops) and injected directly 0onto a preparative HPLC. The products are lyophilized to dryness.
Stille Method: To a 1 dram (4 ml) vial was added sequentially the quinolone (1 equivalent), tin reagent (1.8 equivalent), Pd(dppf)C2 C2CH2 (0.2 equivalents), and DMF (0.5 1 ml). The reaction was flushed with argon, capped and heated at 60-85 0 C for 4 hours. Once done, the reaction is cooled to room temperature, and filtered with a syringe filter disk. The clear solution is then neutralized with TFA (a couple of drops) and injected directly onto a preparative HPLC. The products are lyophilized to dryness.
Method NHR N R-YH NHR N X N X
N
N O 90-95 C HI H VNM H18h R x, x' F, CI, I Y NH, O, S A dihaloquinolone such as a difluoroquinolone (12-15 mg) was placed in a 1 dram (2 ml) vial. NMP (dry and pre-purged with argon for minutes) was added to the vial (0.5 ml). The amine reagent (40-50 mg) was added next. If the amine was an HC1 salt, the reaction was neutralized with TEA 1.2equivalents). The reaction was purged again with argon for about 5 seconds, and immediately capped. The reaction was typically heated in a heating block at 90-95 0 C for 18 hours. The reaction was followed by HPLC or LCMS. After taking samples for HPLC, the vial was purged with argon again and capped. Some coupling partners took 24 or 48 hours to reach completion. Less nucleophilic -106- 4 amines like pyrrole required the addition of a strong base to reach completion. In these cases, cesium carbonate (2 equivalents based on the amine used) was added to the reaction. Once done, the reaction was cooled to room temperature, and filtered 00 with a syringe filter disk. The clear solution was then neutralized with TFA (a O 5 couple of drops) and injected directly onto a preparative HPLC. The products were Slyophilized to dryness.
In Example 1 Ethyl 2-benzimidazol-2-ylacetate A solution of 1,2-phenylenediamine (1.0 eq) and ethyl 3-ethoxy-3iminopropanoate hydrochloride (1.3 eq) in ethanol was stirred at 90°C overnight.
The reaction was cooled to room temperature and the solvent was removed in vacuo. Water and CH2Ch were added to the residue. The organic layer was separated, dried over Na2SO4 and the solvent removed. The solid recovered was used without purification. LC/MS m/z 205.2 R 1.44 minutes.
5-(4-Methylpiperazinyl)-2-nitrobenzenecarbonitrile 5-Fluoro-2-nitrobenzenecarbonitrile (1.02 eq) and Nmethylpiperazine (1.0 eq) were dissolved in NMP. Triethylamine (2.1 eq) was added, and the resulting solution heated at 100*C for 1 hour. The solution was cooled to room temperature and poured into H20. A precipitate formed which was filtered to yield the desired product as a green solid. LC/MS m/z 247.3 Rb 1.46 minutes.
2-Amino-5-(4-methylpiperazinyl)benzenecarbonitrile 5-(4-Methylpiperazinyl)-2-nitrobeenecarbonitrile (1.0 eq) was dissolved in EtOAc. The flask was purged with nitrogen, and 10% Pd/C (0.1 eq) was added. The flask was evacuated and purged with 12 three times. The resulting mixture was stirred for three days at room temperature. The mixture was filtered through Celite and the filter pad was washed with EtOAc. The solvent was removed in vacuo to give a yellow solid which was purified by silica gel -107chromatography (5:1:95 MeOH:Et3N:Et0Ac) to give the desired product as a yellow solid. LC/MS in/z 217.3 Rt 0. 95 minutes.
00 IND Method A 4 -Amino-3-benziniidazol-2.yl-6-(4-methylpiperazinyl)hydroqiiin...2one cI 5 Ethyl 2-benzimidazol-2-ylacetate 1 eq) and 2-amino-5-(4methylpiperazinyl)benzenecarbonitrile (1.0 eqi) were dissolved in 1,2c-I dichioroethane, and then SnC14 (11 eq) was added. The mixture was heated at reflux overnight. Upon cooling, the mixture was concentrated in vacuo. NaOil (3 M) was added to the solid, and the mixture heated at 80*C for 0.5 hours. The solid was filtered and washed sequentially with H20, CH2Cb, and acetone. LCIMS indicated that the product was present in the acetone layer and the solid." These fractions were combined and purified by silica gel chr omatography (5-10% MeOH in CH2CE with 1 EtbN) to give the desired. product. LC/MS rn/z 375.4 (MH+)
R
1 1. 65 minutes..
Example 2 6 -Aniino-2-(2-morpholin-4-ylethoxy)benzenecarbonitrjle 4-(Hydroxyethyl)morpholine (1.02 eq) 'was added to Nail (1.2 eq) in NMP. After 10 minutes, 6-amino-2-flutorobenzenecarbonitrile 0 eq) was added in NMP. The resulting mixture was heated at 100*C for 1 hour. The mixture was then cooled and poured into 1120. The aqueous layer was extracted with EtOAc.
The combined organic layers were washed with brine, dried over Na2SQ4, filtered, and concentrated in vacuo to a yield a brown gum. The crude material was purified by silica gel chromatography (5:1:95 MeQH:Et3N:EtOAc) to give the desired product. LCIMS m/z 248.3 (MU R, 1.26 minutes.
4-Amiino-3-benziumidazol-7,yl-5-(2-morpholin-4-ylethoxy)hydroquinolin-2oneThe -title compound was synthesized as described in Example 1, Method A using 6-amino-2-(2-morpholin-4-ylethoxy)benzenecarbonitrile. LC/MS m/z 406.4 (MH Rtl1.-67 minutes.
-108- Example 3 4-(2-Morpholin-4-ylethoxy)-2-nitrophenylamine Dilsopropyl azodicarboxylate 1 eq) was added dropwise to a 00 sirdslto f4aio3ntohnl(. qtihnlhshn 11e) n streIouinoNDnio--irpeo 10e) rphnlhshn 11e) n S 5 N-{2-hydroxyethyl)morpholine (1.0 eq), in THF at 0 0 C. The mixture was allowed to warm to room temperature and left to stir for 18. hours. The solvent was evaporated and the product was purified by silica gel chromatography (98:2 CC2:MeOH) to yield a dark reddish-brown oil. LC/MS m/z 268.0 (MU R 1.01 minutes.
4-(2-Morpholin-4-ylethoxy)benzene-1,2-diamine To a solution 4-(2-morpholin-4-ylethoxy)-2-nitrophenylamine in EtOH was added'Pd/C 1 eq). The reaction vessel was repeatedly purged with nitrogen, then stirred under a hydrogen atmosphere (1 atmi) for 18 hours. The product was filtered through a Celite plug, and the plug washed with EtOH. The diamine was used without purification. LC/MS m/z 23 8.3 RZI 0.295 nunutes.
Ethyl 2-[5-(2-morpholin-4-ylethoxy)benziniidazol-2-yllacetate The title compound was synthesized as described in Example 1 using 4-(2-morpholin-4-ylethoxy)benzene-1,2-diaxnine. The organic layer was concentrated and the residue was purified by silica gel chromato graphy (10: 1:2 CH2hb:MeOH:EtOAc) to yield a dark reddish brown oil. LCIMS m/z 334.4 (MH Rt 1.08 minutes.
4-Amino-3-[5-(2-morphftlin-4-ylethoxy)benzimidazol-2-yl]-6-nitrohydroquinolin- 2-one The title compound-Was synthesized as described in Example 1, Method A using ethyl 2-[5-(2-morpholin-4-ylethoxy)benzmiazol-2-yl]acetate and The crude product was purified by silica gel chromatography 10 MeOH in CH2Ch with 1 Et3N) to give the desired product. LC/MS m/z 451.2 (MH lb 1. 89 minutes.
-109- Example 4 4-Ainxo-5-(2-morpholin-4-ylethoxy)-3-[5-(2-morpholin-4-ylethoxy)benziinidazol-2-yl]hydroquinolin-2-one 00 IND The title compound was synthesized as described in Example 1, cI 5 Method A using ethyl 2-[5-(2-morpholin-4-ylethoxy)benzimidazol-2-yl]acetate and (N 6-amino-2-(2-morpholin-4-ylethoxy)benzenecarbonitrile. LCIMS m/z 535.4 Rt 1.44 minutes.
Example acid The title compound was synthesized as described in Example 1 using 3,4-diaminobenzoic acid. The crude material was purified by silica gel chromatography (5:95 MeOH:ClliCb2) to afford the desired product as. a white to off-white solid. LCIMS m/z 249.1 R 1 1.35 minutes.
Ethyl 2-[5-(N,N-dimethylcarbamoyl)benzimidazol-2-yllacetate 2-[(Ethoxycarbonyl)methyl]benzimidazole-5-carboxylic acid (1.0 eq) was dissolved in THE. HBTU (1.1I eq) and diisopropylethylamine (2.0 eq) were added, followed by diniethylaxnine (2.0 M in THF, 1.1 eq). The reaction-was stirred at room temperature overnight then concentrated and the resulting residue was purified by silica gel chromatography (5:95'MeOH:CHZ2Cl2) to -afford the desired compound. LC/MS m/z'276.2- P, 1. 18 minutes.
[2-(4-aino-2-oxo(3-hydroquinolyl))benzimidazol-5-yl]-N,N dimethylcarboxamide.
The title compound was synthesized as described in Example 1, Method A using ethyl 2-[5-(N,N-dimethylcarbamnoyl)benzimidazol-2-yl~acetate and anthranilonitrile. T Ihe resulting solid was collected by filtration and. washed with water followed by acetone to afford the desired product as a white solid. LCIMS m/z 348.3 R, 1.87 minutes.
-110- SExample 6
S
4 -Amino- 3 -[5-(morpholin-4-ylcarbonyl)benzimidazol-2-yl]hydroquinolin-2-one.
acid (1.0 eq) 00 IN was dissolved in THF. HBTU (1.1 eq) and diisopropylethylamine (2.0 eq) were added, followed by morpholine (1.1 eq). The reaction was stirred at room temperature for 3 days then concentrated and purified by silica gel chromatography (5-10% methanol/dichloromethane). The product-containing fractions were Sconcentrated and dissolved in anhydrous 1,2-dichloroethane. Anthranilonitrile eq) was added followed by SnCL (5.0 eq) and the reaction was heated at overnight. The reaction mixture was concentrated and the resulting residue was redissolved in NaOH (2 M) and heated at 90C for 4 hours. After cooling to room temperature, the resulting solid was collected and washed with water followed by acetone to afford the desired product. LC/MS m/z 390.2 RP 1.95 minutes.
Example 7 4-Bromobenzene-l,2-diamine A solution of 4-bromo-2-nitroaniline (1.0 eq) and SnCh2(2.2 eq) in EtOH was heated at reflux for 3 hours. After this time, the solution was poured onto ice, brought to pH 10 with 2M NaOH and extracted with Et2O. The combined organic layers were dried over MgSO4 and concentrated. The resulting brown oil was purified by silica gel chromatography (0-50% EtOAc:hexanes) to provide a light yellow solid. LC/MS m/z 187.1 R 1.33 minutes.
2-Nitro-4-(2-thienyl)phenylamine 4-Bromo-2-nitroaniline (1.0 eq) and Na2COs (2.0 eq) were dissolved in DMF/H20 at room temperature. Nitrogen was bubbled through the reaction mixture for 5 minutes and PdCl2(dppf)2 (0.1 eq) was added. After stirring at 23"C for approximately 10 minutes, 2-thiopeneboronic acid (1.1 eq) in DMF was added and the reaction was heated at 90 0 C for 12 hours. After this time, the solution was concentrated and partitioned between EtOAc and H20. The layers were separated and the aqueous layer was extracted with EtOAc. The combined -111organic layers were dried over MgSO4 and concentrated under reduced pressure.
The resulting black residue was purified by silica gel chromatography (0-20% EtOAc:hexanes) to yield an orange solid. LC/MS m/z 221.1 R 2.67 minutes.
Ethyl 2-[5-(2-thienyl)benzimidazol-2-yl]acetate 2-Nitro-4-(2-thienyl)phenylamine (1.0 eq) and 10% Pd/C (0.1 eq) were suspended in anhydrous EtOH at room temperature. The reaction flask was evacuated and subsequently filled with iH. The resulting mixture was allowed to stir under a hydrogen atmosphere for 3 hours. Ethyl 3-ethoxy-3-iminopropanoate hydrochloride (2.0 eq) was then added and the resulting mixture was heated at reflux for 12 hours. After this time, the solution was filtered through a plug of Celite, concentrated, dissolved in 50 ml of 2N HCI and washed with CH2CI2. The aqueous layer was brought to pH 12 with concentrated NH40H(aq) and extracted with CIHC12. The combined organic layers were dried with MgSO4 and concentrated to yield a brown oil which was purified by silica gel chromatography (5:95 MeOH:CH2Cl2) to provide a yellow solid. LC/MS m/z 287.1 R 1.98 minutes.
4-Amino-3-[5-(2-thienyl)benzimidazol-2-yl]hydroquinolin-2-one The title compound was synthesized as described in Example 1, Method A using ethyl 2-[5-(2-thienyl)benzimidazol-2-yl]acetate and anthranilonitrile. LC/MS m/z 359.2 RI 2.68 minutes.
Example 8 5-Fluoro-2-nitrophenylamine 2,4-Difluoronitrobenzene (1.0 eq) was placed in a dry roundbottomed flask equipped with a dry ice condenser charged with acetone/dry ice.
Ammonia was condensed into the flask and the resulting solution was stirred at reflux for 7 hours. A yellow precipitate was formed within 1 hours. After 7 hours, the condenser was removed and the liquid ammonia was allowed to evaporate over several hours. The crude product was purified by flash chromatography on silica -112of gel (85:15 Iiexanes:EtQAc, product at Ri 0.32, contaminant at 0.51).
GO/MS m/Z. 156.1 R 1 11.16 minutes.
00 2-Nitro-5-[1-(1 ,2,4-triazolyl)]phenylaniine IND5-Fluoro-2-nitrophenylamine (1.0 ecj), IH-1 ,2,4-triazole (3.0 eq) and NaHl (3.0 eq) in NMP were heated at .100*0 for 1 hour. The solution was cooled to room temperature and slowly poured onto ice water. The resulting precipitate was filtered and dried under vacuum to yield the desired product. The resulting so lid was recrystallized from EtOl to afford pure product as a bright yellow solid.
LCIMS m/z 206.2 (MH Rt 1. 88 minutes.
Ethyl 2-{5-I-(1,2,4-triazolyl)]benzimidazol-2-yljacetate .The title compound was synthesized as described in Example 7 using 2 -nitro-5-[1-(l,2,4-triazoly)]phenylamine. LC/MS m/z 272.1 R, 1.19 minutes.
4 -Amino-3-{5-[1-(1,2,4-triazolyl)]benziluidazol-2-yllhydroquinoln.2one The title compound was synthesized as described in Example 1, Method A using ethyl ,2,4.-trazolyl)]benzimidazol-2-yl~acetate and anthranilonitrile. The crude solid was collected and purified by silica gel chromatography (92:7:1 Clh2:MeOH:EtSN). LCIMS m/z 344.3 R, 2.01 minutes'.
Example 9 Method B N-(4-Chloro-2..cyanophenyl)-2-(5-morpholin4.ylbenzimidazol-2 yl)acetamideLiHMDS (2.5 eq) was added to ethyl 2-[5-(2-morpholin-4ylethoxy)benzimidazol-2-yllacetate (1.0 eq) in THF at, -78'C. After 1 hour, 2amino-5-clilorobenzenecarbonitrile (0.82 ea) in THIF was added. The reaction was allowed to warm to 2300 and stirred overnight. The resulting mixture was quenched with NH4C1 (aqueous saturated solution) and extracted with EtOAc. The combined organic layers were washed with H20 and brine, dried over Na2SO4, -113filtered and concentrated in vacua to yield a brown solid. The crude material was purified by silica gel chromatography (5:1 EtQAc:hexane) to give the desired product. LC/MS m/z 396.1 Ri 1.79 minutes.
00 4 -Anino-6-chloro-3-(5-morpholin-4-ylbenzimidazo-2-y1)hydroquinoin-2-one N-(4-chloro-2-cyanophenyl)-2-(5-morpholin-4-ylbenzimidazol-2yl)acetamnide (1.0 eci) was heated in NaQMe (0.5 M in MeOH, 18 eq) at 70 0 C for 2 hours. The resulting mixture was cooled, and the resulting solid was filtered and washed with water to give the desired product. LC/MS m/z 396.4 R2.13 minutes.
Example 2-Nitro-S-piperidylphenylamine The title compound was synthesized as described in. Example 8 using piperidine. (3.0 eq, excess acts as base in place of Nail). The desired product was obtained as a yellow, crystalline solid. LC/MS m/z 222.2 -(MH Rr 2. 53' minutes.
Ethyl 2-(5-piperidylbenzimidazol-2-yl)acetate The title compound was synthesized as described in Example 7 using The desired product was obtained as a yellow oil.
LCJMS m/z 288.3 R, 1.31 minutes.
4 -amino-3-(5-piperidylbenzimidazol-2-yI)hydroquinolin-2-one The title compound was synthesiied as described in Example 9, Method B using ethyl 2-(5-piperidylbenziniidazol-2-yl)acetate and anthranilonitrhe.
The acyclic amide was used crude in the NaOMe cyclization step. The desired product was obtained following purification by silica gel chromatography (96.5:3.0:0.5 C112C2:MeOH:EtiN, Rf LC/MS m/z 360.4 Ri 1.83 minutes.
-114k Example 11 [1-(3-Anmino-4-nitrophenyl)pyrrolidin-3-yl]dimethylamine The title compound was synthesized as described in Example 8 using 00 3-(dinethylamino)pyrrolidine (3.0 eq, excess amine was used as the base in place of O 5 Nai). LCIMS m/z 251.3 R 1.25 minutes.
Ethyl 2-{5-[3-(dimethylamio)pyrrolidinyllbenzimidazol-2-yllacetate The title compound was synthesized as described in Example 7 using [1-(3-amino-4-nitrophenyl)pyrrolidin-3-ylldimethylamine. The desired product was obtained as a yellow oil. LC/MS m/z 317.4 Rz 1.36 minutes.
2-{S-[3-Dimethylamino)pyrrolidinyl]benzimidazol-2-yl}-N-(4-chloro-2cyanophenyl)acetamide The title compound was synthesized as described in Example 9, Method B using ethyl 2-{5-[3-(dimethylamino)pyrrolidinyl]benzimidazol-2yl)acetate. LCIMS m/z 423.4 %L 1.67 minutes.
4-Amino-3-{5-[3-(dimethylamino)pyrfrolidinyl]benziidazol-2-yl}-6chlorohydroquinolin-2-one The title compound was synthesized as described in Example 9; Method B using 2-{5-[3-(dimethylamino)pyrrolidinyllbenzimidazol-2-yl}-N-(4chloro-2-cyanophenyl)acetamide. LC/MS m/z 423.4 (MH RL 1.71 minutes.
Example 12 Ethyl 2-[5-(dimethylamino)benzimidazol-2-yl]acetate The title compound was synthesized as described in Example 7 using (3-amino-4-nitrophenyl)dimethylamine. The resulting tan film was purified by silica gel chromatography (5:1:94 MeOH:Et3N: CH2Cl2) to give the desired product.
LC/MS 248.3 m/z Ri 1.24 minutes.
-115- 2[5-(Dimethylamino)benzimidazol-2-yl]-N-(2-cyanophenyl)acetaide The title compound was synthesized as described in Example 9, Method B using ethyl 2-[5(dimethylamino)benzimidazol-2-yl]acetate and anthranilonitrile. LC/MS m/2z320.2 R 1.68 minutes.
4-Aino-3-[5-(dimethylamino)benzimidazol-2-yl]hydroquinoln-2-one The tite compound was synthesized as described in Example 9, Method B using 2.{5-(dimethylamino)benzimidazol-2-yl]-N-(2cyanophenyl)acetamide. LC/MS m/z 320.2 R 1.72 minutes.
Example 13 Ethyl 2-(5-cyanobenziidazol-2-yl)acetate The title compound was synthesized as described in Example 7 using 4-amino-3-nitro-benzonitrile. LC/MS m/z 230.2 Rt 1.29 minutes.
2-(4-Amino-2-oxo-3-hydroquinolyl)benzimidazole-5-carbonitrile The title compound was synthesized as described in Example 9, Method B using ethyl 2-(5-cyanobenzimidazol-2-yl)acetate and anthranilonitrile (no acyclic amide observed so the NaOMe step was not needed). LCIMS m/z 302.3 (MH Rt 2:62 minutes.
Example 14 2-(4-Amino-2-oxo-3-hydroquinolyl)benzimidazole-5-crboxamidine 2-(4-Amino-2-oxo-3-hydroquinolyl)benzimidazole-5-carbonitrile eq) in EtOl was placed into a glass bomb, cooled to OOC and HCl was bubbled through for 15 minutes. The bomb was then sealed, brought to room temperature and stirred overnight. The solvent was removed in vacuo. The residue was* dissolved in EtOH in a glass bomb and cooled to 0 0 C. Nib was bubbled through for 15 minutes and the bomb was sealed and heated to 80'C for 5 hours.
-116- 4 The solvent was removed in vacuo and the crude product was purified by reversedphase HPLC. LC/MS n/z 319.2 IL 1.70 minutes.
00 Example 4-Amino-3-[5-(2-morpholin-4-ylethoxy)-benzimidazol-2-yl]hydroquinolin-2-one The title compound was synthesized as described in Example 9, Method B using anthranilonitrile. The crude acyclic amide was used without purification in the NaOMe cyclization step. The crude final product was purified by reversed-phase HPLC (DMSO/5% TFA). LC/MS m/z 406.4 R 1 1.56 minutes.
Example 16 5-Morpholin-4-yl-2-nitrophenylamine The title compound was synthesized as described in Example 8 using morpholine (3.0 eq, excess amine was used as the base in place of NaH). LC/MS m/z 224.1 l 1.89 minutes.
Ethyl 2 -(5-morpholin-4-ylbenzimidazol-2-yl)acetate The title compound was synthesized as described in Example 7 using 5-morpholin-4-yl-2-nitrophenylamine. The crude yellow oil was purified by silica gel chromatography (89.5:10:0.5 CH2Ch:MeOH:EtN) to yield the desired product as a yellow solid. LC/MS m/z 290.3 Rb 1.31 minutes.
Method C 4-Hydroxy-3-(5-morpholin-4-ylbenziidazol-2-yl)--benzylhydroquinon-2-one To a solution of ethyl 2-(5-morpholin-4-ylbenzimidazol-2-yl)acetate eq) in anhydrous THF at -78 0 C under an atmosphere of nitrogen was added LiHMDS (1 M in THF, 3.1 eq) and the solution was stirred for 1 hour. A solution of 1-benzylbenzo[d]1,3-oxazaperhydroine-2,4-dione (1.05 eq) in anhydrous THF was then added dropwise and the resulting solution was allowed to warm to OOC -117over 1 hour. The resulting mixture 'was quenched with a saturated aqueous solution of ammonium chloride and the organic layer was separated. The aqueous layer was extracted with CH2C02 (4 times). The combined organic layers were dried over 00 IDNa2SO4, concentrated in vacuo, and the crude material was dissolved in toluene and C 5 heated at reflux for 16 hours. The toluene was removed in vacuo and the crude Ci material was used without further purification. The product was obtained as a white solid. LC/MS nm/z 453.1 R 2.91 minutes.
4 -Hydroxy-3-(5-morpholin-4-ylbenzimidazol-2-yl)hydroquinolin-2-one Crude 4-hydroxy-3-(5-morpholin-4-ylbenzimidazol-2-yl)-lbenzylhydroquinolin-2-one (1.0 eq) was dissolved in trifluoromethanesulfonic acid and heated at 40 0 C for 16 hours. The resulting solution was diluted with water and neutralized with 6 N NaOH whereupon a yellow precipitate formed. The crude solid was isolated by centrifugation and purified by reversed-phase HPLC to produce the desired product as a bright yellow solid. LC/MS m/z 363.3 P, 1.77 minutes.
Example 17 N-[l-(3-Amino-4-nitrophenyI)pyrrolidin-3-yl](tert-butoxy)carboxamide The title compound was synthesized as described in Example 8 using 3-(tert-butoxycarbonylamino)pyrrolidine (1.01 eq) with diisopropylethylamine eq) as the base (in place of NaH). The product was obtained as an orange, crystalline solid. LC/MS m/z 323.3 Ri 2.53 minutes.
Ethyl 2-(5-{3-[(tert-butoxy)carbonylamino]pyrrolidinylbenzimidazol-2yl)acetate The title compound was synthesized as described.in Example 7 using N-[-(3-amino-4-nitrophenyl)pyrrolidin-3-yl](ter-butoxy)carboxamide. The product was obtained as a yellow oil. LC/MS m/z 323.3 RL 2.53 minutes.
-118- 4 3-[5-(3-aminopyrrolidinyl)benziidazol-2-yI]4-hydroxyhydroquinolin-2-one The title compound was synthesized following the procedure described in Example 16, Method C using ethyl 2-(5-{3-[(tert- 00 butoxy)carbonylamino]pyrrolidinyl}benzimidazol-2-yl)acetate. The product was obtained as a yellow solid following cleavage of the benzyl group (see procedure in Example 15). LCIMS me 362.3 R, 1.55 minutes.
Example 18 (3-Amino4-nitrophenyl)[2-(dimethylamino)ethyl~methylamine The title compound was synthesized as described in Example 8 using 1,1,4-trimethylethylenediamine (1.01 eq) with dilsopropylethylamine (2.0 eq) as the base (in place of Nai). The product was obtained as a bright yellow, crystalline solid. LCJMS m/z 239.3 ML 1.29 minutes.
Ethyl 2-(5-{[2-(dimethylamino)ethyllmethylamino~benzmidazol-2-yl)acetate The title compound was synthesized as described in Exaiple 7 using (3-amino4-nitrophenyl)152-(diethylamino)ethyl]methylamine. The desired product was obtained as a yellow oil. LCIMS m/z 305.2 RM), RL 1.17 minutes.
3-(-Q2-(Dimethylamino)ethyl]methylamino~benzimidazol-2-yl)4-hydroxy-1benzyihydroquinoin-2-one The title compound was synthesized as described in Example 16, Method C using ethyl 2-(5-([2-(diethylamino)ethyl]methylamino~benzimidazol-2yl)acetate. The product was obtained as a pale yellow solid. LC/MS m/z 468.4 R 2.26 minutes.
3-(5-f{[2-(Dimethylauino)ethyljmethylaminolbenziidazol-2-yl)4hydroxyhydroquinolin-2-one The title compound was synthesized as described in Example 16, Method C using 3-(5-{[2-(dimethylamino)ethyl]methylamino benzimidazol-2-yl)4hydroxy-I-benzylhydroquinolin-2-one. The crude material was purified by -119reversed-phase HPLC to yield the product as a yellow solid. LCIMS in/z-378.4 (MH R, 1.99 minutes.
00 Example 19 N ~Method
D
4-Chloro-3-(5-morpholin-4- ylbenzimidazol-2-yl)-l-benzylhydroqun'oUln-2-one A solution of 4-hydroxy-3-(5-morpholin-4-ylbenzimidazol-2-yl)-.1benzylhydroquinolin-2-one (1.0 eq) and POC13 in a dry, round-bottomed flask was heated at 80'C for 2 hours. The excess P0Gb was removed in vacuo and the crude material was quenched with water. The crude product was collected by filtration and purified by silica gel chromatography (1:9 MeOH:CH2Ch). 4..Chloro-3-(5morpholin-4-ylbenziinidazol-2-yl)-1-benzylhydroquinolin-2-one was isolated as a red solid. LC/MS m/z 471.4 Rr 2.35 minutes.
4-[(2-Methoxyethyl)amino]-3-(5-morpholin-4-ylbenzimidazol-2-y)-1benzylhyoroquinolin-2-one A solution of 4-chloro-3-(5-morpholin-4-ylbenzimidazol-2-yl)-lbenzylhydroquiolin-2-one (1.0 eq) and EtOH was treated with 2-methoxyethylamine (10 eq) at room temperature. The resulting solution was heated at reflux for 16 hours and then the solvent was removed in vacuo. The crude solid was sonicated in water, filtered, sonicated in hexanes, and filtered again. The crude product was used without further purification. LCJMS m/z 510.4 (MH Z~ 2.20 minutes.
4-[(2-Methoxyethyl)amino]-3-(5-morpholin-.4-ylbenzimidazol-2yl)hydroquinofin-2-one 4-[(2-methoxyethyl)amino]-3-(5-morpholin-4-ylbnzimidazol.2yl)-l-.
benzylhydroquinolin-2-one was debenzylated using the procedure described in Example 16 to produce the title compound. LC/MS m/z 420.2 R 1157 minutes. 4-[(2-hycfoxyethyl)ainino]-3-(5-morpholin-4-ylbenzimidazo-2yl)hydroquinolin-2-one was p roduced as a side product (see below).
-120- 2-one The title compound was obtained as a side-product of the 00 debenzylation of 4-(-ehxehlaio--5mopoi--leimdzl2y) 0 5 1-benzylhydroquinolin-2-one using the procedure described in Example 16 and was isolated by reversed-phase, HPLC as a yellow solid. LCIMS m/Z 406.2 (MB R, 1.39 minutes.
4 -(Methoxyamtino)-3-(5-morpholin-4.ylbenziniidazol-2.y)-l- 'benzylhydroquinolin-2-one The title compound was synthesized as described in Example 19, Method D using O-methylhydroxylamine. The product was used without purification.
4 -Mdethoxyamino)-3-(5-morpholin-4ylbenzmdazo2yl)hydroquinoin2.ne The title compound was obtained as a yellow solid after debenzylati on of 4-(methoxyaniino),-3-(5-morpholin4-ylbenziidazol-2-yl).1.
benzylhydroquinolin-2-one using the procedure described in Example 16.LCM m/z 392.2 Rt 1.82 minutes.
Example 21 tent-Butyl-3-{[3-(5-morpholi4-ylbenzimpidazol-2yl)-2.xo-.1.benzyI4hydroquinolyllamnino~piperidinecarboxylate The title compound was synthesized as described in Example 19, Method D using 1-terr-butoxycarbonyl-3-aminopiperidine. The product was used without purification.
3 (5-Morpholin4-ybenzimidazo-2-y)4-(3-piperidyamino)hydroquinolifr-one The product was obtained as a yellow solid after debenzylation of tert-butyl-3-{ 3 -1(5-morpholi-4-ylbenzimidazol-2-yl)-2-oxo--benzyl-4 hydroquinolyllamino~piperidinecarboxylate using the procedure described in -121- Example 16. The t-butoxycarbonyl group is removed under the reaction conditions.
LC/MS in/z 445.4 %i 1.73 minutes.
00 1-10 Example 22 tert-Butyl-3-({(3-(5 -morpholin-4ylbenziuidazol-2-yl)-2..oxo-1-benzyl-4hydroquinolyl]amino~methyl)piperidinecarboxylate The title compound was synthesized as described in Example 19, Method D using 1-tert-butoxycarbonyl-3-aniinomethylpiperidine. The product was used without purification.
3 -(5-Morpholin-4-ylbenzimidazol-2-yI)-4-[(3-piperidylmethyl)amino]hydroquinolln-2-one The title compound was obtained as a yellow solid after.
debenzylation of tert-butyl-3-({[3-(5-morpholin-4-ylbenzimidazol-2-yl)-2-oxo-1benzyl-4-hydroquinolyllainino~methyl)piperidinecarboxylate using the procedure described'in Example 16. LC/MS rn/z 459.6 Ri 1.71 minutes.
Eape2 4 -{t2-(Dimnethylamino)ethylamino}-3-(5-morpholin.4-ylbenzmdzo-2-y)-lbenzylhydroquinoin-2-one The title compound was synthesized as described in Example 19, Method D using 1, 1-dimethylethylenediamine. The product was used without purification.
4-{[2im.Dhethyaino)ethy~amino)-3-(5-morpholin-4ylbenzhisdazolI4.
yI)hydroquinolin-2-one The title compound was obtained as a yellow solid after debeuzylation of 4-{[2-(dimnethylamino)ethyl]amino}-3-(5-xnorpholin-4ylbenzimidazol-2-yl)-l -benzylhydroquinolin-2-one using the procedure described in Example 16. LC/MS m/z 433.4 Ri 1.55 minutes.
-122- Example 24 3-(5-Morpholin-4-ylbenzimidazol-2-yl)-4-[(oxolan-2-ylmethyl)amino]-1benzylhydroquinolin-2-one 00 The title compound was synthesized as described in Example 19, 0 5 Method D using 2-aminomethyltetrahydrofuran. The product was used without purification.
3-(5-Morpholin-4-ylbenzmidazol-2-yl)-4-[(Oxolan-2-ylmethyl)amino]hydroquiolin-2-one The title compound was obtained as a yellow solid after debenzylation of 3-(5-morpholin-4-ylbenziniidazol-2-yl)-4-[(oxolan-2 yhnethyl)aiuino]-1-benzylbydroquinolin-2-one using the procedure described in Example 16. LC/MS m/z 446.5 (MH K 1 2.19 minutes.
4-{[2-(Methylamino)ethyl]amino)-3-(5-morpholin-4-ylbenzimidazol-2-yl)-lbenzylhydroquinolin-2-one The title compound was synthesized as described in Example 19, Method D using 1-tert-butoxycarbonyl-1-methylethylenediamine. The product was used without purification.
4-{[-(Methylamino)ethylJamino}-3-(5-morphoin-4-ylbenzimidazol-2yl)hydroquinolin-2-one The title compound was obtained as a yellow solid after debeazylation of [2-(methylamino)ethyllamino}-3-(5-morpholin-4ylbenzimidazol-2-yl)-1-benzylhydroquinolin-2-one using the procedure described in Example 16. The t-butoxycarbonyl group is removed under the reaction conditions.
LC/MS ni/z 419.4 %e 1.50 minutes.
-123- Example 26 tert-Butyl-3-{p-(5-morphoin-4-ylbenzimdazol-2-yl)-..oxo-1-benzyl4A hydroquinolyllamino~pyrrolidinecarboxylate 00 Tettecmon a yteie sdsrbdi xml 9 ThIilNopunDa yteizda eciedi xml 9 Method D using 1-tert-butoxycarbonyl-3-aminopyrrolidine. The product was used without purification.
3 -(S-Morpholin-4-ylbenzimidazol-2-yl)-4-(pyrrolidin-3-ylamino)hydroquinolin-4.
CI one The title compound was obtained as a yellow solid after debenzylation of tert-butyl-3-{[3-(5-morpholin4-ybezimdazol-2-yly.2oxo-1benzyl-4--hydroquinolyl]amino~pyrrolidinecarboxylate using the procedure described in Example 16. LCIMS m/z 431.4 1.50 minutes.
Example 27 4-[((2S)-2-Amino-4-methylpentyl)aininoI-3-(5-morpholin.4-ylbenziinidazol-2.yl).
1-benzylhydroquinofin-2-one The title compound was synthesized as described in Example 19, Method D using (2S)-2-ten-butoxycarbonylamno-4-methylpentylaniine. The product was used without purification.
4 2 S)-2.-Amino-4-methylpentyl)amino}.3-(-morphon4ybenzmdazol..zyl)hydroquinolin-2-one The title compound was obtained as a yellow solid after debeuzylation of 4-I((2S)-2-amino-4-methylpentyl)aniino]-3-r(5-naorpholin-4ylbenzimidazol-2-yl)-1-benzylhydroquinolin-2-one using the procedure described in Example 16. LC/MS rn/Z 461.4 (MU R 1.78 minutes.
-124- Example 28 t-Butoxycarbonyl protected 4-[((2S)-2-amino-3-methylbutyl)anino]-3-(5morpholin-4-ylbenzimidazol-2-yI)-1-benzylhydroquinolin-2-one 00 The title compound was synthesized as described in Example 19, Method D using (2S)-2-tert-butoxycarbonylamino-3-methylbutylamine. The product was used without purification.
4-((2S)-2-Amino-3-methylbutyl)amino]-3-(5-morpholiu-4-ylbenzimidazol-2yl)hydroquinolin-2-one The title compound was obtained as a yellow solid after debenzylation of 4-[((2S)-2-amino-3-methylbutyl)amino]-3-(5-morpholin-4ylbenzimidazol-2-yl)-1-benzylhydroquinolin-2-one using the procedure described in Example 16. The t-butoxycarbonyl group is removed under the reaction conditions.
LClMS n/z 447.5 R 2.96 minutes.
Example 29 4-Amino-3-(S-morpholin-4-ylbenzimidazol-2-yl)-1-benzylhydroquinolin-2-one The title compound was synthesized as described in Example 19, Method D using ammonia in a sealed glass tube. The product was used without purification.
4 -Amino-3-(5-morpholin-4-ylbenzimidazol-2-yl)hydroquinolin-2-one The title compound was obtained as a bright yellow solid after debeuzylation of 4-amino-3-(5-morpholin-4-ylbenzimidazol-2-yl)-lbenzylhydroquinolin-2-one using the procedure described in Example 16 and purification by reversed-phase JPLC. LC/MS m/z 362.3 RI 1.61 minutes.
Example 3-Benzindazol-2-yl4hydroxy-p-benzylhydroquinoin-z.one The title compound was synthesized as described in Example 16, Method C using ethyl 2-benzinidazol-2-ylacetate. The product was obtained as a -125white solid and used without further purification. LC/MS m/z 368.4 b 2.99 minutes.
00 3 -(Benzimidazol-2-y)-4-chloro-1-benzylhydroquinolin-2-one
NO
The title compound was synthesized as described in Example 19, Method D using 3 -benzimidazol-2-ylA4-hydroxy-1-benzylhydroquinolin2-one The crude product was used without purification.
Example 31 3 -Benzimidazol-2-yl-4-(methylamino)hydroquinolin-2-one The beuzylated title compound was synthesized as described in Example 19, Method D using methylamine and 3-(benzimidazol-2-yl)-4-chloro-1benzylhydroquinolin-2-one. The product was obtained after debenzylation as a yellow solid using the procedure described in Example 16. LC/MS mn/z 291.3 (MR R 1 1.64 minutes.
Example 32 3 -Benzinidazol-2-yl-4-(ethylanino)hydroquinolin-2one The benzylated title compound was synthesized as described in Example 19, Method D using ethylamine and 3-(benzimidazol-2-yl)-4-chloro-lbenzylhydroquinolin-2-one. The title compound was obtained after debenzylation as a yellow solid using the procedure described in Example 16. LC/MS m/z 305.3 (ME Rt 2.01 minutes.
Example 33 3 -Benzimidazol-2-yI-4-[(oxolan-2.ylmethyl)amino]hydroquinolin2one The beuzylated title compound was synthesized as described in Example 19, Method D using 2-aminomethyltetrahydrofuran and 3-(benzimidazol- 2-yl)-4-chloro-1-benzylhydroquinolin-2-one. The title compound was obtained after debeuzylation as a yellow solid using the procedure described in Example 16.
LC/MS nz/z 361.2 R 1.74 minutes.
-126- 4Eample 34 3-Benzidazol-2-yl-4-[(4-piperidylmethyl)aminojhydroquinoln-2-one The protected title compound was synthesized as described in 00 Example 19, Method D using 1-tert-butoxycarbonyl-4-aminomethylpiperidine and 0 5 3-(benzimidazol-2-yl)-4-chloro-1-benzylhydroquinolin-2-one. The title compound was obtained after deprotection and debeuzylation as a yellow solid using the V) procedure described in Example 16. LC/MS in/z 374.3 R, 1.29 minutes.
Example 3-Benzimidazol-2-yl-4-[(4-fluorophenyl)amino]hydroquinolin-2-one The beuzylated title compound was synthesized as described in Example 19, Method D using 4-fluoroaniline and 3-(benzimidazol-2-yl)-4-chloro,-1benzylhydroquinolin-2-one. The title compound was obtained after debenzylationas a yellow solid using the procedure described in Example 16. LCIMS m/z 371.2 (MH Rt 1. 92 minutes.
Example 36 3-Benzimidazol-2-yl-4-.(methoxyamino)hydroquinolin-2-one The benzylated title compound was synthesized as describe In Example: 19, Method D using O-methylh ydroxylamine, and 3-(benzimidazol-2-yl)-4chloro-1-benzylliydroquinolin-2-one. The title compound was obtained after debenzylation as a yellow solid using the procedure described in Example 16.
LCIMS m/z 307.3 Rr 1.77 minutes.
Example 37 3-Benzimidazol-2-yI-4-(benziinidazol-6-ylano)hydroquinolin-2--one The benzylated title compound was synthesized as described in Example 19, Method D using 5-aminobeuzimidazole, and 3-(benzimidazol-2-yl)-4chloro-1-benzylhydroquinolin-2-one. The title compound was obtained after debenzylation as a yellow solid using the procedure described in Example 16.
LC/MS m/z 393.4 Rt 1.41 minutes.
-127- Example 38 3 -Benzimidazol-2-y1-4-(phenylamino)hydroquinolin-2.one The benzylated title compound was synthesized as described in 00 IND Example 19, Method D using aniline and 3-(benzimidazol-2-yI)-4-cbloro-lbenzylhydroquinolin-2-one. The title compound was obtained after debenzylation as a yellow solid using the procedure described in Example 16. LC/MS m/z 353.4 Rt2.38 minutes.
Example 39 3 -Benzinidazol-2-y1-4-(quinuidin3ylamino)hydroquinoin2.one The benzylated title compound was synthesized as described in "Example 19, Method D using 3-aminoquinuclidine and 3-(benzimidazol-2-yl)4chloro-1-benzylhydroquinolin-2-one. The title compound was obtained after debeuzylation as a yellow solid using the procedure described in Example 16.
LC/MS m/z 386..4 Rt 1.82 minutes.
3 -Benaimidazol-2-yl4[(midaol-5ylmethy)amno]hydroquinoi-2-ne The benzylated title compound was synthesized as described in Example 19, Method D using 4-aminoniethyl-1H-imidazole and 3-(benzimidazol-2yl)-4-cliloro-1-benzylhydroquinolin-2-one. The title compound was obtained after debeuzylation as a yellow solid using the procedure described in Example 16.
LC/MS m/z 357.4 Rt 1.34 minutes.
-128- 4 Example 41 3-Benzimidazol-2-yl-4-(morpholin-4-ylamino)hydroquinolin-2-one The benzylated title compound was synthesized as described in 00 Example 19, Method D using 4-aminomorpholine and 3-(benzimidazol-2-yl)-4- 0 5 chloro-l-benzylhydroquinolin-2-one. The title compound was obtained after Sdebenzylation as a yellow solid using the procedure described in Example 16.
n LC/MS m/z 362.4 Rt 1.42 minutes.
Example 42 3-Benzimidazol-2-yl-4-hydrazinohydroquinolin-2-one The benzylated title compound was synthesized as described in Example 19, Method D using hydrazine and 3-(benzimidazol-2-yl)-4-chloro-1- -benzylhydroquinolin-2-one. The title compound was obtained as a yellow solid after debenzylation using the procedure described in Example 16. LC/MS m/z 292.3 Rt 1.19 minutes.
Example 43 3-Benzimidazol-2-yl-2-oxohydroquinoline-4-carbonitrile 3-Benzimidazol-2-yl-4-chloro-l-benzylhydroquinolin-2-one (1 eq) was dissolved in DMA, and CuCN (10 eq) was added in one portion. The reaction mixture was stirred at 90 0 C overnight. The resulting mixture was allowed to cool to room temperature, water was added, and the orange precipitate was removed by filtration. The solid was treated with a solution of hydrated FeCb at 70 0 C for 1 hour. The suspension was centrifuged and the solution removed. The remaining solid was washed with 6N HCI (2 times), sat. Na2C03 (2 times), water (2 times) and lyophilized. The resulting powder was dissolved in 1 mL of triflic acid and heated at 60 0 C overnight. The resulting mixture was cooled to 0°C and water was slowly added. Saturated LiOH was added dropwise to the suspension to a pH of 8, then the solid was filtered and washed with water (3 times). Purification by reversed-phase HPLC afforded the desired product. LC/MS m/z 287.1 Ri 1.89 minutes.
-129- Exa mple 44 Ethyl 2-(5,6-dimnethylbenzimidazol-2-yI)acetate The title compound was synthesized as described in Example 1 using IND 4,5-dimethylbenzene-l ,2-diamnine. The crude yellow oil was purified first by silica CI 5 gel chromatography (96.5:3.0:0.5, CflzC1:MeOH:E3N), and then by recrystallization from toluene to yield the title compound as a pale, yellow solid.
LCIMS m/z 233.1 (MHff+), Ri 1.73 minutes.
3-(5,6-Dimnethylbenzimidazol-2-y1)4-hydroxy-1-benzylhydroquinolin-2.one The title compound was synthesized as described in Example 16, Method C using ethyl 2-(5,6-dimethylbenzimidazol-2-yl)acetate. The crude material was purified by silica gel chromatography (98.5:1.5, CII2CI2:MeOH) to yield the title compound as a yellow solid. LCIMS mlz 396.2 (MH+,R 3.60 minutes.
3-(5,6-Dimethylbenzimidazol-2-y)-4-chloro-1-benzylhydroquinoln-2-one The title compound was synthesized as described in Example 19, Method D using 3-(5,6-dimethylbenzimidazol-2-yl)-4-hydroxy-lbenzylhydroquinolin-2-one. The title compound was obtained as an orange-yellow solid.. LCIMS m/z 414.2 Rt 2.47 minutes.
tert-Butyl 3-{[3-(5,6-dimethylbenzimidazol-2-yl)-2-oxo-1-benzyl-4hydroquiuolyl]ainino~piperidinecarboxylate The title compound was synthesized as described in Example 19, Method D using 1-tert-butoxycarbonyl-3-aminopiperidine- The crude material was purified by silica gel chromatography (99:1 CH2Cl2:MeOff) to yield the title compound as a yellow solid. LCIMS m/z 578.5 MH+) R 1 30b5 minutes.
3-(5,6-Dimethylbenzimidazol-2-yl)-4-(3-piperidylamino)hydroquinoin-2-one tert-Butyl ,6-dimethylbenzimidazol-2-yl)-2-oxo-1-benzyl-4hydroquinolyl]amino~piperidine-carboxylate was debenzylated as described in Example 16. The crude material was purified by reversed-phase HPLC to yield the tidle compound as a light yellow solid. LCIMS m/z 388.4 1.61 minutes.
-130- SExample 3H-Imidazo[4,5-b]pyridin-2-ylacetonitrile Ethyl cyanoacetate (1.5 eq) and 2,3-diaminopyridine (1 eq) were 00 I 5 heated at 185 0 C for 30 minutes. The reaction mixture was cooled to room
O
C temperature and the black solid was triturated with ether. The desired product was C- thus obtained as a dark brown powder. LC/MS m/z 159.1 PR0.44 Sminutes.
0 Ethyl 3H-imidazo[4,5-b]pyridin-2-ylacetate 3H-Imidazo[4,5-b]pyridin-2-ylacetonitrile was suspended in EtOH, and gaseous HCI was bubbled through for 3 hours. The suspension initially seemed to dissolve, but a precipitate started forming almost immediately. The reaction mixture was cooled to 0°C and a cold saturated NaHCO3 solution was carefully added. Solid NaHCOs was also added to bring the pH to a value of 7.6. The aqueous phase was then extracted with EtOAc, and the organic extracts were dried (Na2S04). After evaporation of the solvent under reduced pressure, the residue was purified by chromatography on silicagel (10% MeOH in CH2Ch with 1% EtsN) providing the desired product as a light brown solid. LC/MS m/z 206.1 R, 0.97 minutes, 4-Amino-3-(3H-imidazo[4,5-b]pyridin-2-yl)quinolin-2(1H)-one LiHMDS (3.0 eq) was added to ethyl 3H-imidazo[4,5-b]pyridin-2ylacetate (1.0 eq) in THF at -78 0 C. After 20 minutes, a solution of 2aminobenzenecarbonitrile (1.1 eq) in THF was added. The resulting mixture was allowed to warm to room temperature, stirred for 3 hours, and then refluxed overnight. The mixture was cooled to 0°C and quenched with an aqueous saturated NH4CI solution. A precipitate formed, was filtered off, and was washed repeatedly with ether to yield the desired compound as a light brown solid. LC/MS m/z 278.2 R 1.82 minutes.
-131- Example 46 6 -Morpholin-4-yl-3-nitropyridin-2-amine Morpholine (4 eq) was added to a suspension of 6-chloro-3- 0 nitropyridin-2-amine (1 eq) in CH3CN, and the reaction mixture was stirred at O 5 70°C for 5 hours. The solvent was evaporated under reduced pressure, and the Sresidue was triturated with ether to afford the desired compound as a bright yellow l n powder. LC/MS m/z 225.0 RI 1.79 minutes.
CI Ethyl (5-morpholin-4-yl-3H-imidazo[4,5-b]pyridin-2-yl)acetate To a solution 6-chloro-3-nitropyridin-2-amine (1.0 eq) in EtOH was added Pd/C (0.1 eq). The reaction vessel was repeatedly purged with hydrogen and then stirred under a hydrogen atmosphere (1 atm) for 18 hours. Ethyl 3-ethoxy-3iminopropanoate hydrochloride (2.0 eq) was added in one portion, and the reaction mixture was refluxed overnight. The reaction mixture was cooled to room temperature, filtered through a celite plug, and the plug was washed with EtOH.
After evaporation of the solvent under reduced pressure, the residue waspurified by silica gel chromatography MeOH in CH2C2 with 1% EtbN) providing the desired product as a brown solid. LC/MS m/z 291.3 R 1.71 minutes.
4 -Amino- 3 -(5-morpholin-4-yl-3H-imidazo[4,5-b]pyridin-2-yl)quinolin-2(1H)-one The title compound was synthesized as described in Example Method E using ethyl 2-(5-morpholin-4-ylimidazolo[5,4-b]pyridin-2-yl)acetate and 2-aminobenzenecarbonitrile, with a modified workup procedure.. After quenching with a saturated aqueous ammonium chloride solution, the two phases were separated and the aqueous phase extracted with EtOAc. Upon standing, a solid formed and precipitated out of the organic extracts. The precipitate, a dark brown solid, was filtered off and dried. Purification by reverse phase chromatography afforded the desired product as a reddish solid. LC/MS m/z 363.2 R2.20 minutes.
-132- Example 47 4 -Amino-5-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-3-(3H-imidazo[4,5-b]pyridin- 2-yl)quinolin-2(1H)-one 00 LiHMDS (3.0 eq) was added to ethyl 3H-imidazo[4,5-b]pyridin-2- 0 5 ylacetate (1.0 eq) in THF at -78 C. After 20 minutes, a solution of 2-amino-6- 0 [(2R,6S)-2,6-dimethylmorpholin-4-yl]benzonitrile (1.1 eq) in THF was added. The itn resulting mixture was allowed to warm to room temperature, stirred for 2 hours and Sthen heated to 60°C overnight. The mixture was cooled to 0°C and quenched with an aqueous saturated NH4CI solution. The aqueous phase was extracted with CH2Cl (5 times) and the organic extracts were collected, dried (Na2SO4), and concentrated. The crude product was purified by HPLC. LC/MS m/z 391.2 R 2.35 minutes.
Example 48 Ethyl {5-[3-(dimethylamino)pyrrolidin-1-yl]-3H-imidazo[4,5-b]pyridin-2yl}acetate 6-chloro-3-nitro-2-aminopyridine (1.0 eq) and 3- (dimethylamino)pyrrolidine (1.1 eq) were dissolved in CH3CN and eq) was added. The reaction mixture was heated at 70 0
C
overnight. The solution was cooled to room temperature, and the solvent was evaporated. The residue was triturated with ether and water and dried under vacuum (LC/MS m/z 252.2 R, 1.09 minutes). The isolated product eq) and 10% Pd/C (0.1 eq) were suspended in anhydrous EtOH at room temperature. The reaction flask was evacuated and subsequently filled with H2.
The resulting mixture was allowed to stir under a hydrogen atmosphere overnight.
Ethyl 3 -ethoxy-3-iminopropanoate hydrochloride (2.0 eq) was then added and the resulting mixture was heated at reflux overnight. The solution was then filtered through Celite and evaporated under reduced pressure. The residue was suspended in CH2Cl and concentrated NH4OH was added until a pH of 11 was achieved. The NH4Cl thus formed was filtered off. The two phases were separated, and the organic phase was dried (Na2SO4). Evaporation of the solvent and trituration of the -133residue with ether gave a light green powder. LC/MS m/Z318.1 Ri 1.11 minutes.
00 IND 4 -Amino- 3 -{5-[3-(dimettylamino)pyrrolidin-1yU-3H-imidazo[4,s-blpyridjn-2 yl~quInolIm-2(1H)-one cI 5 LiHMDS eq) was added to ethyl (dimethylamino)pyrrolidi-1-yl]-3H-imidazo[4,5-b]pyridin-2yl} acetate (1.0 eq) in CI THF at 40 After 10 minutes, a solution of 2-aminobenzenecarbonitrile (1.1I eq) in THF was added. The resulting mixture was allowed to warm to room temperature, stirred for 1 h and then heated to 60 0 C overnight. The mixture was cooled to room temperature and quenched with NH4Cl (aq, saturated). The aqueous phase was extracted with CIh2Ch (5 times). The product crashes out of the organic solution during the extractions. Evaporation of the solvent under reduced pressure afforded a brown solid that was triturated repeatedly with MeOH and acetone to obtain a yellow greenish powder. LCJMS m/z 390.2 1.48. minutes.
Example- 49 2-( 4 -Ethylpiperazinyl)-6-itrobenzenecarbonitrufe 2,6-Dinitrobenzenecarboxiitrile (1.0 eq) and ,ethylpiperazine (3.6 eq) were dissolved in DMF. The resulting solution heated at 90 0 C for 2 hours. The solution was cooled to room temperature and poured into H0. A precipitate formed which was filtered to yield the desired product as a brown solid. LCJMS m/z 260.1 RI 1.69 minutes.
6 -Amino-2-(4-ethylpiperazinyl)benzenecarbonitrile 2-(4-Ethylpiperazinyl)-6-nitrobenzenecarbonitjje (1L0 eq) was dissolved in EtOH and EtO)Ac. The flask was purged with N2, and 10% Pd/C 1 eq) was added. The flask -was evacuated and purged with H2 three times. The resulting mixture was stirred overnight at room temperature. The mixture was filtered through Celite, andL thefilter pad was washed with EtOAc. The solvent was -134k removed in vacuo to provide the desired product as a yellow solid. LC/MS m/z 231.2 R 1.42 minutes.
00 0 4-Amino-3-(1H-benzimidazol-2-yl)-5-(4-ethylpiperazin-1-yl)quinolin-2(1H)-one C t-BuLi (3.1 eq) was added to ethyl 2-benzimidazol-2-ylacetate eq) and 6 -amino-2-(4-ethylpiperazinyl)benzenecarbonitrile (1.0 eq) in THF at 0°C.
The reaction was stirred overnight. The resulting mixture was quenched with NH4CI (aq, saturated) and extracted with EtOAc. The combined organic layers were washed with H20 and brine, dried over Na2SO4, filtered, and concentrated in vacuo to yield a brown solid. The crude material was triturated with CH2Ch and MeOH to provide a tan solid. LC/MS m/z 389.1 R 1.80 minutes.
Examples 50-154 The 2-aminobenzonitriles or isatoic anhydride starting materials used to synthesize Examples 50-154 are readily recognizable by one skilled in the art.
They were either commercially available or synthesized following the examples shown above Examples 1, 2, and 49). The anhydride 6-chloro-1- (phenylmethyl)-2H-3,1-benzoxazine-2,4(1H)-dione was synthesized following the general isatoic anhydride synthesis methods described in J. Med. Chem. 1981, 24 735 and J. Heterocycl. Chem. 1975, 12(3), 565.
The benzimidazole acetates were formed by reacting aryl diamines with ethyl 3 -ethoxy-3-iminopropanoate hydrochloride as shown in Example 1. The requisite diamines used in the syntheses are also readily recognizable by one skilled in the art and may be synthesized following Methods 1-9. The isatoic anhydrides were coupled with the benzimidazole acetates using methods C and D. The 2aminobenzonitriles were coupled with the benzimidazole acetates using method B, the coupling method of example 49, or the general procedure set forth below.
-135- Method E LiHMDS (3-4 eq) was added to-the beuzimidazole acetate (1.0 eq) in THF (at a constant temperature ranging from -78*C to 0 0 After 20 minutes, a solution of the 2-aininobenzonitrile (1.1I eq) in THF was then added. The resulting mixture was allowed to war-m to room temperature, stirred for 1-3 hours and was then heated to approx. 40CC 65 0 C (1 hour 'to 12 hours). The mixture was cooled to 0 0 C and quenched with NH4CI (aq, saturated). The aqueous phase was extracted with CH2Ch or EtOAc, and the organic extracts were collected, dried (Na2SO4), and filtered. Evaporation of the solvent under reduced pressure and purification of the residue by silica gel chromatography or HPLC provided the 4-amino quinolinone products.
Example Name LC/MS mz 4-amino-3-{5+[3S)-3- .389.4 (d imethylarniino)pyrrolidin-1 -ygI1Hbenzimidazocl-2-yi~guinolin-2(1 H)-one- 51 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3- 420 (I H-benzirnidazol-2-yl)-6-chloroquinolin- 2( H)cne 52 4+[3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 420 3-(1 H-ben2:,imidazol-2-yI)-6-chloroquinolin- .2(1 53 3-(1 H-ben2.imidazol-2-yI)-4-[(3R- 374.2 (dimethylarnino)pyrrolidin-1 -y~qUInolin- 2(1 H)-one 54 3-(1 H-benz-,Imidazol-2-yI)-6-chloro-4-[(3R)- 408.1 3-(dimethylamino)pyrroidin-1 -yl]quinolin- 2(1H)-one 4-amino-3-!(5-(4-ethylpiperazin-I -yl)-1 H- 403.2 benzimida2ol-2-yl]-1 -methylquinolin-2(1 H)one 56 4-amino-34,6-piperazin-1-y-1 H- 361.2 _______benzimidaz,.ol-2-yI)quinolin-2(I H)-one 57 4-amino-3-16-(pyridin-ylmethyl-. H- 368.2 benzimidazo-2-yjguinoin-2(1 H)-one 58 14-amino-3-15+[31R,5S)-3,5- 3 89.4 dimethylpiperazin-1 -yl]-1 H-benzimidazol-2- _______yIlguinolin- 2(1 H)-one 59 4-amino-3-[5-(4-methylpiperazin-1 -yI H- 375.2 benzimidazol-2-yl]guinolin-2(1 H)-one 4-amino-3-(6-methyl-5-morpholin-4-y-1 H- 376 benzimidazol-2-y)gunolin-2(l H)-one 61 4-amino-3-{5-[(1 -methylpiperidin-3-yI)oxy]- 390.1 1 H benzimidazol-2-yl~guinolin-2(I 11)-one 62 4-amino-3.-{5-[2R,6S)-2,6- 408.2 dimethylmorpholin-4-y]-6-fluoro-1 Hbenzimidazol-2-yl~guinolin-2(l H)-one 63 4-amnino-3-{5-[(1 -methytpyrrolidin-3-yl)oxy]- 376.2 I H-benzimidazol-2-ylquinolin-2(I H)-one 64 4-amino-3-[5-(4-methyl-1 ,4-diazepan-1 389.2 1 H-benzimidazol-2-y]guinolin-2(I H)-one 4-amino-3-{5-[(3R)-3- 389.2 (dimethylamino)pyrrolidin-1 -yl]-l Hbenzimidazol-2-yl}guinolini-2(l H)-one 66 4-amino-6-chloro-3-{5-(3R)-3- 423 (dimethylamino)pyrrolidin-1 -yII-1 H- _______benzimidazol-2-ylI uinolin-2(I H -ne 67 ethyl (4-[2-(4-amino-2-oxo-1 .447.2 dihydroquinolin-3-y}-i H-benzimidazol-6viipiperazin-1 -yI~acetate 68 4-amino-3-{6-[methyl(1 -methylpiperidin-4- 403.1 yl)amino]-1 H-benzimidazol-2-ylquinolin- H)-one. 69 3-[6-(4-acetylpiperazin-1 -yI)-1 H- 403.3 benzimidazol-2-yI]-4-aminoquinolin-2(1 H)- 4-amino-3-[6-(1 ,4'-bipiperidin-1 H- 443.3 71 benzimldfazol-2-yI]quinolin-2(1 11)one '1 2-(4-amino-2-oxo-1 ,2-dihydroquinolin-3-yl)-, 321.2.
H-benzimidazole-6-carboxylic acid 172 4-amino-5-(methyloxy)-3-[6-(4- 405.3 methylpiperazin-1 -yl)-l H-benzimidazol-2- _______yflquinolin-2(1 H)-one 73 4-amino-3-{6-[4-(1 -methylethyl)piperazin-1 403.3 yI]-1 H-benzimidazol-2-y~quinolin-2(1 H)one 74 {4-[2-(4-amino-2-oxo-1 ,2-dihydroquinolin-3- 419.2 yI)-1 H-benzimidazol-6-y]piperazin-1 _______yIqacetic acid 4-[(3S)-1-azabicyclo[2.2.2oct-3-ylamino]-3- 386.1 (I H-benzimidazol-2-yl)guinolin-2(1 H)-ohe 76 -azabicyclo[2.2.2]oct-3-ylamino]- 386.1 3-(1 H-benzimidazo-2-y)guinolin-2(1 77 4-amino-3-[5-(4-ethylpip'erazin-1 -yl)-1H- 389.1 ________benzimidazol-2-y]gulnoin-2( 1 11)-one -137- 78 4-amlno-3,-(5-{(2S,5S)-2- 433.3 methylmoirpholin-4-y)-1 H-benzimidazol-2yl)guinolin-2(l H)-one 79 4-amino-6-chloro-3-[5-(4-methylpiperazin- 409.2 1 -yI)-l H-b Bnzimidazol-2-y]quinolin-2(1 H)- 4-amino-6-chloro-3-{5-[3S)-3- 423.1 (dimethylamino)pyrrolidin-1 -yI]-1 Hbenzimidazol-2-y~quinolin-2(1 H)-one 81 4-amino-5,6-dichloro-3-{5-[(3S)-3- 457.2 (dimethylamino)pyrrolidin-1 -yI]-1 Hbenzimidazol-2-y)guinolin-2(l H)-one 82 4-amino-5.,6-dichloro-3-[5-(4- .443.2 methylpiperazin-1 -yI)-l H-benzimidazol-2yIlguinolin*.2(l H)-one 83 4-amino-3.(1 H-benzimidazol-2-yl)-6-- 384.2 [Rpyridi -2.letyly]uinoin-2(1 H)-one 84 4-amino-34.1 H-benzimidazol-2-yI)6- 390.1 [(2R,6S)-2 ,6-dimethylmorpholin-4yI~guinolin-2(l H)-one 4-amino-3-.(1 H-benzimidazol-2-yI)-6-. 362 _______morpholin-4-ylguinolin-2(1 H)-one 86 4-amino-3-.(1 H-benzmldazol-2-yJ)-5+l( 390.2 methylpipe rid in-3-y)oxy]guinolin,2(1 H)-ane 87 4-amino-3-(1 H-benzimidazol-2-yi)-5-. 384.1 [(py~2idn-methy)oxy]uinolin-2(1 H)-one 88 4-am ino-3-(S-morpholin-4-yi-1 H- 469.2 benzimidaz:ol-2-yI)-5-[(pyrdin-4ylmethyl)ox.yguinolin-2(1 H)-one 89 4-amino-3-(1 H-benzimidazol-2-yi)-5- 307.1 (methyloxy)guinolin-2(l H)-one 4-amino-3-(5-methyl-1 H-benzimidazol-2- 321.1 nolin-2(i H)-one 91 4-amino-3-(5-[(2R,6S)-2,6- 420.2 dimethylmorpholin4-y]-1 H-benzimidazol- 2-yl}-5-(methyloxy)guinolin-2(l H)-one 92 4-amino-3-(1 H-benzimidazol-2-yi)-5- 362.2 _______morpholin-t-ylguinolin-2(1 H)-one 93. 4-amino-3-{1 H-benzimidazol-2-yI)-5- 390.2 B-dimethylmorpholin-4- Iuinolin -l 94 4-amino-3-i(1 H-benzimidazol-2-yI)-5-(4- 375.1 methylpiperazin-1 -yI)guinolin-2(1 H)-one 4-amino-5,A3-dichloro-3-(5-morpholin-4-yI- 430 lH-benzimidazol-2-yl)quinolin-2(l H)-one -138- 96 3-{5-[(2-morpholin-4-yethyl)oxy]-I H- 391.3 ______benzimidazol-2-yil~uinolin-2(l H)-one 97 4-amino-3-{5-[(3-pyrrolidin-1 -ylpropyl)oxy- 404 H-benzimidazol-2-ylquinolin-2(I H)-one 98 4-amino-3-{5-f(3-mor-pholin-4-ypropyl)oxy]- 420.4 I H-benzimidazol-2-yl~quinolin-2(I H)-one 99 4-amino-6-fluoro-3-(5-morphoin-4-ylI- H- 380 benzimidazol-2-y)guinolin-2(1 H)-one 100 4-amino-3-{5-[3-(dimethylamino)pyrrolidin- 407 1 -yg-1 H-benzimidazol-2-yi}-6- _______fluoroguinolin-2(l H)-one 101 4-amino-3-(1 H-benzimidazol-2-yI)-6- 295 fluoroguiinolin-2(1 H)-one.
102 4-amino-3-(6-fuoro-5-morphoin-4-ylI- H- 380 benzimidazol-2-y)guinolin-2(1 H)-one 103 4-amino-3-{5-[(tetrahydrofuran-2- 377 ylmethyl)oxy]-I H-benzimidazol-2- _______yllguinolin-2(l H)-one 104 4-amino-6-fluoro-3-(6-fluoro-5-morpholin-4- 398 H-benzimidazol-2-y)guinolin-2(1 105 4-amino-3-[6-fluoro-5-(4-methylpiperazin-1 393 yi)-1 H-benzimidazol-2-y~quinolin-2(I H)one 106 4-amino-3-(5-[2-(methyloxy)ethyjoxy)-1 H- 351 benzimidazo-2-y)guinoin-2(1 H)-one 107 4-amino-3-f4,6-dlfuoro-5-(4- 411 methylpiperazin-1 -yI)-1 H-benzimidazol-2y]guinolin-2(1 H)-one: 108 4-amino-3-{5-[3-(dimethytamino)pyrrolldin- 407.1.
I -yI]-1 _______fluoroguinolin-2(1 H)-one 109 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1 393.1 yI)-1 H-benzimidazo-2-ygquinolin-2(1 H)- 110 4-a mino-5-chloro-3-[5-(4-methylpiperazin- 409.1 1 -yI)-1 H-benzimidazol-2-yl]qu inolin-2(1 H)- ___one 111 4-amino-3-{5-[3-(d imethylamino)pyrrol idin- 407.1 1 -yi]-6-fluoro-I H-benzimidazol-2yIjguinolin-2(1 H)-one 112 4-amino-5-chloro-3-{5-[3- 423.1 (dimethylamino)pyrrolidin-1 -yI]-1 H- _______benzimidazol-2-ylquinolin-2(1 H )-one *113 4-amino-.6-chloro-3-{5-[3- 441 (dimethylamino)pyrrolidin-1 -yIJ-6-fluoro-1 H- _______benzimidazol-2-yllgunolin-2(l H)-one -139- 114 4 -amino-5-[(2R,6S)-2, 6-dimethylmorpholin- 391.2 4-yl]-3-(311-imidazo[4,5-b]pyridin-2- _______yl)guinoli i-2(1 H-)-one 115 4-amino-3 -(6-thiomorpholin-4y-l H- 378.4 benzimida-zol-2-y)quinolin-2(l H)-one 116 4 -amino-Sl--[5r-(4-cyclohexylpiperazin-1 443.1 1 H-benzirnidazol-2-y]quinolin-2(1 H)-one 117 4-amino-$.'-{6-13-(diethylamino)pyrro lidin-1 417.1 yI]-1 H-berlzimidazol-2-yI)quinolin-2(1
H)-
one 118 4 -amino-3,-[6-(4-pyridin-2-ylpiperazin-1 438.3 1 H-benzirniidazol-2-yIlquinolin-2(1 H)-one 119 4 -amino-3-[5-(4-methyipiperazin-1 -yI>-3H- 376.3 imidazo[4, 5-b]pyridin-2-yqquinolin-2.(1
H)-
one 120 4-amino-6-chloro-3-[5-(4-methylpiperazin- 410.2 1 -yI)-1 H-irnidazo[4,5-bjpyridin-2-yl]quinolnn- 1 2H)one .121 2-(4-amino-2-oxo-1 ,2-dihydroquinolin-3-yI)- 431.3 N-methyl-1-(1 -methylpiperdin.4-yI)-1
H-
122 4-amino-3.-(5-{[4-(1 -methylethyl)piperazin- 431.3 1 -yI]carboiiyi}-1 H-benzimidazol-2- _~yI)quinolin.2(1 H)-one, 123 4 -amino-3.{[5-(4-,methylpiperazn-1 -yI)-1 H- 420.2 benzimida wI-2-yfj-6-nitroquinolin-2(1
H)-
.one 124 4-amino-3..[5-(I ,4'-blpiperidin-1 471.1 ylcarbony)-1 H-benzimidazol-2-yIgquinolin- 2(1 H)-one 125 4 -amino-3..{5-[(4-methylpiperazin-1 .403.3 yI)carbonya-1 H-benzimidazol-2-ylquinolin- 2(1 H)-one 126 4-amino-3.[5-(1 -oxidothiomorpholin-4-yi)- 394.5 1 H-benzirridazol-2-yI]quinonin-2(1 H)-one 1-27 3-{5-[(4-a'cetylpiperazin-1y+ aboy]1H 431.3 benzimidazol-2-yl-4-amlnoquinolin-2(1
H)-
one 128 417.4 (dimethylai-nino)pyrrolidin-1 -yI]carbonyl}- H-benzim idazol-2-yl)guinolin-2(1 H)-one -140- 129 4-amino-3-(5-{[(3S)-3- 417.4 (dimethylamino)pyrrolidin-1 -yljcarbonyl}- I H-benzimidazol-2-y)guinolin-2(I H)-one 130 4-amino-3-(5-ff4-(dimethylamino)pipeidin- 431.4 I -yljcarbonyl)-1 H-benzimidazol-2yI)guinolin-2(l H)-one 131 methyl 2-(4-amino-5-fluoro-2-oxo-1 353.2 dlihydlroquinoin-3-y)-1 H-benzimidazole-6- 132 4-amino-3-[5-(1 ,3-bipyrrolidin-1 H- 415.5 benzimidazol-2-y]quinolin-2(1 H)-one 133 4-amino-3-[5-(pyidin-3-yloxy)-1 H- 370.2 benzlmidazo-2-;y]quInolin-2(1 H)-one 134 4-amino-5,6-bis(methyoxy)-3-[5-(4- 435.5 methylpiperazin-1 -yI)-1 H-benzimidazol-2yllguinoin-2(1 H)-one 135 2-:(4-amino-2-oxo-1 ,2-dihydroquinolin-3,,y)- 405.3 N-12-(dimethylamino)ethyl]-N-methyl-1 H- 136 2-(4-aminio-2-oxo-1 ,2-dihydroquinolin-3-yl)- 417.2 N-methy--(1 -mnethylpyn-olidlin-3-yl)-1 H- 137 4-a mino-3-{5-[(5-methyl-2,5- 415.2 diazabicyclo[2.2.1I]hept-2-yI)carbonyl]-1 H- _______benzimidazol-2-yl}quinolin-2(i H)wone..
138 4-amino-3-{5-[.(4-cyclohexylplperazin-1 471..6 yl)carbony]-1 H-benzimldazol-2-y~quinolin- 20 H)-one 139 4-amlno-3-{5-;[(2-ppeddin-1 -ylethyl)amino]- 403.2 1 H-benzimldazol-2-y~quinolin-2(1 H)-one 140 ethyl 4-{[2-(4-amlno-2-oxo-1 447.3 dihydroquinolin-3-y)-1 y~amino}piperidine-1 -carboxylate 141 4-amino-3-[5({5R-5-. 405.2 [(methyloxy)methyipyrrolidin-3-yJ~amino)- 1 H-benzimidazol-2. yI]quinolin-2(I H )-one 142 4-amino-3-{5-[(pyridin-2-ylmethyl)amino]- .383.3 1 H-benzimidazol-2-yl~quinolin-2(1 H)-one 143 4-amino-3-[5-(piperidin-3-ylamino)-1 H- 375.2 benzimidazol-2-yl]quinolin-2(1 H)-one 144 .4-amlno-5-fluoro-3-{s-[(pyridin-2- 401.3 ylmethyl)aminoj-1 H-benzimidazol-2vtguinolin-2(1 H)-one -141- 145 ethyl 4-{[2:-(4-amino-5-fluoro-2-oxo-1 465.5 dihydroqu inolin-3-yl)-1 yl]amino~lpiperidine-1 -carboxylate 146 4-amino-5r-fluoro-3-[5-(piperidin-3-ylamino)- 393.3 1 H-benzirnidazol-2-y~quinolin-2(1 H)-one 147 4-amino-3 H-benzimidazol-2-yI)-6- 357.1 bromoquinolin-2(1 H)-one 148 4-amino-3-(1 H-benzim idazol-2-yl)-7- 357.1 bromoquinolln-2(1 H)-one 149 4-amino-3-(5-bromo-1 H-benzimidazol-2- 357.1 yI)quinolin-2(1 H)-one 150 N ,N-dimel hyl-2-(2-oxo-1 ,2-dihydroquinolin- 333.1 3-yl)-1 151 4-amilno-3-(5-thien-2-yl-1 H-benzimidazol-2- 359.2 yl)quinolin-2(1 H)-one 152 2-(4-amino-2-oxo-1 ,2-dihydroquinolin-3-y)-. 384.1 N,N-dimethyl-1 ________sulfonamide 153 4-amino-6-iodo-3-[5-(4-methylpiperaz~in-1 501.11.
yI)-1 H-berizimidazol-2-yJqquinolin-2(1 HYI) one 154 4-amino-3-(5.{2-[(dimethylamino)methyl]- 419.2 morpholn.4-y}-1 H-benzimidazol-2- ________yl)quinolin -2(1 H)-one Examples'155-270 Examples 155 to 270 shown in the following Table were synthesized using the methods describe d above such as Methods 1-15 and those set forth in the Schemes and other Examples or modified as apparent to one of reasonable skill in the art using commercially available materials.
-142- Example Name IC/MS mlz 155 4-[3R)-l -azabicyclo[2.2.2]oct-3-ylamino]- 547 3-(1 H-benzimidazol-2-yI)-7-chloro-6odo uinolin-2(I H -ne 156 4+[3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 431 3-(1 H-benzimidazol-2-yI)-6-nitroquinolin- Hl)-one 157 4-(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 401 3-(1 H-benzimidazol-2-yl)-6-methylquinolin- 2(1 H)-one 158 -azabicyclo[2.2.2]oct-3-ylaminol- 422 3-(1 H-benzimidazol-2-yI)-6.7- ________difluoroguinolin-2(l H)-one 159 -azabicyclo[2.2.2]oct-3-ylamino]-3- .421 (1 H-benzimidazol-2-yI)-7-chloroquinolin- H)-one 160 -azabicyclo[2.2.2]oct-3-ylamino]- 465 3-(1 H-benzimidazol-2-yi)-6-bromoquinolin- 2(1 161 -azabicyclo[2.2.2]oct-3-ylamino]- 411 3-(1 H-benzimidazol-2-yl)-2-oxo-1 ,2dihydroquinoline-6-carbonitrile 162 -azabicyclo[2.2.2]oct-3-ylamino]- 404 3-(1 H-bertzimidazol-2-yI)-6-fluoroquinolin- 2(1 H)-one 163 -azabicycio[2.2.2]oct-3-ylamino]-3- 447 (1 H-benzimldazol-2-yI)-6,7- _______bis(methylMx)quInolIn-2(1 H)-one 1-64 -azabicyclo[2.2.2]oct-3-ylamino]- 455 3-(1 H-benzimidazol-2-yI)-6,7dichlorogulholin-2(i H)-one 165 1 -[4-[(3S)-1-azabicyclo[2.2.2]oct-3- 531 ylamlno]-3-(1 H-benzimidazol-2-yI)-6-fluoro- 2-oxo-l ,2-dihydroquinolin-7-yljpiperidine-4carboxamide 166 4-[3S)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3-. 478 (1 H-benzimldazol-2-yI)-6-fluoro-7-[(3-.
hydroxypropyl)amino]guinolin-2( H )-one 167 -azabicycio[2.2.2]oct-3-ylaminoj-3- 448 (1 H-benzimidazol-2-yl)-7-(dimethylamino)- 6-fluoroguinolin-2(1 HY)-one 168 4-[(3R)-lI-azabicyclo[2.2.2]oct-3-ylamino]- 404 3-(1 ,2(1 Hl)-one -143- 169 -;azabicyclo[2.2.2]oct-3-ylamino]- 508 3-(l H-benzimidazol-2-yi)-6-(4ntrophen il)guinolin-2(1 H)-one.
170 azabicyclo[2.2.2]oct-3-ylamino]-3- 491 (I H-benzirnidazol-2-yI)-7-([2- (dimhethylaimino)ethygamino)-6- _______fluoroguinoDlin-2(l H)-one 171 -zabicyclo[2.2.2]oct-3-ylamino]-3- 471 (I H-benzir-nidazol-2-yI)-6-fluoro-7-(1
H-
imidazol-1 uinoin-2(1 F-)-one 172. 4-f(3R)-1 -aizabicyclo[2.2.2]oct-3-ylamino]- 493 3-(i H-bean zimidazol-2-yI)-6-[4- ,(methyloxyf)phenyl]quinolin-2(I H)-one 173 -azabicydlo[2.2.2]oct-3-ylamino]-3- 490 (I H-benzitnidazol-2-yI)-6-fluoro-7orphiolin 4yluinolin-2(1 174 -azabicyclo[2.2.2]oct-3-ylamino]" 423 6,7-difluoro)-3-(3H-imidazo[4,5-bpyricjin-2yl)quinolin..2(1 H)-one -azabicyclo[2.2.2]oct-3-ylamino]- 508 3-(1 H-benzimidazol-2- yI)-6-(3- _______nitrophenyl)guinolin-2(1 H)-one 176 1 -[4-[(3S)-l1-azabicyclo[2.2.2loct-3- 531 ylamino]-3,-(1 H-benzimidazl-2-yi)-B-fluoro- 2-oxo-1 ,2-diihydroquinolin-7-y~pfperidine-3carboxamie 177 -zabicyclo[2.2.2]oct-3-ylamino]-3- 401 (1 21 H-ne 178 6-(3-acetylphenyl)-4-(3R)-1 506 azabicycloI[2.2.2]oct-3-yIamino]-3-(3Himidazo[4,15-b]pyridiln-2-yI)quinoin-2(1
H)-
one 179 -azabicyclo[2.2.2]oct-3-yamino]-3- 421 (1 1 180 4-[3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 491 6-fluoro-3-'3H-imidazo[4,5-b]pyridin-2-yI)- _______7-mnorpholini4-ylguinolin-2(1 181 4-[3S)-1 -azabicyclo[2.2.2]oct- 3-ylamino]-3- 460 (I H-benzinhidazol-2-yI.7- (cyclopropvflamino)-6-fluoroquinolin-2(I H)one 182 -azabicyclo[2.2.2]oct-3ylamino]-3- (3H-imidazo[4,5-b]pyridin-2-yI)- 2-oxo-1 ,2-dlihydroquinolin-6yIjphenylacetamlde, -144- 183 -azabicyclo[2.2.2]oct-3-ylamino]-3- 503 (1 H-benzimidazol-2-yl)-6-fluoro-7-(4methylpiperazin-I -yI)guinolin-2(l H)-one 184 -azabicyclo[2.2.2]oct-3-ylamino]- .472 6-fluoro-7-(1 H-imidazol-1 -yI)-3-(3Himidazo[4,5-b]pyridin-2-yt)quinolin-2( I H)- 185 44[(33)-I -azabicyclo[2.2.2]oct-3-ylamino]-3- 525 (1 H-benzimidazol-2-yI)-6-fluoro-7-[(2pyidin-2-ylethyl)aminolquinolin-2( I H)-one 186 -azabicyclo[2.2.2Joct-3-ylaminoj-3- 488 (I H-benzimidazol-2-yI)-6-fluoro-7-piperidin- 1 -ylguinolin-2(1 H)-one 187 6-chloro-3-(3H-imidazo[4,5-b]pyridin-2- 298 ________yI)guinolin-2(i H)-one 188 ethyl I -azabicyclo[2.2.2joct-3- 560 ylamino]-3-(1 H-benzimidazol-2-yl)-6-fluoro- 2-oxo-1 ,2-dihydroquinolin-7-yl]piperidine-4carboxylate 189 4+[3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 519 3-(1 H-be nzim idazol-2-yi)-6-(1 -benzothien- _______2-yl)guinolin-2(i H)-one 190 4+(3S)-1 -azabicyclo[2.2.2]oct-3-ylamino]-3- 474 (I H-benzimidazol-2-yl)-6-fluoro-7pyrrolidin-I -ylguinolin-2(1 H)-one 191 -azabicyclo[2.2.2]oct-3-ylamino]- 532 3-(3H-imidazo[4,-5-bpyldin-2-y)-6-[2- _______(trifluoromethyl)phenyfiguinolin-2(1 H)-one 192 4+[3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 494 -3-(3H-imidazo[4,5-b]pyidin-2-yI)-6-[2- (methyloxy)phenyllguinolin-2(l H)-one 193 ethyl I -[4-[(3S)-1-azabicyclo[2.2.2]oct-3- 560 ylamino]-3-(1 H-benzimidazol-2-yl)-6-fluoro- 2-oxo-1 2-dihydroquinolin-7-ylgpiperidine-3- ________carboxylate 194 4-[3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 491 3-(1 H-benzimidazol-2-yI)-6-(4ethylphenyl)guInolin-2(I H)-one_ 195 -azabicyclo[2.2.2]oct-3-,ylamino]-3- 476 (1 H-benzimidazol-2-yi)-6-fluoro-7-[(2methylpropyl)amino]guinolin-2(l H-one 196 4-E3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 401' 3-(1 2(1 H)-one 17 4-(3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 532 6-(2,4-dichloropheny)-3-(3H-midazo[4,5.
bjpyrdIn-2-yl)guinolin-2(1 H)-one -145- 198 '4-[(3R)-1-azabicycio[2.2.2]oct-3-ylamino]- 531 3-(l H-berizimidazol-2-yI)-6-[3- (trifluoro methyl)phenyl]guinolin-2(1 H>-one 199 3-(1 H-berizimidazo-2-yI)-4- 305 (dimethylamino)qunolin-2(l 200 4-hydroxy-3-(l H-imidazo[4,5-flquinolin-2- 329 I y)guinoli -2(l 201 4-hydroxy-3-(1 H-imidazo[4,5-b]pyridin-2- 279 v)guinolin-2(l 202 -azabicyclo[2.2.2]oct-3- 525 ylamino]-3;.(1 H-benzimidazol-2-yI)-s-fluoro-, ,2 dihydroquinolin-q-yljbenzoic 203 -azablcyclo[2.2.2]oct-3- 524 ylaminoJ-3-(1 2-oxo-1 ,2-dihydroguinolin-6-yI]benzamide 204 -azabicyclo[2.2.2]oct-3- 538 ylamino]-3-(1 2-oxo-1 ,2-dihydroquinolin-6- Yllphenyllacetamide 205 -azabicyclo[2.2.2]oct-3- 525 ylamino]-3.(1 ,2-dihydroquinolin-6-yi]benzoic acid 206 -4-[4-((3R)-lI-azabicyclo[2.2.2]oct-3- .,525 ylamino]-3..(1 H-benzi mildazol-2-y)-7-fluoro..
,2-4Jihydroguinolin-6-yl~benzoic acid 207 -azabicyclo[2.2.2]oct-3- 538 ylamino]-3..(1 H-benzimidazol-2-yi)-7-fluoro- 2-oxo-1 ,2-dihydrboquinolin-6yhen I acetamide_______ 208 -azablcyolo[2.2]c3ylmn] 511 3-(l H-benzimidazol-2-yI)-7-chloro-6-(2.
methylphe iyl)guinolin-2(1 H)-one 209 4+[3R)-1 -azabicyclo[2.2.2]oct-3-ylamino]- 41.1 3-(1 H-ben2:imidazol-2-yI)-2-oxo-1 ,2- _______dihydroquinioline-7-carbontrile 210 -azabicyclo[2.2.2]oct-3-ylaminoj- 417 3-(l H-benziMidazol-2-yI)-7- (methylqxy)quinolin-2(1 H)-one 211 -azabicyclo[2.2.2.]oct-3- 506 .ylamino]-3-(1 H-benzimidazol-2-y)-2-oxo- I,2-dihydroguinolin-7-yI]benzamicje 212 4+[3R)-1 -a zabicyclo[2.2.2]oct-3-ylamino]- 434 3-(1 H-benzimidazol-2-yI)-6-fluoro-7- (MethyloxY)guinolin-2(1 H)-one 213~ -azabicyclo[2.2.2]oct-3-ylaimino]- 3-(1 H-benzimidazol-2-yi)-6-chloro-7- (dimethyJa nino)quinoin-2(1 H)-one 464
I
-146- 214 -azabicyclo[2.2.2]oct-3-ylamino]- 555 H-benzimidazol-2-yI)-7- _______(dimethylamino)-6-iodoguinolin-2(l H)-one 215 3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3- 573 ylamnino]-3-(1 H-benzimnidazol-2-y)-7-(1 Himidazol-1 -yI)-2-oxo-1 ,2-dihydroquinolin-6- Yflbenzoic acid 216 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3- 590 yfamino]-3-(1 H-benzimildazol-2-yI)-2-oxo-7piperidin-1 -yI-1 ,2-dihydroquinolin-6yfbenzoic acid 217 -azabicyclo[2.2.2]oct-3-ylamino]- 571 3-(1 H-benzimidazol-2-yI)-7-(methyloxy)-6- [4-(methytsulfonyl)phenyl]quinolin-2(1 H)- 218 -azabicyclo[2.2.2]oct-3-yamino]- 401 3-(l H-benzimidazol-2-yI)-8-methylquinolin- 2(1 H)-one 219 -azabicyclo[2.2.2]oct-3-ylamino]-3- 422 (1 H-benzimidazol-2-yI)-6,7-difluoroquinolin- 2(1 220 3-(l H-benzimidazol-2-yl)-6-methyl-4- 374 (piperidin-3-ylamino)cjuinolin-2(I H)-one 221 4-[(3S)-1-azabicyclo[2.2.2Joct-3-yamino]-3- 493 _______(methyloxy)phenyljguinolin-2(1 H)-one, 222 -azabicyclo[2.2.2Joct-3-ylamino]- 3- 493 (1 H-benzimidazol-2-yi)-6-[3- (mthyoxy)phenyjguinolin-2(1 H)-one 223 3-(l H-benzlmldazol-2-yI)-6,7-diluoro-4- 396 _______(Piperidin-4-ylamino)quinolin-2(1 H)-one 224 3-(1 H-benzimidazol-2-yI)-6,7-difluoro-4- 382 (pyrrolidin-3-ylamino)guinolin-2(1 H)-one 225 3-(1 H-benzimidazol-2-yI)-6-chloro-4- 13- 439 morpholin-4-ylpropyl)aminolquinolin-2(1 H)one 226 6-chloro-3-(5-morpholin-4-yiI- H- 480 benzimldazol-2-yI)-4-(piperidin-4- ______yLamino)guinolin-2(i H)-one_ 227 6-chloro-3-(5-morpholin-4-y-1 H- 494 benzimidazol-.2-yI)-4-[(piperidin-2- Ilmeth I amino quinolin-2(I H -ne 228 4-[(3S>-1-azabicyclo[2.2.2]oct-3-ylamino]-6- 506 chloro-3-(5-morpholin-4-yi-1 H- _______benzimidazol-2-yl)guinolin-2(i H )-one -147- 229 6-chlo ro-3-(5-morpholin-4-yiI- H- 480 benzimidazol-2-yI)-4-(piperidin-3ylamino)guinolin-2(1 H)-one 230 6-chloroA-{[2-(dimethylamino)ethyl]amno.. 468 3-(5-morpholin-4-yi-1 H-benzimidazol-2- -yI)guinolin-2( IH)-one 231 -azabicyclo[2.2.2]oct-3-ylamlno]-50 6-oh Ioro-3-(5-morpholin-4-yiI1 Hbenzimidazol-2-yI)guinolin-2(1 H)-one 232 6-chloro-3-(5-morpholin-4-yiI1 H- 494 benzimidazol-2-yI)-4-[(piperidin-3ylmethyl)amino~guinolin-2(l H)-one 233 6-ohloro-3-(5-morpholin-4-y-1 H- 494 benzimidazol-2-yi)--4-[(piperdin-4.
yimethyl)amino]guinolin-2(i H)-one 234 R,2R)-2-aminocyclohexyl]amino)-6- 494 chloro-3-(5-morpholin-4-yi-1
H-
benzimidazol-2-y)guinolin-2(l H)-one, 235 4-[(4-arninocyclohexyl)amino]-6-ohloro-3- 494 (5-morpholin-4-yiI- H-benzimidazol-2y)guinolin-2(1 236 4-{[(2S)-2-amino-3-methylbutyl~amino)-6- 482 chloro-3-(5-morpholin-4-yiI1
H-
benzimidazol-2-y)guinolin-2(i H)-one 237 4-({[4-(aminomethyl)phenyljmethyl}amino)- 516 6-chloro-3-(S-m orpholin-4-yiI- Hbenzimidazol-2-yi)guinolin-2(1 H)-one 238 6-chloro-3-(5-morpholin-4..yt-IH- 480 benzi midazol-2-yi)-4-(pyrroli in-2ylmethyl)aminolquinolin-?2(i 239 R)-1 -(aminomethyl)propyloamino)-6- 468 chloro-3-(5-morphoin-4-yiI1
H-
benzimidazol-2-y)quinolin-2(l H)-one 240 S,)-2-amino-1 530 (phenylmethyl)ethyllamino)-6-chloro-3-(5morpholin-4-y-l H-benzimidazol-2yJ)guinolin-2(l H)-one 241 6-chloro-4-{[3-(4-methylpiperazin-I .537 yI)propyl]aminol-3-(5-;morpholin-4-y-I
H-
benzimidazol-2-y)guinolin-2(l H)-one 242 6-chloro-3-(5-morpholin-4-y-1 H- 570 benzimidazol-2-y)-4-[l (phelnylmethyl)piperidin-4- ________ylaminolguinolin-2(l H)-one 243 6-chloro-3-(5-morpholin-4-yI-l H- 524 benzimidazol-2-y)-4-[(3-morpholin-4ylpropy)aminoquinolin-2(l H)-one -148- 244 6-chloro-3-(5-morpholin-4-y-1 508 benzimidazol-2-yI)-4-[(2-.piperidin-1 ylethyl)aminolguinolin-2(l H)-one 245 6-chloro-3-(5-morpholin-4-y-1 H- 488 benzimidazol-2-y)-4-[(pyridin-3ylmethyl)aminolguinolin-2(l H)-one 246 6-chloro-4-{[3-(1 H-imidazol-1- 505 yl)propygamino}-3-(5-morpholin-4-yI Hbenzimidazol-2-y)guinolin-2(1 H)-one 247 6-chloro-3-(5-morpholin-4-y-1 H- 488 benzimldazol-2-y)4+[pyddcln-4ylmethyl)amino]guinolin-2(l H)-one 248 6-chloro-4-{(2-(methylamino)ethyl]amino)- 454 3-(5-morpholin4-yi-1 H-benzimidazol-2yI)guinolin-2(l H)-one 249 6-chloro-4-{[(2-methyl-1 -piperidin-4-yI-1 H- 624 benzimidazol-5-yI)methyl]amino)-3-(5morpholin-4-y-1 H-benzimidazol-2yI)quinolin-2(l H)-one 250 6-chloro-3-(5-morpholin-4-yi-1 H- 494 benzimidazol-2-yi)-4-[(2-pyrrolidin-1 _______yiethyl)amlnolguinolin-2(l H)-one 251 6-chloro-3-(5-morpholin-4-yiI- H- 466 benzimidazol-2-yt)A-(pyrjrolidin-3- _______ylamino)guinolin-2(l H)-one 252 R,2R)-2-aminocyclohexy~amlno}-6- 507 chloro-3-[5-(4-meth-ylpiperazin-1 -yI)-1 Hbenzimidazol-2-J ioj-2(l H)-one 253 4-[(4-aminocyclohexyl)amino]-6-chloro-3- 507 [5-(4-methytpiperazin-1 -yI)-1 H- .benzimidazol-2Aylunolin-2(1 H )-one -254 4-({[4-(aminomethyl)phenylqmethyl~amino)- 529 6-chloro)-3-[5-(4-methylpiperazin-1 -yI)-1 Hbenzimidazol-2-yoguinolin-2(i H)-one 255 6-chloro-4-{[2-(methylamino)ethyl]amino}- 467 3-[5-(4-methylpiperazin-1 -yI)-1 Hbenzimidazol-2-ygquinolin-2(l H)-one.
256 .6-chloro-3-115-(4-methylpiperazin-1 -yI)-1 H- 550 benzimldazol-2-y]-4-{[3-(4rnethylpiperazin-1 -yI)propyljamino}quinolin- H)-one 257 6-chloro-3-[5-(4-methylpiperazin-1 H- 583 benzimidazo-2-y-4-{[1 (phenylmethyl)piperidin-4- _______ygamino~quinolin-2(l H)-one 00 -149- 258 6-chloro-3-[5-(4-methylpiperazin-1 -yl)-l H- 507 benzimidazol-2-yi]-4-[(2-pyrrolidin-1 _______ylethyl)amlno]guinolln-2(1 259 6-chloro-3-[5-(4-methylpiperazin-I H- 479 benzimiclazol-2-y]-4-(pyrrolidin-3- ,ylamino)guinolin-2(1 H)-one 260 6-chloro-3-[5-(4-methylpiperazin-1-y)-1 H- 493 benzimidazol-2-y]-4-(piperidin-4vamino)guinolin-2(l H)-one 261 6-chloro-3-(5-morpholin-4-yi-1 H- 508 benzimidazol-2-yi)-4-[(2-piperidin-2ylethy amino quinolin-2(I H -ne 262 -azabicyclo[2.2.2]oct-3-yiamino]-7- 506 chloro-3-(5-morpholin-4-yl-1 Hbenzimidazol-2-y)guinolin-2(l H)-one 263 7-chloro-3-(5-morpholin-4-y-1 H- 480 benzimidazol-2-yI)-4-(piperidin-3yiamino)guinolin-2(1 H)-one 264 6-chloro-3-[5-(4-methylpiperazin-1-yI benzimidazol-2-yl-4-[(piperidin-2- ________methyl)amin]gunolin-2(1 H)-one 265 6-chloro-3-[5-(4-methylpiperazin-I -yi)-l H- 493 benzimidazol-2-yJ-4-{[(2S)-pyrrolidin-2ylmethyl]amino~guinolin-2(i -266 6-chloro-3-(5-(4-methypiperazin-1-y)-1 H- 493 267 6-chloroli-4-({[(2S)1tylpyrroldin-2-52 yI)lm enzil~midaol-Iquinolin-2( 1 H)-on 268 6-chloro-4-({[(2R)-1 -ethylpyrrolidin-2- 521 yllmethyl}amino)-3-[5-(4-methylpiperazin-1 y1)-1 H-benzimidaz o-2-yjquino in-2(l H)one 269 {2-aylo[2.2.2]o3lmin-3- 493 (1 H-enzillmiaol2y)-6-[4-ehlieai- (methyloxy)phenyl]gunoln-2(1 H)-one 270 6-(3-aminopheny)-4-[(3S)-1 478 azabicyclo[2.2.2]oct-3-yamino]-3-(l
H-
_______benzimidazol-2-y)guinolin-2(l H)-one -150- 4 Assay Procedures In vitro kinase assays for receptor tyrosine kinases 0The kinase activity of various protein tyrosine kinases can be N measured by providing ATP and a suitable peptide or protein tyrosine-containing C, 5 substrate, and assaying the transfer of phosphate moiety to the tyrosine residue.
Cl Recombinant proteins corresponding to the cytoplasmic domains of the fit-1 O (VEGFR1), KDR (VEGFR2), and bFGF receptors were expressed in Sf9 insect CI cells using a Baculovirus expression system (InVitrogen) and purified via Glu antibody interaction (for Glu-epitope tagged constructs) or by Metal Ion Chromatography (for His tagged constructs). For each assay, test compounds were serially diluted in DMSO then mixed with an appropriate kinase reaction buffer plus ATP. Kinase protein and an appropriate biotinylated peptide substrate were added to give a final volume of 100 pL, reactions were incubated for 1-2 hours at room temperature and stopped by the addition of 50 xiL of 45 mM EDTA, 50 mM Hepes pH 7.5. Stopped reaction mix (75 L) was transferred to a streptavidin coated microtiter plate (Boehringer Mannheim) and incubated for 1 hour. Phosphorylated peptide product was measured with the DELFIA time-resolved fluorescence system (Wallac), using a Eu-labeled anti-phosphotyrosine antibody PT66 with the modification that the DELFIA assay buffer was supplemented with 1 mM MgCh for the antibody dilution. Time resolved fluorescence was read on a Wallac 1232 DELFIA fluorometer. The concentration of each compound for 50% inhibition (ICso) was calculated by non-linear regression using XL Fit data analysis software.
Fit-l, KDR, and bFGFR kinases were assayed in 50 mM Hepes pH 2 mM MgClh 10 mM MnC2. 1 mM NaF, 1 mM DTT, 1 mg/ml BSA, 2 jtM ATP, and 0.42 iM biotin-GGGGQDGKDYIVLPI-NH2. Fit-1, KDR, and bFGFR kinases were added at 0.1 gxg/mL, 0.05 g/mL, or 0.1 pg/mL respectively.
-151- Each: of the following compounds was synthesized and assayed using the procedures described above: IN -5(-mnpeoy-Hbniiazl2yj4hdoy2I)q oioe 3-{6- 2 -(dimethylamino)ethyI(methy)amino]1bezimidazo2yI}Ahydroxy2(IH)quinolinone; 4 -hydroxy-3-[5-(4-morpholiny)lHbenadazol12-y]2(H)quinolinone; 3-5(-mn--yrldnl-Hbezmdzl2yl4hdoy2l) quinolinone; N,N-diiuethyl-2-(2-oxo-1 ,2-diydro-3-quinolinyl)-1H-benzimudazole-5 carboxamide; 3 -{5-[2-(4-mophoiny)ethoy]-I1benzimidazol2yl}-2(H..
quinolinone; 3-5[-dmtyaio--yrldiy]I-ezmdzl2y)2I) quinolinone; 3-(1H-benzimidazol-2-y)-2-oxo-1 ,2-dihydro-4-quinolinecarbonitrile; 4 -amino- 3 2 4 -morpholiny)ethoxy].Hbenzimdazol.2.yl}.2(11i)-uinolimone; 4 -amino- 3 6 -(4-morpholinyl)-1Hbenzimidazol12-y1]2(l)quinoinone; 4-amino- 3-6(-mn--yrldnl-Hbnzmdzl2y]2l)qioioe 2-(4axnino-2-oxo-1,2dhdo3 inlnl-H-ezmdzl--bntie 2-(4axnino-2-oxo-1,2dhdo3qioinl carboxainide; 4 -amino-3-{5-[3-(dimethylamino)-1-pyrrolidinyI].1w-benzimidazol.2yl}-2(1H)-quinolinone; 2-(4-amino-2-oxo-1 ,2-dihydro-3-quinolinyl)-1Hbenznmidazole-6-carboximidlamide, 4-aino-3-[5-(4-morpholinylcarbonyl)-1Hbenzimidazol-2-ylI-2(111)-quinolinone, 4-'amino-3-[5-(1H-1 ,2,4-triazol-1-yl)-1Hbenzinlidazol-2-yl]-2(1u)-quinolinone; 4-amino-3-[5-(dimethylamino}-1Hbenzimidazol-2-yl]-2(lH)-quinolinone; 4-amiuo-3-[5-<1-piperidinyl)-1Hbenzimiidazol-2-yl]-2(lH)-quinolinione; 4-amino-3-[5-(2-thienyl)-1H-benzinidazo1-2yl]-2(1H)-quinolinone; 4 -amino- 3 5-[3-(1-pyrrolidinyl)propoxy]-rn-benzimdazol.
2 -yI}- 2 (lH)-quinqlinone; 4 -anhino-3-{5-[3-(4-morpholinyl)propoxy]-1Hbenzimidazol-2-yl}-2(1H)-quinolnone; 4-amino-3-[5-(3 ,5-diinethyl-1-piperazinyl)- IH-benzimidazol-2-ylI-2(lH)-quinolinone; 4-amino-3-[5-(2,6-diniethyl-4mopoiy)I-ezmdzl2y]2l)qioioe 4-amino-3-115-(4-methyl- 1pieaiy)l-ezniaol2y]2l)qioioe 4-amino-3-(1Hbenzimidazol-2-y)6hydroxy(oxdo)amino]-2(lH)-uinoinone; 4-ainino-3-(1Hbenzimidazol- 2 -y)-5-[2-(4-mophoinyl)ethoxy]-2(n}..quinoinone; 4-amino-3-(lH- -152- 02 benzimidazol-2-yl)-6-(4-methyl-1-piperazinyl)-2(1H)-quinolinone; 4-ainino-3-(1Hbenzimidazol-2-.yl)-5-[(1-methyl-3-piperidinyl)oxy]-2(lH)-quinolinone; 4-amino-6chloro-3-[5-(4-morpholinyl)-1IH-benzihuidazol-2-yl]-2(1H)-quiniolinone; 4-aniino-6- 00chloro-3-{5-[3-(dimethylaniino)-l-pyffolidinyl]-H-benzimidazol-2-yl}-2(1I1)- 0 5 quinolinone; 4-aniino-.6-Ilkydroxy(oxido)amino]-3-{5-[2-(4-morpholinyl)ethoxy]- 1Hbenzimidazol-2-yI}-2(1H)-quinolinone; 4-amino-5-[2-(4-morpholinyl)ethoxy]-3-{5- [2-(4-morpholinyl)ethoxy]-1H-benzimidazol-2-yl}-2(1H)-quinolinone; 4-aniino-3- (1H-benzimidazol-2-yI)-6-(2-pyridinylnethoxy)-2(lH)-quiinolinone; 4-amino-6fluoro-3-[5-(4-inorpholinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone; 4-amino-3- {5-[3-(dineieylaxnino)-l-pyrrolidinlyl]-1H-benzimidazol-2-yl}-6-fluoro-2(1Hy..
quinolinone; 3-(1H-benzimidazol-2-yI)-4-[(tetrahydro-2-furanymethyl)amino]- 2(111)-quinolinone; 3-(1H-benzimidazol-2-yl)-4-(methylaminio)-2(1H)-quinoliuone; 3-(1H-benzimidazol-2-yl)-4-(ethylamfino)-2(1H)-quinolinone; 3-(1H-benzimidazol-2yl)-4-{12-(-methyl-2-pyrrolidinyl)ethyl]amino}-2(1H)-quinolinone; 3-(lHbenzimidazol-2-yl)-4-[(4-piperidinylmethyl)amino]-2(1H)-quinolinone; 3-(1Hbenzimidazol-2-yl)-4-(4-fluoroanilino)-2(lH)-quinolinone; 4-(1azabicyclo[2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2-yl)-2(1H)-quinolinone; 3- (1H-benzimidazol-2-yl)-4-(1H-benzimidazol-6-ylamino)-2(1ll)-quinolinone; 4anilino-3-(1H-benzimidazol-2-yI)-2(1H)-quinolinone; 3-(1H-benzimidazol-2-yi)-4- (methoxyamino)-2(1H)-quinolinone; 3-(1H-benzimidazol-2-yl)-4-[(1H-imidazol-5ylmethyl)amino)-2(1H)-quinolinone; 3-(1H-benzimidazol-2-yl)-4-(4niorpholinylamino)-2(1ll)-quinolinone; 3-(1H-benzimidazol-2-yl)-4-Iiydrazino- 2(111)-quinolinone; 4-(1-azabicyclo(2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2-yl)- 2(1H)-quinolinone; 4-(1-azabicyclo[2.2.2]oct-3-ylamino)-3-(1H-benzimidazol-2-yl)- 2( 1H)-quinolinone; 4-J(2-methoxyethyl)amino]-3-[6-(4-morpliolinyl)-1Hbenzimidazol-2-yl]-2(1H)-quinolinone; 4-[(2-hydroxyethyl)amino]-3-[5-(4morpholinyl)-1H-benziuidazol-2-yl]-2(1H)-quinolinone; 4-(methoxyamino)-3-15-(4morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone; 3-[5-(4--morpholinyl)-1Hbenzimnidazol-2-yI-4-(3-piperidinylauino)-2(1I{)-quinolinone; 3-[5-(4-morpholinyl)lH-benzimidazol-2-yl]-4-[(3-piperidinyhnethyl)anino]-2(lH).quinolinone; (dimethylamino)edhy1]amino)-3-[5-(4-morpholinyl)-lH-benzimidazol-2-y1]-2(lH)- -153quinolinone; 3 -[5-(4-morpholinyl)-1H-benzimidazol-2;-yl]y4-[(tetrahydro-2furanylmethyl)amino]-2(1H)-quinolinone; [2-(methylamino)ethyl]ainino}-3-[5-(4- 00poiy)l-ezmdzl2y]2I)-unlnn;3[-4mrhlnl-H 00 benzimidazol-2-yII-4-(3-pyrrolidinylaxino)2(IH)-quinolinone; 4-[(2-amino-4methylpenty)amino]-3-[5-(4-morpholiyl) 1H-benziniidazoI-2-yl]-2(111quinolinone; 4 2 -amino-3-methylbutyl)amino]-3-[5-(4-morphoinyl)-IHn benzimnidazol-2-yl]-2(1H) 1 uinolinone; 3-(5,6-dmethy-H-benzimidazo-2-y)...(3piperidinylamino)-2(1H)-quinolinone; 4-{(2-aminocyclohexyl)amio]-3[5-(4morpholinyl)-1H-benzimidazol-2yp-2(11)-uinolinone; 4-[7(2amnccoey~mn]3[-4mrhoiy)l-ezmdzl2yl2I) quinolinone; 3 -(lH-benzimidazol-2-yl)-4-hydroxybenzo~g]quinolin.2(1H)one; 4- ,amino-3-(3H-iinidazo[4,5-blpyridin-2-y)qiuinolin-2(H).One; 4-arnino-3-(5mopoi--l3-mdz[,-~prdn2y~unlnZI)oe [(RS-26dmtymrhln4yl3(-Hiiao45bprdn2y~unln 2(1H)-one; 4 -amino-3-{5-[-(dimethylamino)pyrrolidin-1-y1]-3Himidazo[4,5-.
blpyr-idin-2-yl~quinolin-2(1H).one; .4-axnino-3-{5-jI(3S)-3- (dmtyaiopfoii--l-Hbezmdzl2y~unln2l)oe I-zbcco222ot3yaio--l-bniiao--l--hoounln 2(111)-one; 4
-R(
3 R)-1-azabicyco[2.2.2]oct-3-ylamro]-3(rn-benzimidazol-2..yl-& chloroquinolin-2(1H)-one; 3-(1H-benzimidazol-2-yl)4[(3R)-3- (dimethylamino)pyrrolidin-1..y1qujnoin2(lH)-one; 3-(1H-benzimildazol-2-yI)-6& chloro- 4 [(3R)-3-(dimetlamno)pyffoidin1y]qolin-2(1)ne 4-amino-3-[5- (4-ethylpiperazin- l-yl)-1H-benzimidazol-2-yI]-1-methylquinolin-2(lH)-one;1 4amino-!3-( 6 -piperazin-1-ylI H-benzimidazol-2.yl)quinolin-2( 1H)-one; 4-Aniino-3-16- (pyridin- 4 -ylmeffy)-Hbenziidazo12-y1Iquinolfi2(LH)one; 4-amiino-3-{5- 3 R,5S)-3,5-dimethylpiperazin-1 -yl]-IH-benziznidazo]-2-yl~quinolin-2(IH)-one; 4amino- 3 -[5-(4-methypiperaziny)lHbenzimdazo-2-y]quinolin-2(11)ne; 4amino- 3 6 -methyl-5morphoin4y11wHbenziidazo12-Y1)quinoin2(H)-one; 4amn--5[Imtypprdn3y~x]-Hblzmdzl2y~unln2I) one; 4 -amino-3-{5-[(2R,6S)-2,6dimethynorholin4y1]-6fluoro 111benzimidazol-2-yl}quinolin.2(ln).one; 4-amino-3-{5-[(l- methylpyrrolidin-3- -154yl)oxy]-1H-benzimidazol-2-yl~quinolin-2(IH)-one; 4-amino-3-[5-(4-methyl-1,4diazepan-1-yl)-1H-benzimidazolb2-yl]quinolin-2(ln)-one; 4-amino-3-{5-[(3R)-3-.
(dimethylamino)pyrrolidin-1-yl]-lH-benzimidazol-2-yl~quinolin-2(lH)-one; 47 00 ~amino-6-chloro-3-{5-[(3R)-3-(dimethylamino)pyrrolidin-1-yl}4lH4,enzimidazol-2 S 5 yl~quinolin-2(LH)-one; ethyl {4-(2-(4-alnino-2-oxo-1,2-dihydroquinolin-3-yl)-1Hbenzimidazol-6-yl]piperazin-1-yl} acetate; 4-auiino-3-{6-[methyl(1-methylpiperidn- 4 -yl)anhino]-1H-benziniidazol-2-yllquinolin-2(1II)-one 3-'[6-(4-acetylpiperazin-1yl)-lH-benziniidazol-2-yl]-4-aminoquinolin-2(IH)-one; 4-amino-3-[6-{1 ,4 bipiperidin-1 1H-benzimidazol-2-yljquinolin-2(1H)-one; 2-(4-amino-2-oxo-1 ,2dihydroquinolin-3-yl)-l-benzimidazole.6.caboxylic acid; 3 6 -(4-methylpiperazin-1-yl)-1H-benziniidazol-2-ylquinolin-2(H one; 4-amino-3- {64[4-(1-methylethyl)piperazin-1-yl]-lHwbenzinidazol-2-yllquinolin-2(H).one; {4- [2-(4-axnino-2-oxo-1 ,2 -diydroquinoli-3-yl),-1H-benzimidazol-6-yIlpiperazin-1yl~acetic acid; 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylaminol-.3-(1lH-benzimidazol-2yl)quinolin-2(lH)- one; 4-[(3R)-l-azabicyclo[2.2.2]oct-3-ylamino]-3-(lHbenzinlidazol-2-yl)quinolin-2(1H)-one; 4-amino-3-[5-(4-ethylpiperazin.-1-yl)-1Hbenzimidazol-2-yljquinolin-2(1u)-one; 4-arnino-3-(5-{(2S,5S)-2- [(dimnethylamino)methyl]-5-methylmorpholin-4.yl}-1H-benzmidazol.2y)quinolin 2(11)one; 4 -amino-6-chloro-3-15-(4-methylpiperazin-1-yl)-1{-benzmidazol.2 yl]quinolin-2(1H)-one; 4-andno-6-ch loro-3-{5-[(3S)-3-(dimethyLaxnino)pyrrolidin-1yl]-1H-benzimidazol-2-yl~quinolin-2(1H)-one; 4-amino-5 ,6-dichloro-3-{5-[(3S)-3- (dimethylaxino)pyrrolldin-1-y1]-lH-benzimidazol-2-y)quinoin2(lH)-one; 4amino-S 6 -dichloro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2"yllquinolin- 2(1H)-one; 4 -amino- 3-(111-benzimidazolb2-yl)-6-[(pyridin-2-ylmethyl)oxy]quinolin- 2 (1I{)-one; 4 -amino-3-(1H-benzimidazol-2-yl)-6-[(2R,6S)- 2,6-dixnethiylmorpholin-4yllquinolin-2(1H)-opne; 4-amino-3-(1H-benzimidazol-2-yl)-6-morpholin-4ylquinolin-2(1IH)-one; 4-amino-3-(1H-benziinidazol-2-yI)-5-[(1-methylpiperidin-3yl)oxy]quinolin-2(1H)-one; 4-aniino-3-(111-benzhnidazol-2-yl)-5-[(pyridin-2ylmethyl)oxylquinolin-2(lH)-one; 4-amnn-3-(5-morpholin-4-yl-H-benzinidazol-2yl)-5-[(pyridin-4-yllnethyl)oxy]quinolin-2(IH)-one; 4-amino-3-k lH-benzimidazol-2yI)-5-(methyloXY)quinolin-2(1l.)..one; 4-amino-3-(5-methyl4lH-benzinidazol-2-y)- -155- 5-(methyloxy)quinolin-2(1H)-one; 4 -amino-3-{5-[(2R,6S)-2,6-dilnethylmorpholinA4 yl]-lH-benzimidazol-2-y}--(methyloxy)quinolin2(lly-one; 4-amino-3-(1R- 00 benzimidazol-2-yl)-5-morpholin-4-ylquinolin2(lH)-one; 4-aniino-3-(11- NO benzimidazol-2-y)-5[(2R,6S)-2,6diethylmorpholin-4y1]quini2(1H)ne; 4- NI 5 amino- 3 -(lH-benzimidazol-2-yl)--(4-methylpiperazinl1yl)quinolin..2(1H)-one; 4- 6 -dichloro-3-(5-morphoin4-yHbenzimidazo2yl)quinoin2(lHy-one; 3-5[2mrhln4yehloy-Hbezmdzl2y~unln2l)oe 4one; 4-mn--5[3mrhln4ypoy~x]l-ezmdzl2y~unln 2(111)-one; 4 -amino-6-fluoro-3-(5-morpholin-4-y1-1H-benzimdazo2.y)quinolin- 2(111)-one; 4 -amino-3-{5-[3 -(dimethylamino)pyrroidin-1-y]-1H-beinzimidazo12.
yi}-6-fluoroquinolin-2(1H)-one; 4-amino-3-( 11-benziniidazol-2-yl)-6fluoroquinolin-2(1IH)-one; -amino-3-(6-fluoro-5-morphoin-4-yl-11-benzimidazol.
2 -yl)quinolin-2(111)-one; 4 -amino-3-{5-[(tetrahydrofuranl-2-ylmetllyl)oxy]411benzimidazol-2-yl)quinolin-2(1H)-one; 4-amino-6-fluoro-3-(6-fluoro-5-morpholin-4.
ylIH-benizimidazol-2-yl)quinolin-2(111)-one; 4-amino-3-[6-fluoro-5-:(4-' metIhylpiperaznm-1-y)-H-beniidazo12-y]quinolin-2(1H)-one; 4-amino-3-(5-{ [2- (mtyoyehloy-Hbniiao--lqion2I)oe 4-aniino-3-[4,6diloo5(-ehlieai--l-H-ezmdzl2y~unln2l)oe 4amiko-3-{5-[3-(dimethylamino)pyrrolidinl1yl]yllvbenziidazol2yl}.5 fluoroquinolin-2(rn).one; 4 -amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)ylH benzimidazol-2-yl]quinolii-2(H)ne; 4-axnino-5-chloro-3-(5-(4-methylpiperazin-1yl)-1H-benzmidazol-2-yl]quinolin-(IH)-.one; 4-amino-3-{5-[3- (dmtyaioproii--l--looI-ezmdzl2y~unln2l)oe 4 -amino-5-chloro-3-{5-[3-(dimethyamino)pyrroid1y]IH-benzimjdol.2yl~quinolin-2(1H)-one;. 4-amino-6-chloro-3-{5-[3-(dhnethylamino)pyffolidin-1y] 6-fluoro-1H-benzimidazol-2-yl}quinolin-2(1H)-one; 4-amino-5-[(2R,6S)-2,6dintymrhln4y]3(Hiiao45bprdn2y~unln2l)oe 4anino- 3 -(6-thiomorpholin-4.y1411.benzimidazol.2yl)quinolin.2(11y-one; 4-amino- 3-5(-ylhxlieai--i-Hbezmdzl2y~unln2l)oe 4amino- 3 -{6-[3-(diethylamno)pyffolidin-1-y-1Hbenzinidazol2-YI}quinoin2(pH>.
-156one; 4 -an:ino-3-16-(4-pyridin-2-ylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin- 2(111)-one; 4-amino-3-[5-(4-methylpiperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2.
yI]quinolin-2(1H)-one; 4-amino-6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H- 00 imidazo[4,5-b]pyridin-2-yljquinolin-2(1H)-.one; 2-(4-amino-2-oxo-1 ,2- 0 5 dihydroquinolin-3-yl)-N-methy-N-(-methypiperidin4y)-1H-benzimidazole-5.
carboxainide; 4-amino-3-(5-{[4-(1-methylethyl)piperazin-1-yl]carbonyl}-1IHbenzimidazol-2-yl)quinolin-2(1H)-one; 4-axnino-3-[5-(4-methylpiperazin-1-yl)-111benzimidazol-2-yl]-6-nitroquinolin-2(lH)-one; 4-amino-3-[-{1,4 '-bipiperidin-1 ylcarbonyl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; 4-amino-3-{5-[(4methylpiperazin-1-yl)carbonyll-1H-benziniidazol-2-yl~quinolin-2(rn)-one; 4-amino- 3-[5-(1-oxidothiomorpholin-4-yl)-1H-benzimidazol-2-yl]quinolin-2(lH)-one; [(-ctlieai--lcroy]l-ezmdzl2y)4aiounln2l) one; 4-amino-3-(5-{[(3R)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}-1ubenzimidazol-2-yl)quinolin-2(1H)-one; 4-amin-3-(5 (dimnethylamino)pyrrolidin-1-yIlcarbonyl-rn-benzimidazol-2-yl)quinolin-2(1n)one; 4-amino-3-(5-{[4-(dimethylamino)piperidin-1-yl]carbonyl}-1H-benzimidazo1-2.
~yl)quinolin-2(1H)-one; methyl 2-(4-amino-5-fluoro-2-oxo-1,2-dihydroquinolin-3-yj)- 1H-benzimidazole-6-caboxylate, 4-anuno-3-[5-(1 ,3 '-bipyrrolidin-1 '-yl)-1Hbenzimidazol-2-yI]quinolin-2(1H)-one; 4-amino-3-[5-(pyridin-3-yloxy)-IHbenzimnidazol-2-yljquinolin-2(1H)-one; 4-amino-.5,6-bis(methyloxy)-3-[5-(4metbylpiperazin-1-yl)-lH-benzimidazol-2-yl]quinolin-2(lIH)-one; 2-(4-amino-2-oxo- 1, 2 -dihydroquinolin-3-yl)-N-[2-(diethyamino)ethy]-N-methy-lH-benzimidazoe.
5-=aboxamide; 2-(4-ainino-2-oxo-1 ,2-dihydroquinolin-3-yl)-N-methyl-N-(1methylpyrrolidin-3-yl)-1H-benzimidazole-5-carboxamnide; 4-amino-3-{5-i(5-methyl- 2,5-diazabicyclo 1]hept-2-yl)carbonyl]-1H-benzimidazol-2-yl~quinolin-2(1H)one; 4-amino-3-{5-[(4-cyclohexylpiperazin-1-yl)carbonyl]pl-benzimidazol-2yl~quinolin-2(1H)-one; 4-amino-3-{5-[(2-piperidin-1-ylethyl)aniino]-1Hbenzimidazol-2-yl~quinolin-2(1H)-one; ethyl [2-(4-.aniino-2-oxo-1 ,2dihydroquinolin-3-yl)-1H-benzimidazol-5-yllamino~piperidine-1-carboxylate; 4amino-3-[5-({ (5R)-5-[(nethyloxy)mthypyrroidin-3-yl}amino)-1H-benzimidazol- 2-yl]quinolin-2(1H)-one; 4 -aniino-3-{5-[(pyridin-2-ylmethyl)anino]-111- -157benzimidazol-2-yljquinolin-2(IH)-one; 4 -amnino-3-[5-(piperidin-3 ylamjno)-lHw benzinlidazol-2-yl]quinolin-2(lH)-one; 4-anino-5-fluoro-3-{S-[(pyridjn-2 ylmethyl)amino]-1H-benzimidazok2-y1}quio1i2(1D..
4 ne; ethyl 4 -{[2-(4-amino-5- 00fluoro-2-oxo-1,2dhdounln3yl Hbniiao--ylmn~ieiiel carboxylate; 4 amino--5-fluoro-3-[5-(piperidin-3-ylanmjnoy. 1H-benziinidazol-2yl]quinolin-2(1H)-one; 4-amino-3-.( H-benzinlidazol-2-yl)-6-bromoquinolin.2(111)one; 4 -amino- 3 -(1H-benzimidazol-2-y)-7-.bromoquifloln2(1Hp-ne; 4-amino-3-(5bromo-lH-benzimidazol-2-y)quinoin2(1H)-ne; N,N-dimethyl-2-(2-oxo-1 ,2diyrqion3y)I-ezmdzl--uoaie 4 -aniino-3-(5-thien-2-yllH-benzimidazol-2-yl)quiuolin-2(lH).one; 2-(4-amino-2-oxo-1 ,2-dihydroquinolin-3- 4anino-6-iodo-3-[5-(4methylpiperazin-1-y)1n-benziidazop2-y1]quinolin-2(lH)-one; 4-arnino-3-(5-{2- [(dimethylamno)methymorphon y 1}1RHbenzi idao2y)io 2 (lH.-ne; 4-(R--zbcco222ot3yaio]3(Hbniiao--l--hoo6 -iodoquinolin-2(1H)-one; 4 -[(3R)-1-azabicyclo[2.2.2]oct-3-ylaminoy-3-(1 benzimidazol-2-yl)-6-nitroquinolin..2(1H)-one; 4-[(3R)-1-azabicyclo[2.2.2]oct-3.
ylamino]- 3 -(lH-benzinhidazob-2yl).&methylquinolin.2(1H).one; azabicyclo[Z 2 2 ]oct-3-yamino]3(1Hbenzimidazol12yl).6,7-ifuoroquinolin..
2(111)-one; lmn]3(HbniiaoIy)7 chloroquinolin-2(III)-one; 4-[(3R)-l-azabicyclo[2.2.2]oct-3-ylamino]-3-(1 bezmdzl2y)6boounln2I)oe 4-[(3R)-.1-azabicyclo[2.2.2]oct-3yla o-3-(lH-benzimidazol-2.y)-2ox-1 ,2-dihydroquinoline-6-cabonitrile; 4- [(R--zbcco222ot3ywio--(Hbniiao--l--loounln 2(111)-one; 4-(S--zbcco222ot3yaio--I-ezniao.2y) 6 ,7-bis(mnethyloxy)quinoin-2(1{)o 1 e; 4-[(3R)-1-azabicyclo[2 .2 2 ]oct-3-ylamino]-.
3 -(lH-benzimidazol-2-yl)-6,7-dichloroquinolin-2(11)-one; azabicyclo[2 2 2 1 oct-3-ylaxn no]-3-(111-benzimidazol-2-y)-6-fluoro-2-oxo-1,2dihydroquinolin-7-y]piperidine-4-carboxamide; 4-[(3S)-1-azabicyclo[2.2.2]oct-3ylaniino]-3-( Hbniiao--l--loo7[(-yrxpoy~mn~unln 2(111)-one; 4-[(3S)-l-azabicyco[2.2]oct3y ino]3(Hbeiidzo12yl)- (dimethylamino)-6-fluoroquinolln..2(11)ne; 4-[(3R)-l-azabicyclo[2.2.2]oct-3- -158- Ylamino-3(1H-benzimidazol-2-yl)-5-fluoroquinolin-2(1H)-one; azabicyclo [2.2 .2]oct-3-ylamino]-3-(1H-benziniidazol-2-yl)-6-(4nitrophenyl)quinolin-2(1H)-one; 4-[(3S)-1-azabicyclo[2.2.2oct-3-ylanino]-3-(11- 00 benzimidazol-2-yl)-7-{[2-(dimethylamino)ethyllamino}-6-fluoroquilolin-2(H).one; 0 5 4[3S)-l-azabicyclo[2.2.2]oct-3-ylamno]-3-(1H-benzimidazol-2-yl)-6fluoro7.(1H iinidazol-1-yl)quinoli-2(1H)-one; 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylaiuino]-3-(1Hbenzimidazol-2-yl)-6-[4-.Qethyloxy)phenyl]quinolin-2(1H)-one; azabicyclo[2.2.2]oct-3-ylamno]-3-(1H-beniidazo-2-yl)y.&fluoro-.7-morphon-A..
ylquinolin-2(1H)-one; 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamixioj-6,7-difluoro-3- (3H-imidazo[4,5-blpyridin-2-yl)quinolii-2(II)-one; 4+{3R)-1-azabicyclo[2.2.2]oct- 3 -ylaino]-3-(H-benziidazo-2-y)-6-(3-nitropheny)quinoin-2(II)-one; 14[4- [(3S)-1-azabicycl6[2.2.2]oct-3-ylanino]-3-(IH-benzimidazol-2-yl .fluoro2.xo.
1 ,2-dihydroquinolin-7-yl]piperidine-3-carboxamide; 4-[(3S)-1-azabicyclo[2.2.2]oct- 3-ylamino]-3-(1H-benzimidazol-2-yl)-5-methylquinolin-2(H)-one; 6-(3acetylphenyl)-4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3(3Hivaidazo[4,5blpyridin-2-yl)quinolin-2(1H)-one; 4-[(3S)-1-azabicyclo[2.2.2j]oct-3-ylaxnino]-3- (1H-benziniidazol-2-yI)-5-chloroquinolin-2(1H)- one; azabicyclo[2.2.2]oct-3-ylamino]-&fluoro- -(3H-imidazo[4,5-b]pyridin-2yl)7.
morpholin-4-ylquinolin-2(lH)-one; 4-[(3S)-l-azabicyclo[2.2.2]oct-3-ylaxnino]-3- (1H-benzimidazol-2-yI)-7-(cyclopropylamino)-6-fluoroquinoiin-2(lH)-one; N-f [(3R)-1-azabicyclo[2.2.2]oct-3-ylaiino]-3-(3H-imidazo[4,5-b]pyriin2-yl..2oxol,2-dihydroquiinolin-6-yl]phenyl)acetamide; 4-[(35)-1-azabicyclo[2.2.2]oct-3ylamino]-3-(1II-benzimidazo-2-y)-6-fluoro-7-(4-methypiperazin-1-y)quinoi-_ 2(111)-one; 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-fluoro-7-(1H-imidazol-1yl)-3-(311-iridazo[4,5-blpyridin-2-yl)quinolin-2(1H)-one; azabicyclo [2.2 .2]oct- 3 -ylaminol-3-(1H-benzimidazol-2-yl)-6-fluoro-7-{(2- pyridin-2ylethyl)aniino]quinolin-2(1H)-one; 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylainino]-3- (lH-benzimidazol-2-yl)-6-fluoro-7-piperidin-1-ylquinolin-2(11)-one; 6-cliloro-3- (3H-imidazo[4,5-b]pyridin-2-yl)quinolin-2(1H)-one; ethyl 1-[4-I(3 azabicyclo[2.2 2 ]oct-3-ylaminol-3-(1H-benzimidazol-2-yl)-6-fluoro-2-oxo-1 ,2clihydroquinolin-7-yIjpiperidine-4-carboxylate; 4-[(3R)-l-azabicyclo[2.2.2]oct-3- -159ylamino]-3-(1H-benzimidazol-2-yl)-6-(1-benzothien-2-yl)quinolin-2(1IHy-one; 4- [(3S)-1-azabicyclo [2 2] oct-3 -ylauiino] -3-(1H -benziniidazol-2-yl)-6-fluoro-7pyrrolidin-1-ylqpinolin-2(1H)-one; 4-IX3R)--azabicyclo[2.2.2]oct-3-ylamino]-3.
00( 3 H-iluidazo[4,5-b]pyridin-2yl)-6.{2-(trifluoromethyl)phenyllqunolin.2(1H).one; 4 3 R)-l-azabicyclo[2.2.2]oct-3-ylamno]-3-(3H-imidazo[4,5-blpyridin-2.y1)-6[2- (niethyloxy)phenyl]quinolin-2(1H)-one; ethyl 1-[4-[(3S)-1-azabicyclo[2.2.2]oct-3-.
ylaniino]-3-.(1H-benziiuidazol-2-yl)-6-fluoro-2-oxo-1 ,2-diliydroquinolin-7yljpiperidine-3-carboxylate; 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H.
benzimidazol-2-yl)-6-(4-ethylphenyl)quinolin-2(H)-one; 4-II3S)-Iazabicyclo[2.2.2]oct-3-ylamino]-3-(rn-benzimidazol-2-y)6fluoro.7{(2 methylpropyl)amino]quinolin-2(1H)-one; 44(3R)-l-azabicyclo[2.2.2]oct-3ylamino]-3-{1H-benzimidazol-2-yl)-5-methylquinolin-2(1H)-one; azabicyclo[2.2.2]oct-3-ylaxino]-6(2,4-dichlorophenyl)3.(3H-imildazo[4,5blpyridin-2-yl)quinolin-2(1H)-one; 4-[R3R)-1-azabicyclo[2.2.2]oct-3-ylamiuo]-3- (lH-benzimidazol-2-yl)-6-[3-(trifluoromethyl)phenyl]quinolin-2(lH)-one; 3-(1Hbenzimidazol-2-yl)-4-(dimethylamio)quinoln-2(H)-one;- 4-hydroxy-3-(1Hixnidazo[4,5-flquinolin-2-yl)quinolin-2(1H)-one; 4-hydroxy-3-(1H-iniidazo[4,5blpyridin-2-y)quinoin-2(lH)-one; 4-[4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylaniino]-3- (1L1-bezixidazol-2-yl)-5-fluoro-2-oxo-1 ,2-dihydroquinolin-6-yllbeiizoic acid; 4-[4- [(3R)-l-azabicyclo[2.2.2]oct-3-yanmino]-3-(1H-benzimidazol2y)s.fluoro2.oxo.
1 ,2-dihydroquinolin-6-yljbenzamide; N-{3-[4-[(3R)-1-azabicyclo[2.2.2joct-3ylamino]-3--(1H-benziinidazol-2-yl)-5-fluoro-2-oxo-1 ,2-dihydroquinolin-6yl]phenyl~acetaxnide; 3-[4-R 3R)-1-azabicyclo[2.2.2loct-3-ylamino]-3-(iIbenzimidazol-2-yl)-5-fluoro-2-oxo-1 ,2-diliydroquinolin-6-yl]benzoic acid; 4-[4- 3 R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzmidazo-2-y)-7-fluoro-2-oxo- 1 ,2-dihydroquinolin-6-yl]benzoic acid; N-{3-[4-[(3R)-1-azabicyclo[2.2.2]oct-3ylainino]-3-(1H-benzhnidazol-2-yl)-7-fluoro-2-oxo-1 ,2-dihydroquinolin-6yl]phenyllacetamide; 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(IHbenzimidazol- 2 -yl)-7-chloro-6-(2-methylphenyl)quinolin-2(1ny-one; azbcco222ot3yaio-3 Hbniiao--l--x-,2dihydroquinoline-7-carbonitrile; 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-' -160benziniidazol-2-yl)-7-(metiyloxy)quinolin-2(1H)-one; azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-2-oxo-1 ,2dihydroquinolin-7-yI]benzamide; 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylainino]-3-(1H- 00 benziniidazol-2-yl)-6-fluoro-7-(me.tkyloxy)quinolin-2(1H)-one; azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-6-chloro-7- (dimnethylamino)quinolin-2(1H)-one; 1-azabicyclo[2.2.2]oct-3-ylaniino]-3- (1H-benzimidazol-2-yl)-7-(dimethylamino)-6-iodoquinolin-2(1H)-one; azabicyclo[2.2.2oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-7-(1H-iidazo-1-y1)-2 oxo-1 ,2-dihydroquinolin-6-yl]benzoic acid; 4-[4-[(3R)-l-azabicyclo[2.2.2]oct-3ylamino]-3-(1H-benzimidazol-2-yl)-2-oxo-7-piperidin-1-yl-1 ,2-dihydroquinolin-6yl~benzoic acid; 4-[(3R)-l-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2yl)-7-(methyloxy)-6-[4-(methylsulfonyl)phenyl]quinolin-2(1iH)-one; azabicyclo[2.2.2]oct-3-ylamino]-3-(lH-benziiidazol-2-yl)-8-methylquinolin-2(H)one; 4-I(3S)-l-azabicycloll2.2.2]oct-3-ylamino]-3-(lH-benzimidazol-2-yl)-6,7difluoroquinolin-2(lH)-one; 3-(1H'-benziniidazol-2-y1)-6-methyI-4-(piperidin-3ylamino)qiiinolin-2(1H)-one;* 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylaniino-3-(1Hbenzimidazol-2--yl)-6-[2-(methyloxy)phenyl]quinolin-2(1H)-one; 4+[3S)-1azabicyclo[2.2..2]oct-3-ylaniino]-3-(1H-benziynidazol-2-yI)-64[3- (methyloxy)phenyl]quinolin-2(1IH)-one; 3-(1H--benzimidazol-2-yl)-6,7-difluoro-4- (piperidinA-ylamino)qunolin-2(lH)-one; 3-(1H-benziiuidazol-2-yI)-6,7-difluoro-4- (Pyrrolidin-3-ylamino)quinolin-2(1H)-one;: 1H-benzinidazol-2-yl)-6-chloro-4-[(3morpholin-4-ylpropyl)auiino]quinolin-2(1H)-one; 6-chloro-3-(5-morpholin-4-yl-1Hbenzimidazol-2-yl)-4-(piperidin-4-ylamino)quinolin-2(lH)-one; 6-chloro-3-(5morpholin-4-yl-1H-benziniidazol-2-yl)4-[(piperidin-2-yinietiyl)aniino]quinoln- 2(111)-one; 4 -[(3S)-1-azabicyclo[2.2.2]oct-3-ylaniino]-6-chloro-3-(5-morpholin.4-yl- IH-benzimidazol-2-yl)quinolin-2(1H)-one; 6-chloro-3-(5-morpholin-4-yl-1Hbenzimidazol-2-yl)-4-(piperidin-3-ylamino)quinolin-2(1H)-one; 6-chloro4{([2- (diinethylainino)ethyl]atnino}-3-(5-morpholin-4-yl-1H-benzimidazol-2-yl)quinolin- 2(111)-one; 4-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]-6-chloro-3-(5-morpholin.4 yl-1H-benzilnidazol-2-yI)quinolin-2(1H)-one; 6-Chloro-3-(5-morpholinA-yl-1Hbenzimidazol-2-y1)-4-[(piperidin-3-yhmethyl)aniino]quinolin-2(1H)-one; 6-chloro-3' -161- 2(111)-one; 4 -{[(lR,2R)-2-aninocyclohexyl1amino}-6-chloro-3-(5morphoin-4yi-.
lIH-benzimidazol-2-yl)quinolin-2(11)-one; 4 4 -aminocyclohexyl)aniinol-:6-chloro- 3 -(5-morpholin-4-y1-1H-benzimidazol-2-y1)quinolin-2(1ny-one; 4-{[(2S)-2-amino 3mehluy~mn)6clr--5mrhli--lI-ezmdzl2y~unln 2(111)-one; [4-(aininomethyl)phenyllmethyl~amino)--6-chloro-3-(5-morpholin-4yl-lH-benziniidazol-2-yl)quinolin-2(1H)-one; 6-chloro-3-(5-morpholin-4-yl-lH- (aminomethy)propy]amino6cloro-3-(-mophoin-yIHbeidao.2 yl)quinolin-2(1H)-one; 4 -{[(lS)-2-anhino-1-(phenyhuethyl)ethyllamino}-6-chloro3.
(5-morpholin-4-yl-111-benzimidazol-2-yl)quinolin-2(11)-one; 6-chloro-4-{[3-(4methylpiperazin-1-yl)propy1amino-3-(-morpholin4.y14wHbenimidazol2yl)quinolin-2(111)-one;. 6-chloro-3-(5-morpholin-y1-1H-benzimidazol-2-y)4-[1..
(phenylmethyl)piperidin4-y1]aino~quinolin-2(11)-one;, 6-chloro-3-(5-morpliolin- 4 -yl-lfl-benzimidazol-2-yl)-4-[(3-morhon4ypropy)amio]quinoin2(H..one; 6-horo-3-(5-morpholin4-yl-1H-benzmdazol-2-y)4-(2-piperidin-lylethyl)amino]quinolin-2(1H)-one; 6-cloro-3-(5-morpholin4-y-IH-benzimidazol.
2 -yl)- 4 -[(pyridin-3-ylmethyl)amino]quinolin-2(1H)-one; 6-chloro-4-{[3-(1Hiidazo-1-y1)propyI]amino}-3-(-morphoin4j1-H-bezimdazo.2y)quinolin.
2(111)-one; .6-chloro-3-(5-morpholin4-yl-ff-benzhmdazol-2yl)4-(pyridin-4.
ylmethyl)aminojquinolin-2(111)-one; 6-chloro-4-{[2-(methylamino)ethyllaxnino}-3- (5-morpholin-4yl-1H-benzixnklazol-2-yl)quinolin-2(lu).one; 6-cliloro-4-{[(2methyl- l-piperidin-4-yl-1H-benzimidazol.5-yl)methyl) mino)-3-(5-morpholin-4-yl- 1H-benuzimidazol-2-yI)quinolin-2(1H)-one; 6-chloro-3-(5-morpholin-4-ylI-1Hbenzimidazol-2-y)4[2-pyrrolidin-1ylethyl)an1ino]quinoin2(rn)-one; 6-chloro-3one; 4 -{[(1R,2R)-2-aminocyclohexyl]amino}-6-chloro-3-[5-(4-methylpiperazin1yl)-lH-benzimidazol-2-yl]quinolin-2(11)one; 4-[4-aminocyclohexyl)amino]-6choo3[-4mtypprzn1y)I-ezmdzl2yjunln2l)oe 4- 4 -(aminomethyl)phenylImethyl~amino)-6-choro-3-[5(4mefiypiperazin..yly..
1H-benzimnidazol-2-y1Iquinolin-2(1H)-one; 6-chloro-4-{[2- -162- (methylalnino)ethyllainino}-3-[5-(4-methylpiperazin-1-yl)-1H-benziniidazol-2yIlquinolin-2(1H)-one; 6-chloro-3-[5-(4-methylpiperazin-1-yl)-lH-benzimidazol-2- [3-(4-methylpiperazin-1-yl)propyl]amiino~quinolin-2(1H).one; 6-chloro-3-[5- 00 (4-meth~ilPiperazin-1-yl)-lH-benzimidazol-2-y]-4-[h(phenylmethyl)piperidin-4 0 5 yllaminO}quinoin-2(1H)-one; 6-chloro-3-[5-(4-methylpiperazin-1-yl)-ll{benzimidazol-2-yl]-4--[(2-pyrrolidin-1-ylethyl)aminolquinolin-2(1H)-one; 6-chloro-3kn .[5-(4-methylpiperazin-1-yl)- H-benzimidazol-2-yl]-4-(pyrroidin-3ylamino)quinolin-2(1H)-one; 6-chloro-3-[5-(4-methylpiperazin-1-yf)-lHbenzimidazol-2-yl]-4-(piperidin-4-ylamino)quinoli-2(1H)-one; 6-chloro-3-(5mo1rphoin4-yl-1H-benzimidazol-2-yl)-4-[(2-piperidin-2-ylethy1)amino]quinolin- 2(1H)-one; 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-7-chloro-3-(5-morpholinA-yl.
IH-benzimidazol-2-yl)quinolin-2(1H)-one; 7-chloro-,3-(5-morpholm-4-yl-1Hbenzimidazol-2-yl)-4-(piperidin-3-ylamino)quinolin-2(lHy..one; 6-chloro-3-[5-(4methylpiperazin-1-yl)-1H-benzixnidazol-2jrl]-4-[(piperidin-2- 15 ylmethyl)aminolquinolin-2(1H)-one; 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1Hbenzilnidazol-2-yl]-4-[(2S)-pyrrolidin-2-ylmethyl]aminojquiuoai-2(IH)-one; 6chloro-3-[5-(4-methylpiperazim-1-yl)-1H-benzimudazol-2-y11-4-{[(2R)-pyfrolidin-2 ylmethyl]aminolquinolin-2(1H)-one; 6-chloro-4-({[(2S)-1-ethylpyrrolidin-2yllmethyl~amino)-3-[5-(4-methylpiperazin-1-yl)-111-benzimidazol-2-yl]quinolin 2(1H)-one; 6-chloro-4-({[(2R)-1-ethylpyrrolldin-2-y]methyqjamino)-3-[..<4methylpiperazin-1-yl)-1H-benzinidazol-2-yl]quinolin-2(1H)-one; 4+[3S)-1aizabicyclo[2.2.2]oct-3-ylaiino-3-(1H-benzmidazol-2-yl)-6-[4- (metIhyloxy)phenyl]quinolin-2(1H)-one; and 6-(3-aminophenyl)-4-[3S)-1azabicyclo[2.2.2]oct-3-ylamino]-3-(ll1-benzimidazol-2-yl)quinolin-2(1H)-one.
Each of the above compounds displayed an 1C5o value of less than jiM with respect to VEGFRI, VEGFR2, and bFGF.
it should be understood that the organic compounds according to the invention may exhibit the phenomenon of tautomerism. As the chemical structures within this specification can only represent one of the possible tautomeric forms, it -163should be understood that the invention encompasses any tautomeric form of the drawn structure.
00 It is understood that the invention is not limited to the embodiments 0 set forth herein for illustration, but embraces all such forms thereof as come within the scope of the following claims.
In
(N'
Claims (12)
1. A method for synthesizing a 4-amino substituted quinolinone 00 Scompound, comprising: reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with a 0 0 substituted or unsubstituted 2-aminobenzonitrile and a base or a Lewis acid, wherein the 4-amino substituted quinolinone compound is provided and the 4-amino substituted quinolinone compound comprises a benzimidazole group.
02. The method of claim 1, wherein the substituted or unsubstituted 2-benzimidazolyl-2-acetate is a substituted or unsubstituted ethyl 2-benzimidazolyl-2- acetate.
3. The method of claim 1, wherein the substituted or unsubstituted 2-benzimidazolyl-2-acetate is reacted with the substituted or unsubstituted 2- aminobenzonitrile and the Lewis acid.
4. The method of claim 3, wherein the Lewis acid is tin tetrachloride. The method of claim 1, wherein the substituted or unsubstituted 2-benzimidazolyl-2-acetate is reacted with the substituted or unsubstituted 2- aminobenzonitrile and the base.
6. The method of claim 5, wherein the base is lithium bis(trimethylsilyl)amide.
7. The method of claim 1, further comprising adding lithium bis(trimethylsilyl)amide to the substituted or unsubstituted 2-benzimidazolyl-2-acetate in tetrahydrofuran, and then adding the substituted or unsubstituted 2- aminobenzonitrile.
8. The method of claim 1, further comprising providing the 2- benzimidazolyl-2-acetate by reacting ethyl 3-ethoxy-3-iminopropanoate hydrochloride with a substituted or unsubstituted 1,2-phenylenediamine. 165118 1 103 S9. The method of claim 8, wherein reacting ethyl 3-ethoxy-3- Siminopropanoate hydrochloride with a substituted or unsubstituted 1,2- phenylenediamine comprises stirring the ethyl 3-ethoxy-3-iminopropanoate and the O substituted or unsubstituted 1,2-phenylenediamine in ethanol at a temperature of 90 0 C. 0 O 5 10. The method of claim 9, further comprising reacting ethyl 2- O cyanoacetate with ethanol to produce the ethyl 3-ethoxy-3-iminopropanoate Shydrochloride.
11. The method according to claim 1, wherein the 4-amino substituted quinolinone compound is 4-amino-5-fluoro-3-[5-(4-methylpiperazin- -yl)- 1 H-benzimidazol-2-yl]quinolin-2( H)-one or a tautomer thereof.
12. The method according to claim 1, wherein the Lewis acid is tin tetrachloride or the base is lithium bis(trimethylsilyl)amide.
13. The method according to claim 1, wherein the 4-amino substituted quinolinone compound is bonded to the benzimidazole group at the 3- position of the quinolinone.
14. The method according to claim 1, wherein the 4-amino substituted quinolinone compound provided has structure I: 165118_1 100 wherein, n Y is a -NR2R 3 group; 00 Z is a NR' 4 group; 0\ R R and R 4 may be the same or different and are independently c 5 selected from the group consisting of H, Cl, Br, F, I, -CN, -NO 2 -OH, OR' 5 groups, -NRR 1 7 groups, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and CI unsubstituted primary, secondary, and tertiary alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and -C(=O)R 8 groups; R 5 R 6 R 7 and R 8 may be the same or different and are independently selected from the group consisting of H, Cl, Br, F, 1, -NO 2 -OH, -OR' 9 groups, -NR20R 2 1 groups, -SH, -SR 22 groups, -S(=O)R 23 groups, S(=0)2R 24 groups, -CN, substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and unsubstituted primary, secondary, and tertiary alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted 165118 1 (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=O)R25 groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted unsubsheterocycyituted aminoalkyl groups, substituted and unsubstituted 5 hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, 00 11substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; R 9 and R' 4 are H; R is H; R 3 is H; R' 5 and R' 9 may be the same or different and are independently selected from the group consisting of substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=O)-alkyl groups, -C(=O)-aryl groups, C(=O)NH 2 -C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, C(=O)N(alkyl) 2 groups, -C(=O)N(aryl) 2 groups, -C(=O)N(alkyl)(aryl) groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl, substituted and unsubstituted diheterocyclylaminoalkyl, substituted and unsubstituted (heterocyclyl)(alkyl)aminoalkyl, substituted and unsubstituted (heterocyclyl)(aryl)aminoalkyl, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; 165118 1 I O( 6 CN R and R2 may be the same or different and are independently selected from the group consisting of H, substituted and unsubstituted alkyl ;Z groups, substituted and unsubstituted aryl groups, and substituted and 00 unsubstituted heterocyclyl groups; 00 5 R" and R21 may be the same or different and are independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, -C(=O)-alkyl groups, C(=O)-aryl groups, -C(=O)NH 2 -C(=O)NH(alkyl) groups, C(=O)NH(aryl) groups, -C(=O)N(alkyl) 2 groups, -C(=O)N(aryl) 2 groups, -C(=O)N(alkyl)(aryl) groups, -C(=O)O-alkyl groups, aryl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, heterocyclyl groups, -C(=O)-O-heterocyclyl groups, C(=O)NH(heterocyclyl) groups, -C(=O)-N(heterocyclyl) 2 groups, C(=O)-N(alkyl)(heterocyclyl) groups, -C(=O)-N(aryl)(heterocyclyl) groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; R 3 R 24 and R 2 5 may be the same or different and are independently selected from the group consisting of H, -NH 2 -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl) 2 groups, -N(aryl) 2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, 165118 1 MUY -N(heterocyclyl) 2 groups, substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, -OH, substituted and ;Z unsubstituted alkoxy groups, substituted and unsubstituted aryloxy 00 groups, substituted and unsubstituted heterocyclyl groups, -NHOH, -N(alkyl)OH groups, -N(aryl)OH groups, -N(alkyl)O-alkyl groups, 00 ID-N(aryl)O-alkyl groups, -N(alkyl)O-aryl groups, and -N(aryl)O-aryl N groups; and R is selected from the group consisting of substituted and unsubstituted alkyl groups, substituted and unsubstituted aryl groups, and substituted and unsubstituted heterocyclyl groups; and further wherein at least one of R R R7, or R is selected from the group consisting of substituted and unsubstituted amidinyl groups, substituted and unsubstituted guanidinyl groups, substituted and unsubstituted saturated heterocyclyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; -OR' 9 groups wherein is selected from the group consisting of substituted and unsubstituted aryl groups, substituted and unsubstituted heterocyclyl groups, substituted and unsubstituted heterocyclylalkyl groups, -C(=O)-aryl groups, -C(=O)NH 2 -C(=O)NH(alkyl) groups, C(=O)NH(aryl) groups, -C(=O)N(alkyl) 2 groups, -C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl 165118 1 I IV N groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and 00 unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted 00 00 diheterocyclylaminoalkyl groups, substituted and unsubstituted N (heterocyclyl)(alkyl)aminoalkyl groups, substituted and unsubstituted N (heterocyclyl)(arlkyl)aminoalkyl groups, substituted and unsubstituted N (heterocyclyl)(aryl)aminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; -NR2()R21 groups wherein is selected from the group consisting of substituted and unsubstituted heterocyclyl groups; -NR20R21 groups wherein R21 is selected from the group consisting of substituted and unsubstituted heterocyclyl groups, -C(=O)-aryl groups, -C(=O)NH 2 C(=O)NH(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl) 2 groups, C(=O)N(aryl) 2 groups, -C(=O)N(alkyl)(aryl) groups, C(=O)O-alkyl groups, -C(=O)O-aryl groups, substituted and unsubstituted aminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted dialkylaminoalkyl groups, substituted and unsubstituted arylaminoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoalkyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; and -C(=O)R 2 5 groups wherein R 2 5 is selected from the group consisting of H, -NH 2 -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl) 2 groups, -N(aryl) 2 groups, -N(alkyl)(aryl) groups, -NH(heterocyclyl) groups, 165118 1 25/07 '07 11:15 FAX 61386184199 FB RICE CO f004 171 R 20 is selected from the group consisting of substituted and unsubstituted heterocyclyl groups; -NR 0 R" groups wherein R 21 is selected from the group consisting of substituted and unsubstituted heterocyclyl groups, -C(=O)-aryl groups, -C(=O)NH2, oo00 5 C(=O)N(alkyl) groups, -C(=O)NH(aryl) groups, -C(=O)N(alkyl) 2 \ogroups, C(=O)N(aryl)2 groups, -C(=O)N(alkyl)(aryl) groups, C(=Q)O-alkyl groups, -C(=O)O-aryl groups, substituted and unsubstituted amminoalkyl groups, substituted and unsubstituted alkylaminoalkyl groups, substituted and unsubstituted diallcylaminoalkyl C 10 groups, substituted and unsubstituted arylaninoalkyl groups, substituted and unsubstituted diarylaminoalkyl groups, substituted and unsubstituted (alkyl)(aryl)aminoallckyl groups, substituted and unsubstituted heterocyclylaminoalkyl groups, substituted and unsubstituted hydroxyalkyl groups, substituted and unsubstituted alkoxyalkyl groups, substituted and unsubstituted aryloxyalkyl groups, substituted and unsubstituted heterocyclylalkyl groups, and substituted and unsubstituted heterocyclyloxyalkyl groups; and -C(=O)RV groups wherein R2 5 is selected from the group consisting of H, -NH 2 -NH(alkyl) groups, -NH(aryl) groups, -N(alkyl)Z groups, -N(aryl) 2 groups, -N(alkyl)(aryi) groups, -NH(heterocyclyl) groups, -N(heterocyclyl)(alkyl) groups, -N(heterocyclyl)(aryl) groups, -N(heterocyclyl)2 groups, substituted and unsubstituted aryl groups, substituted and unsubstituted aryloxy groups, and substituted and unsubstituted heterocyclyl groups.
15. A method according to any one of claims 1 to 14, substantially as hereinbefore described with reference to the examples. Dated this twenty-fifth day of July 2007 Chiron Corporation Patent Attorneys for the Applicant: F B RJCE CO 170616 1.doc COMS ID No: ARCS-154254 Received by IP Australia: Time 11:13 Date 2007-07-25
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005202068A AU2005202068B2 (en) | 2000-09-11 | 2005-05-13 | Quinolinone derivatives as tyrosine kinase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/232,159 | 2000-09-11 | ||
AU2001293275A AU2001293275B2 (en) | 2000-09-11 | 2001-09-11 | Quinolinone derivatives as tyrosine kinase inhibitors |
PCT/US2001/042131 WO2002022598A1 (en) | 2000-09-11 | 2001-09-11 | Quinolinone derivatives as tyrosine kinase inhibitors |
AU2005202068A AU2005202068B2 (en) | 2000-09-11 | 2005-05-13 | Quinolinone derivatives as tyrosine kinase inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001293275A Division AU2001293275B2 (en) | 2000-09-11 | 2001-09-11 | Quinolinone derivatives as tyrosine kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2005202068A1 AU2005202068A1 (en) | 2005-06-02 |
AU2005202068B2 true AU2005202068B2 (en) | 2007-08-09 |
Family
ID=34596381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005202068A Expired AU2005202068B2 (en) | 2000-09-11 | 2005-05-13 | Quinolinone derivatives as tyrosine kinase inhibitors |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2005202068B2 (en) |
-
2005
- 2005-05-13 AU AU2005202068A patent/AU2005202068B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
AU2005202068A1 (en) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2421120C (en) | Quinolinone derivatives as tyrosine kinase inhibitors | |
AU2003226275B2 (en) | Quinolinone derivatives | |
EP1313734B1 (en) | Aza heterocyclic derivatives and their therapeutic use | |
AU2001293275A1 (en) | Quinolinone derivatives as tyrosine kinase inhibitors | |
AU2005202068B2 (en) | Quinolinone derivatives as tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |